Menu

  • Electrophysiology
  • Therapies & Procedures
  • Patient Care Portfolio
  • Reimbursement
  • Education & Training

    • The Medtronic AF advantages across our portfolio

    • Increase the accurate and timely diagnosis of AF1
    • Improve AF patient outcomes2–5
    • May reduce AF-related use of healthcare resources3,6
    • Use the LINQ™ family of ICMs (Reveal LINQ™ ICM and LINQ II™ ICM) to make data-guided management decisions such as medical management, including anticoagulation7–10

    Detect AF

    Timely and accurate AF detection and monitoring through device-based algorithms

    LINQ™ family of ICMs 

    LINQ™ ICMs provide data that enables clinicians to objectively diagnose and monitor both asymptomatic and symptomatic AF.11

    This data results in the measure of true AF burden and enables data-driven decisions, including those related to medications and treatments such as anticoagulants or ablation.7–10

    To view the indications, safety, and warnings, scroll down or click on one of the links below to jump you down the page to that product.

    LINQ II™ ICM ISW

    Brief statement for LINQ II™ insertable cardiac monitor system (ICM) and accessories

    Indications

    The LINQ II™ ICM is an insertable automatically-activated and patient-activated monitoring system that records subcutaneous ECG and is indicated in adult patients, and in pediatric patients who are at least 2 years old, in the following cases:

    • patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
    • patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia

    Contraindications

    There are no known contraindications for the insertion of the LINQ II™ ICM or its accessories. However, the patient’s particular medical condition may dictate whether or not a subcutaneous, chronically inserted device can be tolerated.

    Warnings and precautions

    Patients with the LINQ II™ ICM should avoid sources of diathermy, high sources of radiation, electrosurgical cautery, external defibrillation, lithotripsy, therapeutic ultrasound and radiofrequency ablation to avoid electrical reset of the device, and/or inappropriate sensing as described in the Medical Procedure and EMI Warnings, Precautions, and Guidance Manual. MRI scans should be performed only in a specified MR environment under specified conditions as described in the LINQ II™ MRI technical manual.

    Accessories available for use with LINQ II™ ICM may experience connectivity or performance issues.  See product manuals for details and troubleshooting instructions.

    Potential adverse events or potential complications

    Potential adverse events from the LINQ II™ ICM include, but are not limited to, device rejection phenomena (including local tissue reaction), device migration, infection, and erosion through the skin.

    There are no known adverse events associated with the use of any LINQ II™ ICM accessory.  

    See the device manuals for detailed information regarding the implant procedure, indications / intended use, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at (800) 328-2518 (Technical Services) or (800) 551-5544 (Patient Services).

    Caution: Federal law (United States) restricts prescription devices to sale by or on the order of a physician.

    Brief statement for AccuRhythm™ AI ECG classification system

    Intended use

    The intended use of the system is to reduce false positive cardiac arrhythmia episodes.

    Contraindications

    There are no known contraindications for AccuRhythm™ AI Models ZA400, ZA410, or ZA420.

    Precautions

    The AccuRhythm™ AI ECG classification system may incorrectly adjudicate a true positive episode as an AI false episode, causing that episode to be suppressed in the remote monitoring system.

    See the device manual for detailed information regarding the intended use, contraindications, warnings, precautions, and potential complications/adverse events. For further information, call Medtronic Technical Services at (800) 328-2518.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    MAJ_83662

    Reveal LINQ™ ICM ISW

    Brief statement for Reveal LINQ™ insertable cardiac monitor (ICM) system and accessories

    Indications

    The Reveal LINQ™ insertable cardiac monitor (ICM) is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:

    • patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
    • patients who experience transient symptoms such as dizziness, palpitation, syncope and chest pain, that may suggest a cardiac arrhythmia.

    The device has not been tested specifically for pediatric use.

    Contraindications

    There are no known contraindications for the implant of the Reveal LINQ™ ICM or its accessories. However, the patient’s particular medical condition may dictate whether or not a subcutaneous, chronically implanted device can be tolerated.

    Warnings and precautions

    Patients with the Reveal LINQ™ ICM should avoid sources of diathermy, high sources of radiation, electrosurgical cautery, external defibrillation, lithotripsy, therapeutic ultrasound and radiofrequency ablation to avoid electrical reset of the device, and/or inappropriate sensing as described in the Medical procedure and EMI precautions manual. MRI scans should be performed only in a specified MR environment under specified conditions as described in the Reveal LINQ™ MRI technical manual. 

    Accessories available for use with Reveal LINQ™ ICM may experience connectivity or performance issues. See product manuals for details and troubleshooting instructions.

    Potential adverse events or potential complications

    Potential complications of the Reveal LINQ device include, but are not limited to, device rejection phenomena (including local tissue reaction), device migration, infection, and erosion through the skin.  

    There are no known adverse events associated with the use of any Reveal LINQ™ ICM accessory.

    See the device manuals for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events.  For further information, please call Medtronic at (800) 328-2518 (Technical Services) or (800) 551-5544 (Patient Services).

    Caution: Federal law (United States) restricts prescription devices to sale by or on the order of a physician.

    AccuRhythm™ AI ECG classification system brief statement

    Intended use

    The intended use of the system is to reduce false positive cardiac arrhythmia episodes.

    Contraindications

    There are no known contraindications for AccuRhythm™ AI Models ZA400, ZA410, or ZA420.

    Precautions

    The AccuRhythm™ AI ECG classification system may incorrectly adjudicate a true positive episode as an AI false episode, causing that episode to be suppressed in the remote monitoring system.

    See the device manual for detailed information regarding the intended use, contraindications, warnings, precautions, and potential complications / adverse events.  For further information, call Medtronic Technical Services at (800) 328-2518.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    MAJ_83854

    AccuRhythm™ AI Algorithms ISW

    AccuRhythm AI ECG classification system brief statement

    Indications: The intended use of the system is to reduce false positive cardiac arrhythmia episodes.

    Contraindications: There are no known contraindications for AccuRhythm AI Models ZA400, ZA410, or ZA420.

    Precautions: The AccuRhythm AI ECG classification system may incorrectly adjudicate a true positive episode as an AI false episode, causing that episode to be suppressed in the remote monitoring system.

    See the device manual for detailed information regarding the intended use, contraindications, warnings, precautions, and potential complications/adverse events. For further information, call Medtronic Technical Services at 800-328-2518 and/or consult Medtronic’s website at medtronic.com.

    Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_84705

      

    Highest published detection accuracy of 95–96% episode PPV12–14

    Azure™ XT DR MRI pacemaker

    Percepta™ Quad CRT-P MRI

    Cobalt™ XT DR ICD and CRT-D
    Cobalt™ DR ICD and CRT-D

    Cobalt™ XT VR ICD
    Cobalt™ VR ICD

    Using the TruAF™ detection algorithm, Medtronic single-chamber implantable cardioverter defibrillators (ICDs) are the only ICDs that can detect AF with a traditional lead.

    • 34% of patients had AF detected at six months.15

    Watch as Dr. Alan Cheng discusses the importance of AF detection in a single-chamber ICD.

    Dr. Alan Cheng AF detection video

    Watch as Dr. Alan Cheng discusses the importance of AF detection in a single-chamber ICD.

    Reduce AF

    Exclusive algorithms demonstrated to reduce the risk and duration of AF

    Managed Ventricular Pacing (MVP™)

    Reduces unnecessary RV pacing by 99%16

    • Every 1% of unnecessary RV pacing is accompanied by a 1% greater AF risk.17

    Reactive ATP™ algorithm

    Reduces the duration of AT/AF18

    • ≥ 1 day by 19%
    • ≥ 7 days by 36%
    • ≥ 30 days by 44%

    AdaptivCRT™ algorithm

    46% reduction in AF risk19

    The Reactive ATP™ (rATP) algorithm delivers atrial antitachycardia pacing (ATP) to terminate an ongoing AF episode after a programmed interval, or when the rhythm organizes and/or slows. Recent evidence shows rATP reduces the likelihood of patients experiencing AT/AF.18 Learn more in this informative video as CRHF Chief Medical Officer, Dr. Rob Kowal, discusses the data.

    To view the indications, safety, and warnings, scroll down or click on one of the links below to jump you down the page to that product.

    Implantable Pulse Generators (IPG) ISW

    Brief statement: Medtronic IPG

    Indications

    Implantable Pulse Generators (IPGs) are indicated for rate adaptive pacing in patients who may benefit from increased pacing rates concurrent with increases in activity and increases in activity. Pacemakers are also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and AV synchrony, which include various degrees of AV block to maintain the atrial contribution to cardiac output and VVI intolerance (e.g., pacemaker syndrome) in the presence of persistent sinus rhythm. See device manuals for the accepted patient conditions warranting chronic cardiac pacing. Antitachycardia pacing (ATP) is indicated for termination of atrial tachyarrythmias in patients with one or more of the above pacing indications.

    MRI SureScan IPGs: A complete SureScan pacing system is required for use in the MR environment and includes a Medtronic SureScan device connected to Medtronic SureScan Leads.

    Contraindications

    IPGs are contraindicated for concomitant implant with another bradycardia device and concomitant implant with an implantable cardioverter defibrillator. There are no known contraindications for the use of pacing as a therapeutic modality to control heart rate. The patient's age and medical condition, however, may dictate the particular pacing system, mode of operation, and implant procedure used by the physician. Rate-responsive modes may be contraindicated in those patients who cannot tolerate pacing rates above the programmed Lower Rate. Dual chamber sequential pacing is contraindicated in patients with chronic or persistent supraventricular tachycardias, including atrial fibrillation or flutter. Asynchronous pacing is contraindicated in the presence (or likelihood) of competition between paced and intrinsic rhythms. Single chamber atrial pacing is contraindicated in patients with an AV conduction disturbance. Antitachycardia pacing (ATP) therapy is contraindicated in patients with an accessory antegrade pathway. Medtronic Kappa™ 400 Series pacemakers are contraindicated for use with epicardial leads and with abdominal implantation.

    Warnings and precautions

    Changes in a patient's disease and/or medications may alter the efficacy of the device's programmed parameters. Patients should avoid sources of magnetic and electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device electrical reset or device damage. Do not place transthoracic defibrillation paddles directly over the device.

    MRI SureScan IPGs only: No lead extenders, lead adaptors or abandoned leads present; no broken leads or leads with intermittent electrical contact as confirmed by lead impedance history; the device must be operating within the projected service life, and the system must be implanted in the left or right pectoral region.  For pacemaker-dependent patients, it is not recommended to perform an MRI scan if the right ventricular (RV) lead pacing capture threshold is greater than 2.0 V at 0.4 ms.  Patients whose device will be programmed to an asynchronous pacing mode when MRI SureScan is on must have no diaphragmatic stimulation at a pacing output of 5.0 V and at a pulse width of 1.0 ms.  It is not recommended to perform MRI scans during the lead maturation period (approximately 6 weeks).  Pace polarity parameters are set to Bipolar for programming MRI SureScan to On (Advisa MRI only); or a SureScan pacing system is implanted with a lead impedance value of ≥ 200 Ω and ≤ 1500 Ω.  Revo MRI patients must have pacing capture thresholds of ≤ 2.0 V at a pulse width of 0.4 ms and a SureScan pacing system that has been implanted for a minimum of 6 weeks.

    Potential complications

    Potential complications include, but are not limited to, rejection phenomena, erosion through the skin, muscle or nerve stimulation, oversensing, failure to detect and/or terminate arrhythmia episodes, and surgical complications such as hematoma, infection, inflammation, and thrombosis.

    MRI SureScan IPGs: SureScan pacing systems have been designed to minimize potential complications in the MRI environment. Potential MRI complications include, but are not limited to, lead electrode heating and tissue damage resulting in loss of sensing or capture or both, or MR-induced stimulation on leads resulting in continuous capture, VT/VF, and/or hemodynamic collapse. 

    See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. See the appropriate product MRI SureScan Technical Manual before performing an MRI Scan. For further information, please call Medtronic at 1-800-328-2518 and/or consult www.medtronic.com or www.mrisurescan.com.

    Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_84705

    CRT IPGs & CRT ICDs ISW

    Brief statement: Medtronic CRT IPG and CRT ICD

    Indications

    CRT-Ps are indicated for NYHA Functional Class III and IV patients who remain symptomatic despite stable, optimal heart failure medical therapy and have a LVEF ≤ 35% and a prolonged QRS duration and for NYHA Functional Class I, II, or III patients who have a LVEF ≤ 50%, are on stable, optimal heart failure medical therapy if indicated and have atrioventricular block (AV block) that are expected to require a high percentage of ventricular pacing that cannot be managed with algorithms to minimize right ventricular pacing.  Optimization of heart failure medical therapy that is limited due to AV block or the urgent need for pacing should be done post implant. Rate adaptive pacing is provided for those patients developing a bradycardia indication who might benefit from increased pacing rates concurrent with increases in activity. Dual chamber and atrial tracking modes are indicated for patients who may benefit from maintenance of AV synchrony. Antitachycardia pacing (ATP) is indicated for termination of atrial tachyarrhythmias in patients with one or more of the above pacing indications.

    CRT-Ds are indicated for ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias and for providing cardiac resynchronization therapy in heart failure patients on stable, optimal heart failure medical therapy if indicated, and meet any of the following classifications: New York Heart Association (NYHA) Functional Class III or IV and who have a left ventricular ejection fraction < 35% and a prolonged QRS duration. Left bundle branch block (LBBB) with a QRS duration > 130 ms, left ventricular ejection fraction < 30%, and NYHA Functional Class II. NYHA Functional Class I, II, or III and who have left ventricular ejection fraction ≤ 50% and atrioventricular block (AV block) that are expected to require a high percentage of ventricular pacing that cannot be managed with algorithms to minimize right ventricular pacing. Optimization of heart failure medical therapy that is limited due to AV block or the urgent need for pacing should be done post implant. Some CRT-Ds are also indicated for use in patients with atrial tachyarrhythmias, or those patients who are at significant risk for developing atrial tachyarrhythmias. The RV Lead Integrity Alert (LIA) feature is intended primarily for patients who have a Medtronic CRT-D device and a Sprint Fidelis lead (Models 6949, 6948, 6931, and 6930), based on performance data. The RV LIA feature may not perform as well with a St. Jude Riata/Durata lead or a Boston Scientific Endotak lead as it does when used with a Medtronic Sprint Fidelis lead. This is because different lead designs may have different failure signatures and conditions that may or may not be detected early by the RV LIA feature.

    A complete SureScan system is required for use in the MR environment.

    Contraindications

    CRT-Ps are contraindicated for concomitant implant with another bradycardia device and concomitant implant with an implantable cardioverter defibrillator. There are no known contraindications for the use of pacing as a therapeutic modality to control heart rate. The patient’s age and medical condition, however, may dictate the particular pacing system, mode of operation, and implant procedure used by the physician. Rate-responsive modes may be contraindicated in those patients who cannot tolerate pacing rates above the programmed Lower Rate. Dual chamber sequential pacing is contraindicated in patients with chronic or persistent supraventricular tachycardias, including atrial fibrillation or flutter. Asynchronous pacing is contraindicated in the presence (or likelihood) of competition between paced and intrinsic rhythms. Single chamber atrial pacing is contraindicated in patients with an AV conduction disturbance. Anti-tachycardia pacing (ATP) therapy is contraindicated in patients with an accessory antegrade pathway.

    CRT-Ds are contraindicated in patients experiencing tachyarrhythmias with transient or reversible causes including, but not limited to, the following: acute myocardial infarction, drug intoxication, drowning, electric shock, electrolyte imbalance, hypoxia, or sepsis; patients who have a unipolar pacemaker implanted, patients with incessant ventricular tachycardia (VT) or ventricular fibrillation (VF), and patients whose primary disorder is chronic atrial tachyarrhythmia with no concomitant VT or VF.

    Warnings and precautions 

    A complete SureScan system is required for use in the MR environment. Before performing an MRI scan, refer to the CRT-P or CRT-D MRI SureScan Technical Manual for  MRI-specific warnings and precautions. A complete SureScan pacing system includes a SureScan device with Medtronic SureScan leads or a Model 6725 pin plug for the right atrial port. To verify that components are part of a SureScan system, visit www.mrisurescan.com. For a CRT-D SureScan system, when a single coil SureScan defibrillation lead is used, a Medtronic DF-1 pin plug must be secured in the SVC port to make a complete SureScan defibrillation system. Any other combination may result in a hazard to the patient during an MRI scan.

    Changes in a patient’s disease and/or medications may alter the efficacy of the device’s programmed parameters. Patients should avoid sources of magnetic and electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device electrical reset or device damage. Do not place transthoracic defibrillation paddles directly over the device.

    Certain programming and device operations may not provide cardiac resynchronization. Also for CRT-Ps, Elective Replacement Indicator (ERI) results in the device switching to VVI pacing at 65 ppm. In this mode, patients may experience loss of cardiac resynchronization therapy and/or loss of AV synchrony. For this reason, the device should be replaced prior to ERI being set. Use of the device should not change the application of established anticoagulation protocols.

    Patients and their implanted systems must be screened to meet the following requirements for MRI: no implanted lead extenders, lead adaptors, or abandoned leads; no broken leads or leads with intermittent electrical contact as confirmed by lead impedance history; a SureScan system implanted in the left or right pectoral region. Additionally, for patients whose device will be programmed to an asynchronous pacing mode when MRI SureScan is programmed to On, no diaphragmatic stimulation is present at a pacing output of 5.0 V and at a pulse width of 1.0 ms. For pacemaker-dependent patients, it is not recommended to perform an MRI scan if the right ventricular (RV) lead pacing capture threshold is greater than 2.0 V at 0.4 ms. A higher pacing capture threshold may indicate an issue with the implanted lead. 

    Potential adverse events

    Potential adverse events include, but are not limited to, rejection phenomena, erosion through the skin, muscle or nerve stimulation, oversensing, failure to detect and/or terminate arrhythmia episodes, and surgical complications such as hematoma, infection, inflammation, and thrombosis. An additional complication for CRT-Ds is the acceleration of ventricular tachycardia.

    Potential MRI complications for the SureScan system include, but are not limited to, lead electrode heating and tissue damage resulting in loss of sensing or capture or both, or MRI induced currents on leads resulting in continuous capture, VT/VF, and/or hemodynamic collapse; spontaneous tachyarrhythmia occurring during the scan that is not detected and treated because tachyarrhythmia detection is suspended while MRI SureScan is programmed to On; potential for VT/VF induction when the patient is programmed to an asynchronous pacing mode during MRI SureScan; device heating resulting in tissue damage in the implant pocket or patient discomfort or both; or damage to the functionality or mechanical integrity of the device resulting in the inability of the device to communicate with the programmer. See the CRT-P or CRT-D MRI SureScan Technical Manual before performing an MRI Scan.

    See the appropriate CRT-P or CRT-D Device Manuals for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. See the appropriate CRT-P or CRT-D MRI SureScan Technical Manual before performing an MRI Scan. For further information, call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website at www.medtronic.com or www.mrisurescan.com.

    CAUTION: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_84705

    Implantable Cardioverter Defibrillators ISW

    Brief statement: Medtronic ICD

    Indications 

    Implantable cardioverter defibrillators (ICDs) are indicated for ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias. Some ICDs are also indicated for use in patients with atrial tachyarrhythmias, or those patients who are at significant risk for developing atrial tachyarrhythmias.

    MRI Conditions for Use

    Medtronic SureScan ICD systems are MR Conditional, and as such are designed to allow patients to undergo MRI under the specified conditions for use.  Patients with MRI SureScan ICDs may be scanned using a horizontal field, cylindrical bore, clinical 1.5T or 3T MRI system for hydrogen proton imaging. When SureScan systems are programmed to On, the MRI SureScan feature allows the patient to be safely scanned while the device continues to provide appropriate pacing. A complete SureScan system, which is a SureScan device with appropriate SureScan lead(s), is required for use in the MR environment. When a single coil SureScan defibrillation lead is used, a Medtronic DF-1 pin plug must be secured in the SVC port to make a complete SureScan DF-1 defibrillation system. To verify that components are part of a SureScan system, visit http://www.mrisurescan.com/.  Any other combination may result in a hazard to the patient during an MRI scan.

    Contraindications

    ICDs are contraindicated in patients experiencing tachyarrhythmias with transient or reversible causes including, but not limited to, the following: acute myocardial infarction, drug intoxication, drowning, electric shock, electrolyte imbalance, hypoxia, or sepsis; patients who have a unipolar pacemaker implanted, patients with incessant ventricular tachycardia (VT) or ventricular fibrillation (VF), and patients whose primary disorder is chronic atrial tachyarrhythmia with no concomitant VT or VF.

    Warnings and precautions

    Changes in a patient's disease and/or medications may alter the efficacy of the device's programmed parameters. Patients should avoid sources of magnetic and electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device electrical reset or device damage. Do not place transthoracic defibrillation paddles directly over the device.

    Patients and their implanted systems must be screened to meet the following requirements for MRI: no lead extenders, lead adaptors or abandoned leads present; no broken leads or leads with intermittent electrical contact as confirmed by lead impedance history and the system must be implanted in the left or right pectoral region.

    Potential adverse events

    Potential adverse events include, but are not limited to, body rejection phenomena, device migration, erosion through the skin, muscle and/or nerve stimulation, oversensing, failure to detect and/or terminate arrhythmia episodes, and surgical complications such as hematoma, infection, inflammation, and thrombosis. An additional complication for ICDs is the acceleration of ventricular tachycardia. Potential MRI complications for the SureScan system include, but are not limited to, lead electrode heating and tissue damage resulting in loss of sensing or capture or both, or MRI induced currents on leads resulting in continuous capture, VT/VF, and/or hemodynamic collapse; spontaneous tachyarrhythmia occurring during the scan that is not detected and treated because tachyarrhythmia detection is suspended while MRI SureScan is programmed to On; potential for VT/VF induction when the patient is programmed to an asynchronous pacing mode during MRI SureScan; device heating resulting in tissue damage in the implant pocket or patient discomfort or both; or damage to the functionality or mechanical integrity of the device resulting in the inability of the device to communicate with the programmer. See the MRI SureScan Technical Manual before performing an MRI Scan.

    See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website at www.medtronic.com or http://www.mrisurescan.com/.

    CAUTION: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_84705

    Nearly 20 years of research and physician collaboration resulted in cardiac device algorithm innovations that help manage AF.

    Watch Dr. Amin Al-Ahmad walk through this history and discuss the AdaptivCRT™ algorithm, which reduces AF risk,19 and the Reactive ATP™ algorithm, which reduces AF duration.18

    To view the full webcast, visit medtronicacademy.com/globalgrandrounds.

    Respond to AF

    Exclusive feature to improve effective CRT delivery in the presence of AF

    EffectivCRT™ during AF algorithm

    Up to 16% increase in effective CRT delivery20

     

    The AdaptivCRT™ algorithm optimizes CRT pacing every minute whether AV conduction is normal, prolonged, or blocked. The EffectivCRT™ during AF algorithm automatically changes the pacing rate to increase effective CRT delivery during AF by up to 16%.20

     

    Dive deeper with Ruth Klepfer, senior research manager, as she explains how these two CRT algorithms work together to help manage AF in this short video.

    Treat AF

    Restore life‘s rhythm by unlocking potential through novel and efficient technology built on unmatched experience​.

     

    Arctic Front™ family of cryoballoons

    The only catheters approved for initial rhythm control treatment as an alternative to antiarrhythmic medications.21

    A safe and effective tool for early rhythm control that has been used to treat over one million patients worldwide.22

    Learn more

     

    The Arctic Front™ family of cryoballoons has proven shorter, more predictable procedure times, enabling the lab to benefit from less overtime, block schedule consistency,23,24 increased staff satisfaction,25 and more.

    Read more

    To view the indications, safety, and warnings, scroll down or click on one of the links below to jump you down the page to that product.

    Achieve Advance™ mapping catheter ISW

    Indications (or intended use)

    The Achieve Advance™ Mapping Catheter is indicated for multiple electrode electrophysiological mapping of the cardiac structures of the heart, i.e., recording or stimulation only. The Achieve Advance™ mapping catheter is designed to obtain electrograms in the atrial regions of the heart.

    Contraindications

    The catheter is contraindicated as follows: 1) For use as an ablation device, 2) For use with transseptal sheaths featuring side holes larger than 1.00 mm (0.04 in) in diameter, 3) Retrograde approach.

    Electrophysiology studies are contraindicated when the patient’s underlying cardiac disease makes it likely that induced arrhythmias will be extremely difficult to terminate and carry a high risk of death, as in the following conditions: An active systemic infection, Left atrial thrombus, Pulmonary vein stents, Prosthetic heart valve (tissue or mechanical), Myxoma, Interatrial baffle or patch, Conditions where the manipulation of the catheter within the heart would be unsafe, Acute myocardial infarction.

    Warnings and precautions

    This catheter is intended only to be used once for a single patient. Do not reuse, reprocess, or resterilize these devices for purpose of reuse. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device or create a risk of contamination of the device that could result in patient injury, illness, or death. This equipment should be used only by or under the supervision of physicians trained in cardiac catheterization procedures. If the sterile packaging of the device is damaged, do not use. Do not connect the mapping catheter to a radiofrequency (RF) generator or use it to deliver RF energy.

    Use of fluoroscopy during catheter manipulation and placement is strongly advised. Take all appropriate measures to minimize x-ray exposure to both patients and clinical staff.

    Avoid positioning the catheter around the chordae tendineae as this increases the likelihood of catheter entrapment within the heart. Avoid catheter entanglement with other catheters, devices, or wires. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Introducing any catheter into the circulatory system entails the risk of air or gas embolism, which can occlude vessels and lead to tissue infarction with serious consequences.

    Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade. Do not use excessive force to advance or withdraw the catheter, especially if resistance is encountered. Do not use the catheter if it is kinked, damaged, or cannot be straightened. Bending or kinking the catheter shaft may compromise the structural integrity of the device and increase the risk of catheter failure. Use only isolated equipment (IEC 606011 Type CF equipment, or equivalent) with the mapping catheter. Do not allow the patient to contact grounded equipment that might produce electrical current leakage during ablation or DCCV (Direct Current CardioVersion). Disconnect the catheter from the catheter connecting cable prior to cardioversion/defibrillation. Do not touch the patient or the catheter during cardioversion/defibrillation.

    Use the mapping catheter only with the Medtronic catheter connecting cable Model 2ACHC, and a compatible mating device with a minimum internal diameter of 1.12 mm (0.044 in) and standard 9 Fr hemostasis valve. The mapping catheter is compatible for use with, and may be used to support and position, all catheters in the Medtronic Arctic Front CryoAblation Catheter family. Cardiac catheterization procedures should be performed only in a fully equipped electrophysiology laboratory. Do not immerse the electrical connectors in fluids or solvents. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided and transseptal cardiac procedures. Always rotate the mapping catheter in a clockwise direction to prevent tissue damage. Keep in a dry location away from heat and all sources of light. Exposure to light may cause damage to the catheter. Do not expose the catheter to organic solvents such as alcohol.

    Potential adverse events or potential complications

    Potential adverse events associated with cardiac catheter procedures include, but are not limited to the following conditions: Access site vessel occlusion; Allergic reaction to x-ray contrast media; Arrhythmias, proarrhythmia; Arteriovenous fistula; Bleeding related to anticoagulation; Bradycardia; Cardiac perforation of the heart or other organs during transseptal puncture or other procedures; Cardiac tamponade; Cardiac thromboembolism; Cerebrovascular accident (CVA) or transient ischemic attack (TIA); Chest discomfort; Chronic cough; Death; Dislodgement of implantable cardioverter defibrillator (ICD) or permanent pacing leads; Fever; Heart failure; Hematoma; Hemoptysis; High creatinine phosphokinase or troponin level; Hypotension; Infections; Mitral valve trauma; Myocardial infarction or ischemia; Obstruction, perforation, damage, or spasm of the vascular system including the coronary circulation system; Pericarditis or endocarditis; Pleural or pericardial effusion; Pneumonia; Pulmonary embolism; Pulmonary infiltrates; Pulmonary vein narrowing or stenosis; Pseudoaneurysm in groin; Radiation injury or damage and late malignancy; Respiratory depression; Retroperitoneal bleed; Thrombotic or embolic events; Valvular insufficiency or damage; Vasovagal reaction.

    Refer to the device manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Achieve™ mapping catheter ISW

    Indications (or intended use)

    The Achieve™ Mapping Catheter is indicated for multiple electrode electrophysiological mapping of the cardiac structures of the heart, i.e., recording or stimulation only. The Achieve Mapping Catheter is designed to obtain electrograms in the atrial regions of the heart.

    Contraindications

    The catheter is contraindicated as follows: 1) For use as an ablation device, 2) For use with transseptal sheaths featuring side holes larger than 1.00 mm in diameter, 3) Retrograde approach

    Electrophysiology studies are contraindicated when the patient’s underlying cardiac disease makes it likely that induced arrhythmias will be extremely difficult to terminate and carry a high risk of death, as in the following conditions: An active systemic infection, Left atrial thrombus, Pulmonary vein stents, Prosthetic heart valve (tissue or mechanical), Myxoma, Interatrial baffle or patch, Conditions where the manipulation of the catheter within the heart would be unsafe, Acute myocardial infarction

    Warnings and precautions

    This catheter is intended only to be used once for a single patient. Do not reuse, reprocess, or resterilize these devices for purpose of reuse. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device or create a risk of contamination of the device that could result in patient injury, illness, or death. This equipment should be used only by or under the supervision of physicians trained in cardiac catheterization procedures. If the sterile packaging of the device is damaged, do not use. Do not connect the Achieve Mapping Catheter to a radiofrequency (RF) generator or use it to deliver RF energy.

    Use of fluoroscopy during catheter manipulation and placement is strongly advised. Take all appropriate measures to minimize x-ray exposure to both patients and clinical staff.

    Avoid positioning the catheter around the chordae tendineae as this increases the likelihood of catheter entrapment within the heart. Avoid catheter entanglement with other catheters, devices, or wires. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue).

    Introducing any catheter into the circulatory system entails the risk of air or gas embolism, which can occlude vessels and lead to tissue infarction with serious consequences.

    Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade. Do not use excessive force to advance or withdraw the catheter, especially if resistance is encountered. Do not use the catheter if it is kinked, damaged, or cannot be straightened. Bending or kinking the catheter shaft may compromise the structural integrity of the device and increase the risk of catheter failure. Use only isolated equipment (IEC 60601 Type CF equipment, or equivalent) with the Achieve Mapping Catheter. Do not allow the patient to contact grounded equipment that might produce electrical current leakage during ablation or DCCV (Direct Current CardioVersion). Do not allow any exposed metal portion of the shaft to contact grounded equipment.  Remove the catheter from the patient prior to cardioversion/defibrillation. Do not touch the patient or the catheter during cardioversion/defibrillation. Use the Achieve Mapping Catheter only with Medtronic Achieve Electrical Cable, suitable compatible mating device with a minimum internal diameter of 1.3 mm (0.049”) and standard 9F hemostasis valve. The Achieve Mapping Catheter is compatible for use with the Medtronic Arctic Front CryoAblation Catheter, and may be used to support and position the Arctic Front Catheter. Cardiac catheterization procedures should be performed only in a fully equipped electrophysiology laboratory. Do not immerse the electrical connectors in fluids or solvents. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided and transseptal cardiac procedures. Always rotate the Achieve Mapping Catheter in a clockwise direction to prevent tissue damage. Keep in a dry location away from heat and sunlight. Do not expose the catheter to organic solvents such as alcohol.

    Potential adverse events or potential complications

    Potential adverse events associated with cardiac catheter procedures include, but are not

    limited to the following conditions: Access site vessel occlusion; Allergic reaction to x-ray contrast media; Arrhythmias, proarrhythmia; Arteriovenous fistula; Bleeding related to anticoagulation; Bradycardia; Cardiac perforation of the heart or other organs during transseptal puncture or other procedures; Cardiac tamponade; Cardiac thromboembolism; Cerebrovascular accident (CVA) or transient ischemic attack (TIA); Chest discomfort; Chronic cough; Death; Dislodgement of implantable cardioverter; defibrillator (ICD) or permanent pacing leads; Fever; Heart failure; Hematoma; Hemoptysis; High creatinine phosphokinase or troponin level; Hypotension; Infections; Mitral valve trauma; Myocardial infarction or ischemia; Obstruction, perforation, damage, or spasm of the vascular system including the coronary circulation system; Pericarditis or endocarditis; Pleural or pericardial effusion; Pneumonia; Pulmonary embolism; Pulmonary infiltrates; Pulmonary vein narrowing or stenosis; Pseudoaneurysm in groin; Radiation injury or damage and late malignancy; Respiratory depression; Retroperitoneal bleed; Thrombotic or embolic events; Valvular insufficiency or damage; Vasovagal reaction.

    Refer to the device manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Affera™ Mapping and Ablation System ISW

    Affera™ Mapping and Ablation System

    Indications

    The Sphere-9 catheter is indicated for use in cardiac electrophysiological mapping (stimulation and electrogram recording) and for treatment of drug refractory, recurrent, symptomatic persistent atrial fibrillation (episode duration less than 1 year) and radiofrequency ablation of cavotricuspid isthmus dependent atrial flutter when used with the Affera mapping system.

    The Affera Mapping System is intended to be used for catheter-based cardiac electrophysiological mapping. The mapping system allows pacing and real-time visualization of compatible catheters as well as display of cardiac maps in multiple formats. The acquired patient signals, including intracardiac electrograms, may also be recorded and displayed on the system’s display screen.

    Contraindications

    Do not use this device under the following circumstances:

    • In patients with an active systemic infection.
    • In patients who have had cardiac surgery in the preceding eight weeks, as the risk of perforation may increase.
    • In patients with intracardiac thrombus or myxoma, as the catheter may precipitate an embolus.
    • In coronary vessels with diameter smaller than the expandable ablation electrode, as the catheter may damage the coronary vessels.
    • In patients with prosthetic valves, as the catheter may damage the prosthesis.
    • Using the transaortic retrograde approach in patients who have had aortic valve replacement.
    • Using the transseptal approach in patients with an interatrial baffle or patch, as the opening could persist and result in an iatrogenic atrial shunt.

    Warnings and Precautions

    Do not reuse, reprocess, or resterilize devices labeled single-use only. Only use with compatible devices listed in the IFU. The Affera Mapping System requires use of a disposable Location Reference Patch Kit to detect patient displacement and respiratory motion.

    Treatment location should be confirmed using alternative techniques (e.g. fluoroscopy, intracardiac electrograms, intracardiac echocardiography) before treatment.  

    A connection to a compatible cardiac stimulator is allowed provided the stimulator is electrically isolated or physically disconnected when RF or PF energy is applied to the patient, outputs of the generator and stimulator must be isolated to prevent patient injury or damage to equipment.

    The pacing functionality in the Affera Mapping System is not a life support device and is for diagnostic purposes only. Pacing may induce intentional or unintentional life-threatening cardiac arrhythmias.

    Intravenous heparin must be used to reduce the likelihood of thromboemboli developing during the procedure. Patient injury may result from excessive delivery of fluids. Anticoagulation treatment should adhere to consensus guidelines,

    Avoid steering the Sphere-9 catheter near other catheters to reduce the possibility of the catheters becoming entangled. Cardiac devices may be damaged by energy delivery.  Catheter interactions with implantable leads may result in lead dislodgement or possible thrombus.

    Cardiac ablation may induce intentional or unintentional life-threatening cardiac arrhythmias.

    Care should be taken when ablating near sensitive structures (i.e., conduction system, coronary arteries) as unintended patient harm may occur. Catheter entrapment within the heart is a possible complication of cardiac ablation procedures that could necessitate surgical intervention.

    The Affera Mapping and Ablation System has not been evaluated for safety and compatibility in the magnetic resonance (MR) environment. System operation may be temporarily interrupted if exposed to excessive external electromagnetic disturbance or ESD.

    Potential Adverse Events or Potential Complications

    Atrioesophageal fistula, Cardiac perforation / tamponade, Cardiac or respiratory arrest, Stroke Conduction system injury, Coronary artery spasm / occlusion / stenosis, Damage / dislodgement to ICD or implantable pacemaker, Death, Embolism, Hemoptysis, Infection, Myocardial infarction, Phrenic nerve palsy / paralysis, Pulmonary edema, Pulmonary vein stenosis, Valve damage, Vessel dissection

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_85060

    Back to top

    Arctic Front Advance™ Cardiac Cryoablation Catheter ISW

    Indications (or intended use)

    The Arctic Front Advance™ and Arctic Front Advance Pro™ cardiac cryoablation catheters are indicated for the treatment of drug refractory recurrent symptomatic paroxysmal and persistent atrial fibrillation (episode duration less than 6 months).

    The Arctic Front Advance™ and Arctic Front Advance Pro™ cardiac cryoablation catheters are also indicated for the treatment of recurrent symptomatic paroxysmal atrial fibrillation as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy.

    Contraindications

    Use of the cryoballoon is contraindicated: 1) In the ventricle because of the danger of catheter entrapment in the chordae tendineae, 2) In patients with one or more pulmonary vein stents, 3) In patients with cryoglobulinemia, 4) In patients with active systemic infections, and 5) In conditions where the manipulation of the catheter within the heart would be unsafe (e.g., intracardiacmural thrombus).

    Warnings and precautions

    Do not reprocess or resterilize this device for the purpose of reuse. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided and transseptal cardiac procedures. The Arctic Front family of cryoballoons have not been studied for the safety of changes in anticoagulation therapy in patients with paroxysmal atrial fibrillation. Atrial fibrillation patients with significant left ventricular dysfunction, advanced heart failure, severe left atrial enlargement or significant structural heart disease were excluded from the clinical trials that supported the approved indications. For baseline demographics and clinical characteristics of the patients studied, please see the Clinical Summaries listed in the instructions for use. Do not inflate the balloon inside the sheath or while the catheter is positioned inside a pulmonary vein. Always inflate the balloon in the atrium and then position it at the pulmonary vein ostium. If the balloon cannot be inflated or deflated using the CryoConsole, have a Manual Retraction Kit on hand during the procedure. (Refer to the CryoConsole Operator’s Manual for more detailed instructions on the Manual Retraction Kit). Disconnect the catheter’s electrical connection before cardioversion or defibrillation.

    Catheter handling:

    • Use extreme care when manipulating the catheter.
    • Do not use excessive force to advance, withdraw, or rotate the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened.
    • If the catheter becomes kinked or damaged while in the patient, remove it and use a new catheter.
    • Straighten the shaft before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or balloon segment.
    • Catheter advancement should be performed using fluoroscopy or other appropriate techniques.
    • Do not position the cryoballoon catheter within the tubular portion of the pulmonary vein.

    Do not advance the balloon beyond the guide wire or circular mapping catheter to reduce the risk of tissue damage. Ensure that the guide wire or circular mapping catheter is inserted into the catheter and through the balloon portion for adequate support during vascular access insertion. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Do not pull on the balloon catheter, circular mapping catheter, sheath, umbilical cables, or CryoConsole while the balloon catheter or circular mapping catheter are frozen to tissue. Before moving these components, use appropriate techniques to ensure that the balloon catheter and circular mapping catheter are not adhered to tissue.

    Always advance and withdraw components slowly to minimize the vacuum created and therefore minimize the risk of air embolism. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. The use of fluoroscopy during catheter ablation procedures presents the potential for significant x-ray exposure to both patients and laboratory staff. Give careful consideration before using the device in pregnant women. Flush the guide wire lumen before initial insertion and then frequently throughout the procedure to prevent coagulation of blood in the lumen. Flush the guide wire lumen with saline after each contrast injection. Use only 0.081 cm (0.032 in) or 0.089 cm (0.035 in) guide wires with the catheter. Do not connect the cryoablation catheter to a radiofrequency (RF) generator or use it to deliver RF energy. Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole and catheters. Avoid catheter entanglement with other catheters, devices, or wires.

    Before powering up an RF generator or applying RF energy, disconnect the cryoablation catheter from the CryoConsole. Always deflate the balloon and withdraw the balloon into the transseptal sheath before removing the balloon from the left atrium. If the sterile packaging or catheter is damaged, do not use the catheter. Use only Medtronic cryoablation catheters, 12 FR inner diameter sheaths, circular mapping catheters, refrigerant tanks, and components with the CryoConsole. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. This cryoablation system should be performed only in a fully equipped facility under the supervision of physicians trained in cryoablation procedures.

    Potential adverse events or potential complications

    Potential complications/adverse events from cardiac catheterization and ablation include, but are not limited to, the following: Access site complications (e.g., bruising, ecchymosis); Anemia; Anxiety; Arrhythmia (e.g., atrial flutter, bradycardia, heart block, tachycardia); Back pain; Bleeding from puncture sites; Bronchial constriction; Bronchial fistula; Bronchitis; Bruising; Cardiac tamponade; Cardiopulmonary arrest; Cerebral vascular accident; Chest discomfort/pain/pressure; Cold feeling; Coronary artery spasm; Cough; Death; Diarrhea; Dizziness; Embolism; Esophageal damage (including esophageal fistula); Fatigue; Fever; Headache; Hemoptysis; Hypotension/Hypertension; Infection (e.g., pericarditis, sepsis, urinary); Lightheadedness; Myocardial infarction; Nausea/vomiting; Perforation; Pericardial effusion; Phrenic nerve injury; Pleural effusion; Pneumonia; Pneumothorax; Pseudoaneurysm; Pulmonary edema; Pulmonary hemorrhage; Pulmonary vein dissection; Pulmonary vein stenosis; Shivering; Shortness of breath; Sore throat; Transient ischemic attack; Vagal nerve injury (e.g., gastroparesis); Vasovagal reaction; Visual Changes (e.g., blurred vision).

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.
     

    Back to top

    CardioInsight™ Mapping System ISW

    Indications

    The CardioInsight™ cardiac mapping system is intended for acquisition, analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.

    Contraindications

    There are no known contraindications.

    Warnings and precautions

    Cardiac mapping system

    Warnings
    • Do not modify the attachment plug or use a power adapter. This could cause an electrical hazard. If you require a different electrical socket plug, contact your local Medtronic Representative. CardioInsight™ must always be connected to the power source properly.
    • Ensure that all power sources are appropriately rated and are properly grounded or earthed. If the CardioInsight™ system is not properly grounded or earthed, it becomes a possible electric shock hazard. Protection against electrical shock has been provided through an isolation transformer and chassis grounding via a plug to an appropriate power source.
    • Electroanatomical mapping with CardioInsight™ should ONLY be performed after the risks of the entire procedure, including radiation exposure and time required for signal collection, have been adequately considered for each patient.
    Precautions
    • The installation and setup of CardioInsight™ and its software should ONLY be performed by trained Medtronic personnel.
    • Portable or mobile RF communications equipment may affect CardioInsight™.
    • Extension cords and electrical power bars should NEVER be used with CardioInsight™.
    • CardioInsight™ should not be connected to any equipment that is not supported by or part of the system.
    • The isolation transformer should NEVER be placed on the floor for use.
    • Do not stack other equipment on the mapping amplifier or the system cart.
    • Do not use the cart for any other purpose than storing and using CardioInsight™.
    • The workstation that is supplied as part of CardioInsight™ is not intended for use without the isolation transformer.
    • Devices that connect to CardioInsight™ via Universal Serial Bus (USB) such as an external hard drive should be used ONLY after approval by Medtronic as they may introduce computer viruses.
    • Installation of software not authorized by Medtronic on the CardioInsight™ workstation can cause the system to display inaccurate results or otherwise malfunction, and will void the terms of the product warranty.
    • Do not replace the amplifier fuses while the system is in use or connected to the patient.
    • Assembly, repair, and modifications of the system over its service life will be evaluated based on the requirements of IEC 60601-1 prior to implementation.
    • CardioInsight™ should ONLY be used by trained personnel or under the guidance of trained Medtronic personnel.
    • CardioInsight™ should ONLY be used in an institution’s environment.
    • Do not use CardioInsight™ in the presence of flammable anesthetic mixtures with air, oxygen, or nitrous oxide.
    • The CardioInsight™ acquisition should be performed on the same day as the completion of the CT scan.
    • The system cables, including the Sensor Array signal cables and patient ground reference cable are provided non-sterile. DO NOT sterilize the cables.

    Sensor array

    Warnings
    • DO NOT use the Sensor Array if the patient has sensitivity, open sores, or a severe skin condition or disease of the thorax area.
    • DO NOT perform magnetic resonance (MR) imaging with the Sensor Array on the patient. The Sensor Array may cause harm to the patient if used in MR imaging. Remove Sensor Array prior to performing MR imaging studies.
    • Remove or peel back front Sensor Array panels prior to using an external defibrillator on the patient.
    Precautions
    • The Sensor Array should only be connected to the CardioInsight™ Cardiac Mapping System.
    • The Sensor Array is meant to be used only during computed tomography (CT) imaging procedures that use legally marketed CT scanners.
    • The CardioInsight™ acquisition should be performed on the same day as the completion of the CT scan. The Sensor Array should not be removed or repositioned between the CT scan and the acquisition.
    • The Sensor Array is not sterile and cannot be sterilized. Care should be taken to keep the Sensor Array outside of any sterile field.
    • DO NOT expose the Sensor Array to organic solvents such as alcohol. If an organic solvent is used on patient, allow to dry for at least one minute prior to applying Sensor Array.
    • DO NOT expose the Sensor Array and electrical connectors to fluids or solvents, except when following the cleaning instructions in the Operator’s Manual.
    • Store Sensor Array flat (parallel to the floor) with the correct side facing up, as labeled, according to the environmental storage conditions.
    • Store Sensor Array panels in their sealed protective pouches until use.
    • The Sensor Array is intended for single use ONLY. Reusing the Sensor Array may result in poor system performance or transmission of infection.
    • Panels from different Sensor Array sizes should NEVER be mixed and matched for use.
    • DO NOT cut or fold the circuitry on the Sensor Array.

    Potential Adverse Events

    None known


    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    DiamondTemp™ Ablation Catheter ISW

    Indications (intended use)

    The DiamondTemp™ ablation catheter is indicated for use in cardiac electrophysiological mapping (stimulation and recording) and for treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation when used in conjunction with the DiamondTemp™ RF generator and accessories (DiamondTemp™ catheter-to-RF generator cable, DiamondTemp™ GenConnect™ cable, DiamondTemp™ EGM cable, DiamondTemp™ irrigation pump, DiamondTemp™ irrigation tubing set) and compatible mapping system.

    Contraindications

    Use of the DiamondTemp™ catheter is contraindicated for: 1) patients with active systemic infection, 2) patients with prosthetic valves, 3) patients with intracardiac thrombus or myxoma or interatrial baffle or patch via transseptal approach, 4) patients unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation, 5) pregnant women and children < 18 years of age, and 6) patients who are hemodynamically unstable.

    Warnings and precautions

    Cardiac ablation procedures should be performed only by physicians trained in the techniques of radiofrequency (RF) catheter ablation in a fully equipped electrophysiology (EP) laboratory. The catheter is for single use only. Do not reprocess or resterilize. Reusing, reprocessing, or resterilizing may compromise the structural integrity of the device or lead to product failure, which may result in patient injury, illness, or death. Reuse, reprocessing, or resterilizing may also create a risk of contamination of the device. Contamination may lead to injury, illness, or death of the patient. Pacemakers, implantable cardioverter defibrillators (ICDs), and leads can be adversely affected by RF signals. ICDs should be deactivated prior to ablation, precautions should be taken when the catheter is in close proximity to leads, and complete system analysis should be performed after ablation. Long-term risks of RF ablation lesions have not been established. Ablation too close to the esophageal area can result in esophageal fistula. Ablation near the AV node can cause permanent or partial conduction block. To ensure proper operation of the tissue contact impedance measurement function, all four electrodes and six thermocouples on the catheter tip must protrude from the distal tip of the guiding sheath. Carefully monitor the tissue contact impedance before delivery of RF energy. Do not place the RF electrode in proximity to any other mapping or ablation electrodes, as this may cause inadvertent, ineffective, or unsafe tissue ablation and may increase chances of char, coagulum, or steam pops. Although a higher contact impedance value typically indicates acceptable tissue contact, and low contact impedance values typically indicate lack of tissue contact, caution should be exercised. Areas of previously ablated tissue may also display a low contact impedance value. Other parameters, such as EGM, fluoroscopic images, and intracardiac ultrasound should be monitored before deciding to apply RF. Stimulation of cardiac tissues caused by pacing stimulus or RF energy may lead to inadvertent induction of arrhythmias. These arrhythmias may require defibrillation that could also result in skin burns. Do not use the catheter for epicardial ablation. Using ablation parameters (such as temperature set-point, ablation duration, or irrigation flow rate) other than those recommended by Medtronic may be hazardous to patients. Exercise caution and sound medical reasoning when deciding to deviate from recommended parameters. Perform catheter advancement under fluoroscopic guidance in conjunction with internal contact, electrograms, and impedance monitoring to minimize the risk of cardiac damage, perforation, or tamponade. Tip-to-tissue contact impedance is actively monitored only before and after ablation. During ablation, use caution when the temperature drops suddenly. A drop in temperature may be associated with loss of tissue contact. In case of steam pop or automatic shut off, discontinue RF energy. Remove the catheter for visual inspection and check for coagulum, charring, or other catheter defects.

    Manual prebending of the distal curve may damage the steering mechanism and may cause patient injury. Do not attempt ablation with the catheter without the use of the DiamondTemp™ irrigation pump and DiamondTemp™ generator and approved accessories. Do not attempt ablation without the use of the irrigation pump. Before attempting ablation, make sure the pump flow rate is at the minimum continuous flow and the pump is actively communicating with the generator. The potential adverse events that may be associated with ablation procedures can vary greatly in frequency and severity and may necessitate additional medical intervention, including surgery. Carefully review the specific indications, contraindications, warnings, precautions, and adverse events included with each DiamondTemp™ catheter, prior to use of the DiamondTemp™ generator or irrigation pump. The irrigation pump is designed for use only with sterile heparinized normal saline solution. Specified flow-rate accuracy may not be maintained when used with incompatible fluids or delivery devices. The air bubble detector is disabled during irrigation pump priming and purging functions. Do not prime or purge the catheter when it is inserted in the vasculature of the patient. Do not remove the irrigation tubing set from the irrigation pump while the tubing set is in-line with a catheter that is inside the patient. The DiamondTemp™ generator connection box E is to be used with the DiamondTemp™ ablation system and Ensite™ cardiac mapping and navigation systems configured to use NavX™ navigation technology. Use with other systems has not been assessed and may compromise patient or operator safety. Do not connect the generator connection box E to the Ensite™ amplifier with both the primary and secondary connectors. Only connect using one of the connector options.

    Potential adverse events or potential complications

    Potential complications/adverse events from cardiac catheterization and ablation include, but are not limited to, the following: abnormal vision; air embolism; anaphylaxis; anemia; aneurysm; angina; arrhythmia (including new or worsening of existing condition, or requiring cardioversion); arterial or venous thrombus; atrial septal defect; AV fistula; cardiac arrest; cardiac tamponade; catheter entrapment leading to valve or heart wall damage; catheter insertion site hematoma; chest pain (nonspecific); congestive heart failure exacerbation; component damage to ICD or pacemaker; coronary artery dissection; death; dislodgement of implantable device or permanent pacing lead; dizziness; embolic events, including infarction of other tissues, coronary, pulmonary, and bowel structures; endocarditis; esophageal damage or necrosis; exacerbation of COPD; exacerbation of pre-existing atrial fibrillation; fluid overload; gastroparesis or GI event; hemorrhage; hemothorax; hypotension; hypoxia; inadvertent AV block; infection; myocardial infarction; neck pain, back pain, or groin pain; palpitations; perforation (cardiac); pericardial effusion; pericarditis; peripheral venous thrombosis; phrenic nerve damage; pleural effusion; pneumonia; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary vein stenosis; radiation injury resulting in dermatitis, erythema, etc.; renal insufficiency or failure; respiratory failure; seizure; sepsis; skin burns; stroke or cerebrovascular incident; syncope; thromboembolic event; transient ischemic attack; vasovagal reaction; ventricular arrhythmia; vessel wall or valvular damage or insufficiency.

    See the appropriate product device manuals for detailed information regarding the RF ablation procedure, indications (or intended use), contraindications, warnings, precautions, and potential complications/adverse events. See the appropriate electronic instructions for use (eIFUs) for the DiamondTemp™ catheters, DiamondTemp™ RF generator, DiamondTemp™ irrigation pump, DiamondTemp™ irrigation tubing set, DiamondTemp™ catheter-to-RF generator cable, DiamondTemp™ GenConnect™ cable, EGM cable, and DiamondTemp™ generator connection box E. or further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Flexcath Advance™ Steerable Sheath ISW

    The FlexCath Advance™ steerable sheath is intended for percutaneous catheter introduction into the vasculature and into the chambers of the heart. The sheath deflection facilitates catheter positioning.

    Contraindications

    The FlexCath Advance™ steerable sheath is contraindicated for placement in the left atrium or ventricle if:

    • The patient has an intra-atrial septal patch or has had other surgical intervention in or adjacent to the intra-atrial septum.
    • The patient has had a previous embolic event from the left side of the heart within two months of the procedure.
    • The patient has known or suspected atrial myxoma.

    The sheath should not be used to perform the transseptal puncture.

    Warnings/precautions

    This is a single-use sheath to be used in a single patient. Do not resterilize this sheath for purpose of reuse. Use this sheath with compatible Medtronic diagnostic and ablations catheters that are 10.5 Fr or smaller. Do not use the sheath if it is kinked or damaged. The sheath and dilator have not been tested for compatibility with transseptal needles. Administer appropriate levels of peri-procedural anticoagulation therapy, during and post-procedure anticoagulation therapy according to patient conditions and institutional standards. Introducing any catheter or sheath into the circulatory system entails the risk of air embolism, which can occlude vessels and lead to tissue infarction with serious consequences. To minimize the risk of air embolism, observe and remove any air prior to introducing the sheath and during the procedure. Remove the guide wire and dilator from the sheath or insert the catheter into the sheath before slowly aspirating and flushing the sheath. Minimize catheter exchanges and always advance and withdraw catheters slowly. Follow advancement or withdrawal of catheters with appropriate aspiration and flushing according to institutional standards or consensus statements. Connect to a continuous drip to minimize back-bleeding. Do not pass the sheath through a prosthetic heart valve (mechanical or tissue). The sheath may become trapped in the valve, damaging the valve and causing valvular insufficiency or premature failure of the prosthetic valve. Cardiac catheterization procedures should be performed only in a fully equipped facility. This sheath should be used only by, or under the supervision of, physicians trained in cardiac catheterization procedures. Use extreme care when manipulating the sheath. Do not use excessive force to advance or withdraw the sheath, especially if resistance is encountered.

    Potential adverse events or potential complications

    Potential adverse events associated with cannulation of the peripheral vasculature and intracardiac placement of the sheath and dilator may include the following conditions:

    Access site complications (hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage); air embolism; arrhythmia (atrial fibrillation, atrial flutter, tachycardia); cardiac arrest; chest discomfort, pain, or pressure; coronary artery spasm, dissection, thrombosis; death; endocarditis; heart block, requiring permanent pacemaker; hemothorax; myocardial infarction; perforation of venous cardiac or surrounding tissue; pericardial effusion, tamponade; pericarditis; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; atroke; thrombus; transient ischemic attack (TIA); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

    Back to top

    FlexCath Contour™ Steerable Sheath ISW

    Intended use

    The FlexCath Contour™ steerable sheath facilitates introducing various cardiovascular catheters into the heart.

    Indications for use

    The FlexCath Contour™ steerable sheath is indicated for percutaneous catheter, or transseptal needle introduction into the vasculature and into the chambers of the heart, including the left side of the heart through the interatrial septum. The sheath deflection facilitates device positioning.

    Contraindications

    The FlexCath Contour™ steerable sheath is contraindicated for placement in the left atrium or ventricle if:

    • The patient has an intra-atrial septal patch or has had other surgical intervention in or adjacent to the intra-atrial septum
    • The patient has had a previous embolic event from the left side of the heart within two months of the procedure
    • The patient has known or suspected atrial myxoma

    Compatible catheter sizes:

    • FlexCath Contour™ steerable device (10 Fr) 
      The sheath can be used with Medtronic diagnostic and ablation catheter sizes from 7 Fr (2.3 mm) up to 9.5 Fr (3.2 mm). 
    • FlexCath Contour™ steerable device (12 Fr) 
      The sheath can be used with Medtronic diagnostic and ablation catheter sizes from 7 Fr (2.3 mm) up to 10.5 Fr (3.5 mm).

    Warnings/precautions

    • This is a single-use sheath to be used in a single patient. Do not resterilize this sheath for purpose of reuse. 
    • The dilator is compatible with transseptal needles that are at least 89 cm in length and less than 21 gauge outer diameter. 
    • Do not use the sheath if it is kinked or damaged. 
    • Only physicians trained in left-sided catheterization should use this sheath during transseptal puncture.
    • Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided, right-sided, and transseptal cardiac procedures. 
    • Administer anticoagulation therapy during and post-procedure according to patient conditions and institutional standards. 
    • Introducing any catheter or sheath into the circulatory system entails the risk of air embolism, which can occlude vessels and lead to tissue infarction with serious consequences. 
    • To minimize the risk of air embolism, observe and remove any air prior to introducing the sheath and during the procedure. 
    • Do not advance the dilator or sheath through the interatrial septum without first confirming left atrial access to prevent advancing these components into an undesired location. 
    • Remove the guide wire and dilator from the sheath or insert the catheter into the sheath before slowly aspirating and flushing the sheath. 
    • Minimize catheter exchanges and always advance and withdraw catheters slowly. 
    • Follow advancement or withdrawal of catheters with appropriate aspiration and flushing according to institutional standards or consensus statements. 
    • Connect to a continuous drip to minimize back-bleeding. 
    • Do not pass the sheath through a prosthetic heart valve (mechanical or tissue). 
    • The sheath may become trapped in the valve, damaging the valve and causing valvular insufficiency or premature failure of the prosthetic valve. 
    • Cardiac catheterization procedures should be performed only in a fully equipped facility. 
    • This sheath should be used only by, or under the supervision of, physicians trained in cardiac catheterization procedures. 
    • Use extreme care when manipulating the sheath. 
    • Do not use excessive force to advance or withdraw the sheath, especially if resistance is encountered.
    • Only physicians trained in left-sided catheterization should use this sheath during transseptal puncture.

    Potential adverse events or potential complications

    • Potential adverse events associated with cannulation of the peripheral vasculature and intracardiac placement of the sheath and dilator may include the following conditions:
    • Access site complications (hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage)
    • Air embolism
    • Arrhythmia (such as atrial fibrillation, atrial flutter, heart block requiring permanent pacemaker, ventricular tachycardia)
    • Cardiac arrest
    • Chest discomfort, pain, or pressure
    • Coronary artery spasm
    • Damage to heart tissue or vasculature
    • Death
    • Endocarditis
    • Entrapment of the sheath within the patient
    • Hemothorax 
    • Latrogenic atrial septal defect (iASD)
    • Infection (such as pericarditis, sepsis, urinary)
    • Myocardial infarction
    • Perforation of venous, cardiac or surrounding tissue
    • Pericardial effusion, tamponade
    • Pericarditis
    • Pleural effusion
    • Pneumothorax
    • Pseudoaneurysm
    • Pulmonary edema
    • Pulmonary embolism
    • PV stenosis
    • Stroke
    • Thrombus
    • Transient ischemic attack (TIA)
    • Valve damage
    • Vasovagal reaction

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 and/or consult the Medtronic website at www. medtronic.com.

    Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

    FlexCath Cross™ Transseptal Solution ISW

    Prior to using these devices, please review the instructions for use for a complete list of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. FlexCath Cross™ devices are FDA cleared. Not all FlexCath Cross™ devices are CE marked.

    Back to top

    Freezor™ Cardiac Cryoablation Catheter ISW

    Freezor™ cardiac cryoablation catheter

    Indications

    The Freezor™ cardiac cryoablation catheter, CryoConsole™ system, and related accessories are indicated for the cryoablation of the conducting tissues of the heart in the treatment of adult and pediatric patients over two years of age, with atrioventricular nodal reentrant tachycardia (AVNRT).

    Contraindications

    This device is contraindicated in patients with active systemic infection, cryoglobulinemia, intracardiac mural thrombus, myxoma, interatrial baffle or patch.

    Warnings/Precautions

    Closely monitor AV conduction during cryo energy delivery near the AV node due to possible risk of complete atrioventricular (AV) block. Immediately terminate energy delivery if partial or complete AV block is noted. Cryoablation involving coronary vessels has been associated with subsequent clinically significant arterial stenosis. Care should be taken to minimize unnecessary contact with coronary vessels during cryoablation. Endotoxins may cause pyrogenic responses in patients including inflammation and fever which can result in anaphylactic shock and death. Caution should be used with regard to endotoxins in pediatric populations as standard endotoxin limits do not differentiate between adult and pediatric populations. Ethylene oxide residuals remaining after sterilization are known to cause a potential increase in a number of biological effects including irritation, organ damage, mutagenicity and carcinogenicity. Calculations for ethylene oxide and ethylene chlorohydrin residuals indicate that the risk of these effects may be increased in patients under 3.8 kg. Avoid catheter entanglement with other catheters devices or wires. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. Do not re-use, reprocess, or resterilize this device for purpose of reuse. This device is intended only to be used once for a single patient. The use of CryoMapping mode does not prevent injuries to the patient. CryoMapping mode is used to determine if the site is appropriate for ablation. The Freezor™ catheter contains a pressurized refrigerant during operation. Release of this gas into the circulatory system due to equipment failure or misuse could result in gas embolism. Do not pull on the catheter, sheath, umbilical cables, or console while the catheter tip is frozen to the tissue, as this may lead to tissue injury. Always advance and withdraw components slowly to minimize the vacuum created and therefore minimize the risk of air embolism. Do not connect the Freezor™ catheter to any radiofrequency (RF) generator or use the Freezor™ catheter to deliver RF ablation energy. Before powering up an RF generator of applying RF energy, disconnect the cryoablation catheter from the CryoConsole™ system. The use of fluoroscopy during catheter ablation procedures presents the potential for significant X-ray exposure to both patients and laboratory staff. Give careful consideration before using the device in pregnant women. Avoid positioning the catheter around the chordae tendineae, as this increases the likelihood of catheter entrapment within the heart. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue).

    Catheter handling: 

    • Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade. 
    • Do not use excessive force to advance, withdraw, the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened.
    • Straighten the cooling segment before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or cooling segment.
    • Catheter advancement should be performed under fluoroscopic guidance or other appropriate visualization technique.

    Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole™ system and catheters. The Medtronic cryoablation catheters, refrigerant tanks, and other Medtronic CryoConsole™ components should only be used with the Medtronic CryoConsole™ system. If the sterile packaging or catheter is damaged, do not use the catheter. This equipment should be used only by physicians that perform cardiac ablation. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. Disconnect the catheter’s electrical connection prior to cardioversion/defibrillation. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing right-sided procedures. The Freezor™ catheter has not been evaluated for safety and compatibility in the magnetic resonance (MR) environment. Scanning a patient during the use of this device may result in patient injury.

    Potential Complications

    Potential complications that may be associated with cardiac catheterization and ablation listed alphabetically below include, but are not limited to: Access site complications including, hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage; arrhythmias (such as atrial fibrillation, atrial flutter, tachycardia); cardiac arrest and/or death; chest discomfort, pain or pressure; coronary artery spasm/stenosis; damage to heart tissue or vasculature; endocarditis; entrapment; heart block, requiring permanent pacemaker; hemothorax; infection; perforation of venous, cardiac or surrounding tissue, pericardial effusion, tamponade; pericarditis; phrenic nerve injury; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; stroke; tissue infarction (such as myocardial infarction or renal infarction); thrombus; transient ischemic attack; vagal nerve injury (such as gastroparesis); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-238-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Freezor™ MAX cardiac cryoablation catheter

    Indications

    The Freezor™ MAX cardiac cryoablation catheter is used as an adjunctive device in the endocardial treatment of paroxysmal and persistent atrial fibrillation (episode duration less than six months) in conjunction with the Arctic Front™ family of cardiac cryoablation catheters for the following uses: 1) Gap cryoablation to complete electrical isolation of the pulmonary veins 2) Cryoablation of focal trigger sites and 3) Creation of ablation line between the inferior vena cava and the tricuspid valve.

    Contraindications

    Use of Freezor™ MAX cardiac cryoablation catheter is contraindicated in patients with active systemic infections, in patients with cryoglobulinemia, intracardiac mural thrombus, myxoma or interatrial baffle or patch. The Freezor™ MAX cardiac cryoablation catheter is also contraindicated in patients with a body mass under 4.4 kg.

    Warnings/Precautions

    Do not reuse or reprocess this device for purpose of reuse. This catheter is intended only to be used once for a single patient. Do not connect the cryoablation catheter to a radiofrequency (RF) generator or use it to deliver RF energy. Disconnect the catheter’s electrical connection prior to cardioversion/defibrillation.

    Catheter handling:

    • Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade.
    • Do not use excessive force to advance, withdraw the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened. Straighten the cooling segment before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or cooling segment.
    • Catheter advancement should be performed under fluoroscopic guidance or other appropriate visualization technique.

    Avoid positioning the catheter around the chordae tendineae. The catheter contains pressurized refrigerant during operation. Release of this gas into the circulatory system due to equipment failure or misuse could result in gas embolism. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Use adequate fluoroscopic visualization or other appropriate visualization technique during a transaortic approach to avoid placing the ablation catheter within the coronary vasculature. Do not pull on the catheter, sheath, umbilical cables, or console while the catheter is frozen to the tissue, as this may lead to tissue injury. Always advance and withdraw components slowly to minimize the vacuum created. Closely monitor AV conduction during cryo energy delivery near the AV node due to possible risk of complete atrioventricular block.

    Perform cryoablation procedures only within the environmental parameters. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. The use of fluoroscopy during catheter ablation procedures presents the potential for significant X-ray exposure to both patients and laboratory staff. Give careful consideration before using the catheter in pregnant women. Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole™ system and catheters. The safety of the catheter in the MR environment is unknown (such as any heating, migration, or image artifacts). Scanning a patient during the use of this device may result in patient injury. Avoid catheter entanglement with other catheters, devices, or wires. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. Before powering up an RF generator or applying RF energy, disconnect the cryoablation catheter from the CryoConsole™ system. If the device is damaged or the integrity of the sterilization barrier has been compromised, do not use the product. The Medtronic cryoablation catheters, refrigerant tanks, and other Medtronic CryoConsole™ components should only be used with the Medtronic CryoConsole™ system.

    The Freezor™ MAX catheter was not studied for safety of changes in anticoagulation therapy in patients with paroxysmal atrial fibrillation. This equipment should be used only by physicians that perform cryoablation procedures. Cryoablation procedures should be performed only in a fully equipped facility.

    Potential Complications

    Potential complications/adverse events from cardiac catheterization and ablation include, but are not limited to the following: Access site complications including, hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from the puncture site, hemorrhage; arrhythmias (such as atrial fibrillation, atrial flutter, tachycardia); cardiac arrest; chest discomfort, pain or pressure; coronary artery spasm/stenosis; damage to heart tissue or vasculature; death; endocarditis; entrapment; esophageal damage (such as atrio-esophageal fistula); heart block, potentially requiring implantation of a permanent pacemaker; hemothorax; infection; perforation of venous, cardiac or surrounding tissue, pericardial effusion, tamponade; pericarditis; phrenic nerve injury; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; stroke; tissue infarction (such as myocardial infarction or renal infarction); thrombus; transient ischemic attack; vagal nerve injury (such as gastroparesis); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal Law (United States) restricts this device to sale by or on the order of a physician.

    Back to top

    Freezor™ Xtra cardiac cryoablation catheter

    Indications

    The Freezor™ Xtra cardiac cryoablation catheter, CryoConsole™ system, and related accessories are indicated for the cryoablation of the conducting tissues of the heart in the treatment of adult and pediatric patients over two years of age with atrioventricular nodal reentrant tachycardia (AVNRT). The Freezor™ Xtra catheter is also intended for minimally invasive cardiac surgery procedures, including surgical treatment of cardiac arrhythmias. The Freezor™ Xtra catheter freezes the target tissue and blocks the electrical conduction by creating an inflammatory response or cryonecrosis.

    Contraindications

    The Freezor™ Xtra cardiac cryoablation catheter is contraindicated in patients with the following conditions:

    • Active systemic infections
    • Cryoglobulinemia
    • Intracardiac mural thrombus
    • Myxoma
    • Interatrial baffle or patch

    Warnings/Precautions

    Do not reuse, reprocess, or resterilize this catheter for purpose of reuse. This catheter is intended only to be used once for a single patient. Closely monitor AV conduction during cryo energy delivery near the AV node due to possible risk of complete atrioventricular (AV) block. Immediately terminate energy delivery if partial or complete AV block is noted. The use of CryoMapping mode does not prevent injuries to the patient. CryoMapping mode is used to determine if the site is appropriate for ablation. The catheter contains pressurized refrigerant during operation. Release of this gas into the body or circulatory system due to equipment failure or misuse could result in gas embolism, pericardial tamponade, tissue emphysema, or other patient injury. Always advance and withdraw components slowly to minimize the vacuum created and therefore minimize the risk of air embolism. Endotoxins may cause pyrogenic responses in patients including inflammation and fever which can result in anaphylactic shock and death. Caution should be used with regard to endotoxins in pediatric populations as standard endotoxin limits do not differentiate between adult and pediatric populations. Ethylene oxide residuals remaining after sterilization are known to cause a potential increase in a number of biological effects including irritation, organ damage, mutagenicity, and carcinogenicity. Calculations for ethylene oxide and ethylene chlorohydrin residuals indicate that the risk of these effects may be increased in patients under 3.8kg. Avoid catheter entanglement with other catheters, devices, or wires. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. Do not pull on the Freezor™ Xtra catheter, sheath, umbilical cables, or console while the catheter is frozen to the tissue, as this may lead to tissue injury. Do not connect the Freezor™ Xtra catheter to a radiofrequency (RF) generator or use it to deliver RF ablation energy. Before powering up an RF generator or applying RF energy, disconnect the cryoablation catheter from the CryoConsole™ system. The use of fluoroscopy during ablation procedures presents the potential for significant X-ray exposure to both patients and laboratory staff. Give careful consideration before using the device in pregnant women.

    Catheter handling: 

    • Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade.
    • Do not use excessive force to advance or withdraw the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened.
    • Straighten the cooling segment before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or cooling segment.
    • Catheter advancement should be performed under fluoroscopic guidance or other appropriate visualization technique.

    Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole™ system and catheters. The Freezor™ Xtra catheter has not been evaluated for safety and compatibility in the magnetic resonance (MR) environment. Scanning a patient during the use of this device may result in patient injury. The Medtronic cryoablation catheters, refrigerant tanks, and other Medtronic CryoConsole™ components should only be used with the Medtronic CryoConsole™ system. If the sterile packaging or catheter is damaged, do not use the catheter. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. Disconnect the catheter’s electrical connection prior to cardioversion/defibrillation. Cryoablation involving coronary vessels with liquid nitrous oxide systems has been associated with subsequent clinically significant arterial stenosis. Care should be taken to minimize unnecessary contact with coronary vessels during cryoablation.

    Avoid positioning the catheter around the chordae tendineae, as this increases the likelihood of catheter entrapment within the heart. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing endocardial right-sided procedures. This equipment should be used only by physicians that perform cardiac ablation.

    Potential Complications

    Potential complications that may be associated with cardiac catheterization and ablation listed alphabetically below include, but are not limited to: Access site complications including, hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage; arrhythmias (such as atrial fibrillation, atrial flutter, tachycardia); cardiac arrest and/or death; chest discomfort, pain or pressure; coronary artery spasm/stenosis; damage to heart tissue or vasculature; endocarditis; entrapment; heart block, requiring permanent pacemaker; hemothorax; infection; perforation of venous, cardiac or surrounding tissue, pericardial effusion, tamponade; pericarditis; phrenic nerve injury; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; stroke; tissue infarction (such as myocardial infarction or renal infarction); thrombus; transient ischemic attack; vagal nerve injury (such as gastroparesis); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518.

    Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

    Back to top

    Nitron CryoConsole™ Cardiac Cryoablation System ISW

    Intended use

    The Nitron CryoConsole™ (the console), together with its components and specified catheters, is for use in performing cardiac ablation procedures.

    Contraindications

    See the technical manual for the compatible Medtronic catheter being used.

    Warnings and precautions

    These warnings apply in general to using the Nitron CryoConsole™ for cardiac cryoablation. Refer to the technical manual for console-compatible catheters for more information related to catheter use.

    • Connected electrophysiology (EP) lab equipment. Any equipment (e.g., EP recording system, HDMI) connected to the upper rear connection panel or to the auto connection box ECG cable receptacle of the device shall be IEC 60601-1 compliant or have a 60601-1-compliant isolation transformer on the interconnect cable between the Nitron CryoConsole™ and the EP lab equipment.
    • Electric shock. To avoid risk of electric shock, this equipment must only be connected to a supply main with protective earth.
    • Cryoadhesion. Do not pull on the catheter, sheath, umbilical cables, or console while the catheter is frozen to the tissue, as this may lead to tissue injury.
    • Improper connection. Do not connect a cryoablation catheter to a radiofrequency (RF) generator or use it to deliver RF energy. Doing this may cause catheter malfunction or patient harm.
    • Other accessories, transducers, and cables. Use of accessories, transducers, and cables other than those specified or provided by the manufacturer of this equipment could result in increased electromagnetic emissions or decreased electromagnetic immunity of this equipment and result in improper operation.

    The console meets the requirements of IEC 60601-1. It is the user’s responsibility after installation to verify and ensure that the console meets the applicable local electrical safety requirements. Perform cryoablation procedures only within the environmental parameters. Cryoablation procedures should be performed only in an electrophysiology facility by or under the supervision of physicians trained in cryoablation.  Do not modify this equipment. Modifications may reduce system effectiveness and impact patient health. The system must be installed by a qualified/trained Medtronic representative. All information technology equipment that is attached to the console must be approved by a third party to the requirements of UL 1950 or EN 60950. Minimize exposure to nitrous oxide to prevent short-term behavioral and long-term reproductive health effects.  The console and its accessories have not been evaluated for safety and compatibility in the magnetic resonance (MR) environment and are unknown which may lead to patient injury. Use only compatible Medtronic cryoablation catheters and components and Medtronic-provided refrigerant tanks with the console. The safety and use of other catheters or components has not been tested.

    Potential adverse events

    Potential adverse events associated with console procedures include, but are not limited to, the following conditions:

    • Electric shock
    • Foreign body/biological reaction
    • Long-term reproductive issues
    • Thermal injury

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at  800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    PulseSelect™ Pulsed Field Ablation System ISW

    Indications (or intended use)

    The PulseSelect™ pulsed field ablation (PFA) system is indicated for use in cardiac electrophysiological mapping (stimulation and recording) and for treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation or persistent atrial fibrillation (episode duration less than one year).

    Contraindications

    The PulseSelect™ PFA loop catheter is contraindicated for use in patients with the following conditions:

    • Active systemic infections
    • A known sensitivity to Heparin
    • Blood clotting abnormalities
    • Permanently implanted metallic objects in the left atrium

    The catheter is also contraindicated in conditions where the manipulation of the catheter within the heart would be unsafe, such as intracardiac mural thrombus.

    The catheter is not recommended for use in patients who cannot undergo standard anticoagulation protocol for a left-sided cardiac procedure, or who have had a recent coagulopathy or embolic event.

    Warnings and precautions

    To reduce the possibility of hazards associated with use of the PulseSelect™ PFA loop catheter: 

    • Use the catheter only in the recommended anatomical location.
    • Maintain the catheter position during the ablation.
    • If coughing occurs, reposition the catheter more proximally and review sedation management.
    • Ensure electrodes are not in contact with any metal during ablations (for example the guide wire).
    • Maintain substantially circular array to ensure uniform field distribution.
    • If the electrode array is deployed to deliver ablation energy, avoid continuing to move the slide control forward to prevent the guide wire lumen from coming too close to the electrode array.

    It is recommended that the array be captured while it is submerged to help reduce the possibility of air becoming entrapped around the electrode array during capture and catheter insertion.

    Catheter integrity

    Use care to avoid damage to the catheter.

    • Do not bend or kink the leading end of the catheter. Doing so could cause damage to the catheter lumen and make it unusable.
    • Monitor the catheter throughout the procedure. If a flash is observed in the luer, replace the catheter immediately.

    Electrode-electrode contact

    Avoid contact between electrodes. Contact between electrodes may create a short circuit.

    Embolism risk

    Introducing any catheter or sheath into the circulatory system entails the risk of air, gas, or thromboembolism, which can occlude vessels and lead to tissue infarction with serious consequences.

    • Avoid unnecessary catheter exchanges to minimize sheath-related embolic events.
    • Always advance and withdraw components slowly to minimize the vacuum created and the risk of air embolism.
    • Aspirate and flush the sheath frequently to help minimize the potential for embolic events resulting from the introduction of air or clot formation within the sheath.

    Fluoroscopy use during catheter placement

    Only perform catheter ablation after giving adequate attention to the potential radiation exposure associated with the procedure and taking steps to minimize this exposure. Give careful consideration before using the device in pregnant women.

    For single use only

    The PFA catheter is intended only to be used once for a single patient. Do not reuse, reprocess, or resterilize the PFA catheter.

    Careful manipulation of the catheter is necessary to avoid cardiac damage, perforation, or tamponade.

    • Do not use excessive force to advance, withdraw, or rotate the catheter, especially if resistance is encountered. Excessive force may lead to catheter damage and blood loss.
    • Use imaging guidance during catheter advancement, manipulation, and placement.
    • Vascular perforation is an inherent risk of catheter placement.
    • Performing ablation with the PFA catheter array inside the sheath may result in damage to the array or the sheath and should be avoided.
    • Performing steering manipulation with the PFA catheter array inside the sheath may result in damage to the catheter steering mechanism or the sheath and should be avoided.
    • The PFA generator is capable of delivering significant energy. Do not touch the ablation electrodes of the PFA catheter while operating the generator.
    • If the system is to be tested outside of the body, the electrode array must be immersed in saline solution in a plastic container. Never test PFA delivery in direct contact with skin.

    Use of imaging during catheter manipulation and placement is strongly advised. Manipulating the catheter without imaging may result in damage to cardiac and vascular structures.

    Other devices, wires, or catheters

    Avoid catheter entanglement with other devices, wires, or catheters, for example, intracardiac echo catheters. Failure to do so may increase the risk of entrapment of the array or damage to the array, which may affect retrieval of the device into the transseptal sheath.

    Phrenic nerve injury

    To reduce the potential for phrenic nerve injury, assess for proximity of the ablation catheter to the nerve using an appropriate technique such as pacing for local phrenic nerve capture or using the test pulse feature before ablation. Stop ablation immediately if phrenic nerve impairment is observed and assess for injury.

    Sheath and guide wire required

    Do not attempt to advance or withdraw the catheter through the vasculature without the use of a sheath and guide wire, as it may result in damage to cardiac and vascular structures.

    Implanted devices, such as pacemakers and implantable cardioverter-defibrillators (ICDs), may be adversely affected by PFA energy.

    • Keep external sources of pacing and defibrillation available during ablation.
    • Program pacemaker sensing parameters to asynchronous pacing to ensure that PFA energy is not sensed as an intrinsic event.
    • Deactivate ICD detection during the delivery of PFA energy.
    • Perform complete implantable device testing before and after ablation.
    • Monitor surface and intracardiac electrograms or vital signs during PFA energy delivery to assess for device interaction. Take appropriate action if any interaction is detected.
    • Refer to the appropriate implantable device technical manual for additional information.

    Electrical safety requirements

    The PFA generator meets the requirements of IEC 60601-1. It is the user’s responsibility after installation to verify and ensure that the generator meets the applicable local electrical safety requirements.

    Electric shock

    To avoid risk of electric shock, this equipment must only be connected to a supply main with protective earth.

    Electromagnetic interference (EMI) radiated

    The generator emits energy during ablation at a frequency level that may cause EMI with unshielded electronic equipment. To minimize EMI, the generator should be moved away from any other electronic device. If EMI is apparent during the application of energy, EMI may be reduced by repositioning the generator or other equipment.

    Electromagnetic interference (EMI) susceptibility

    The generator has been designed to minimize EMI. If interference should occur, move the generator away from the device generating the interference or place the generator at a different angle.

    Leakage current from connected devices

    Use only isolated equipment (IEC 60601-1 Type CF equipment or equivalent) with the PFA system and catheters, or patient injury or death may occur.

    Potential adverse events or potential complications

    Potential adverse events associated with cardiac catheter ablation procedures include, but are not limited to, the following conditions:

    • Access site complications (such as, bruising, ecchymosis, arteriovenous fistula, hematoma, pseudoaneurysm)
    • Anemia
    • Arrhythmias, proarrhythmia (such as, atrial flutter, bradycardia, heart block, tachycardia)
    • Bleeding, possibly requiring transfusion
    • Bruising
    • Cardiopulmonary arrest
    • Perforation of the heart or other organs during transseptal puncture or other procedures
    • Cardiac tamponade
    • Catheter entrapment in cardiac structures requiring intervention
    • Cerebrovascular accident such as stroke, transient ischemic attack (TIA)
    • Chest discomfort, pain, or pressure
    • Collateral damage to the conduction system or coronary vasculature
    • Cough
    • Death
    • Embolism
    • Esophageal damage (including atrial esophageal fistula)
    • Hemoptysis
    • Hypotension
    • Hypertension
    • Infections (such as, sepsis)
    • Myocardial infarction or ischemia
    • Nerve injury or nerve damage (for example phrenic nerve injury)
    • Pericarditis or endocarditis
    • Pericardial effusion
    • Pneumothorax
    • Pulmonary edema
    • Pulmonary vein dissection
    • Pulmonary vein stenosis
    • Radiation injury or damage and late malignancy
    • Skin laceration or puncture
    • Sore throat
    • Unintended complete or incomplete atrioventricular node (AV-Node) or sinus node block or damage
    • Valvular insufficiency or damage.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    PulseSelect™ pulsed field ablation system

    The PulseSelect™ pulsed field ablation (PFA) system is a cardiac ablation system that enables both mapping and precise lesion delivery using biphasic waveform optimization.

    Learn more

    To view the indications, safety, and warnings, scroll down or click on one of the links below to jump you down the page to that product.

    Achieve Advance™ mapping catheter ISW

    Indications (or intended use)

    The Achieve Advance™ Mapping Catheter is indicated for multiple electrode electrophysiological mapping of the cardiac structures of the heart, i.e., recording or stimulation only. The Achieve Advance™ mapping catheter is designed to obtain electrograms in the atrial regions of the heart.

    Contraindications

    The catheter is contraindicated as follows: 1) For use as an ablation device, 2) For use with transseptal sheaths featuring side holes larger than 1.00 mm (0.04 in) in diameter, 3) Retrograde approach.

    Electrophysiology studies are contraindicated when the patient’s underlying cardiac disease makes it likely that induced arrhythmias will be extremely difficult to terminate and carry a high risk of death, as in the following conditions: An active systemic infection, Left atrial thrombus, Pulmonary vein stents, Prosthetic heart valve (tissue or mechanical), Myxoma, Interatrial baffle or patch, Conditions where the manipulation of the catheter within the heart would be unsafe, Acute myocardial infarction.

    Warnings and precautions

    This catheter is intended only to be used once for a single patient. Do not reuse, reprocess, or resterilize these devices for purpose of reuse. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device or create a risk of contamination of the device that could result in patient injury, illness, or death. This equipment should be used only by or under the supervision of physicians trained in cardiac catheterization procedures. If the sterile packaging of the device is damaged, do not use. Do not connect the mapping catheter to a radiofrequency (RF) generator or use it to deliver RF energy.

    Use of fluoroscopy during catheter manipulation and placement is strongly advised. Take all appropriate measures to minimize x-ray exposure to both patients and clinical staff.

    Avoid positioning the catheter around the chordae tendineae as this increases the likelihood of catheter entrapment within the heart. Avoid catheter entanglement with other catheters, devices, or wires. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Introducing any catheter into the circulatory system entails the risk of air or gas embolism, which can occlude vessels and lead to tissue infarction with serious consequences.

    Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade. Do not use excessive force to advance or withdraw the catheter, especially if resistance is encountered. Do not use the catheter if it is kinked, damaged, or cannot be straightened. Bending or kinking the catheter shaft may compromise the structural integrity of the device and increase the risk of catheter failure. Use only isolated equipment (IEC 606011 Type CF equipment, or equivalent) with the mapping catheter. Do not allow the patient to contact grounded equipment that might produce electrical current leakage during ablation or DCCV (Direct Current CardioVersion). Disconnect the catheter from the catheter connecting cable prior to cardioversion/defibrillation. Do not touch the patient or the catheter during cardioversion/defibrillation.

    Use the mapping catheter only with the Medtronic catheter connecting cable Model 2ACHC, and a compatible mating device with a minimum internal diameter of 1.12 mm (0.044 in) and standard 9 Fr hemostasis valve. The mapping catheter is compatible for use with, and may be used to support and position, all catheters in the Medtronic Arctic Front CryoAblation Catheter family. Cardiac catheterization procedures should be performed only in a fully equipped electrophysiology laboratory. Do not immerse the electrical connectors in fluids or solvents. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided and transseptal cardiac procedures. Always rotate the mapping catheter in a clockwise direction to prevent tissue damage. Keep in a dry location away from heat and all sources of light. Exposure to light may cause damage to the catheter. Do not expose the catheter to organic solvents such as alcohol.

    Potential adverse events or potential complications

    Potential adverse events associated with cardiac catheter procedures include, but are not limited to the following conditions: Access site vessel occlusion; Allergic reaction to x-ray contrast media; Arrhythmias, proarrhythmia; Arteriovenous fistula; Bleeding related to anticoagulation; Bradycardia; Cardiac perforation of the heart or other organs during transseptal puncture or other procedures; Cardiac tamponade; Cardiac thromboembolism; Cerebrovascular accident (CVA) or transient ischemic attack (TIA); Chest discomfort; Chronic cough; Death; Dislodgement of implantable cardioverter defibrillator (ICD) or permanent pacing leads; Fever; Heart failure; Hematoma; Hemoptysis; High creatinine phosphokinase or troponin level; Hypotension; Infections; Mitral valve trauma; Myocardial infarction or ischemia; Obstruction, perforation, damage, or spasm of the vascular system including the coronary circulation system; Pericarditis or endocarditis; Pleural or pericardial effusion; Pneumonia; Pulmonary embolism; Pulmonary infiltrates; Pulmonary vein narrowing or stenosis; Pseudoaneurysm in groin; Radiation injury or damage and late malignancy; Respiratory depression; Retroperitoneal bleed; Thrombotic or embolic events; Valvular insufficiency or damage; Vasovagal reaction.

    Refer to the device manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Achieve™ mapping catheter ISW

    Indications (or intended use)

    The Achieve™ Mapping Catheter is indicated for multiple electrode electrophysiological mapping of the cardiac structures of the heart, i.e., recording or stimulation only. The Achieve Mapping Catheter is designed to obtain electrograms in the atrial regions of the heart.

    Contraindications

    The catheter is contraindicated as follows: 1) For use as an ablation device, 2) For use with transseptal sheaths featuring side holes larger than 1.00 mm in diameter, 3) Retrograde approach

    Electrophysiology studies are contraindicated when the patient’s underlying cardiac disease makes it likely that induced arrhythmias will be extremely difficult to terminate and carry a high risk of death, as in the following conditions: An active systemic infection, Left atrial thrombus, Pulmonary vein stents, Prosthetic heart valve (tissue or mechanical), Myxoma, Interatrial baffle or patch, Conditions where the manipulation of the catheter within the heart would be unsafe, Acute myocardial infarction

    Warnings and precautions

    This catheter is intended only to be used once for a single patient. Do not reuse, reprocess, or resterilize these devices for purpose of reuse. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device or create a risk of contamination of the device that could result in patient injury, illness, or death. This equipment should be used only by or under the supervision of physicians trained in cardiac catheterization procedures. If the sterile packaging of the device is damaged, do not use. Do not connect the Achieve Mapping Catheter to a radiofrequency (RF) generator or use it to deliver RF energy.

    Use of fluoroscopy during catheter manipulation and placement is strongly advised. Take all appropriate measures to minimize x-ray exposure to both patients and clinical staff.

    Avoid positioning the catheter around the chordae tendineae as this increases the likelihood of catheter entrapment within the heart. Avoid catheter entanglement with other catheters, devices, or wires. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue).

    Introducing any catheter into the circulatory system entails the risk of air or gas embolism, which can occlude vessels and lead to tissue infarction with serious consequences.

    Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade. Do not use excessive force to advance or withdraw the catheter, especially if resistance is encountered. Do not use the catheter if it is kinked, damaged, or cannot be straightened. Bending or kinking the catheter shaft may compromise the structural integrity of the device and increase the risk of catheter failure. Use only isolated equipment (IEC 60601 Type CF equipment, or equivalent) with the Achieve Mapping Catheter. Do not allow the patient to contact grounded equipment that might produce electrical current leakage during ablation or DCCV (Direct Current CardioVersion). Do not allow any exposed metal portion of the shaft to contact grounded equipment.  Remove the catheter from the patient prior to cardioversion/defibrillation. Do not touch the patient or the catheter during cardioversion/defibrillation. Use the Achieve Mapping Catheter only with Medtronic Achieve Electrical Cable, suitable compatible mating device with a minimum internal diameter of 1.3 mm (0.049”) and standard 9F hemostasis valve. The Achieve Mapping Catheter is compatible for use with the Medtronic Arctic Front CryoAblation Catheter, and may be used to support and position the Arctic Front Catheter. Cardiac catheterization procedures should be performed only in a fully equipped electrophysiology laboratory. Do not immerse the electrical connectors in fluids or solvents. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided and transseptal cardiac procedures. Always rotate the Achieve Mapping Catheter in a clockwise direction to prevent tissue damage. Keep in a dry location away from heat and sunlight. Do not expose the catheter to organic solvents such as alcohol.

    Potential adverse events or potential complications

    Potential adverse events associated with cardiac catheter procedures include, but are not

    limited to the following conditions: Access site vessel occlusion; Allergic reaction to x-ray contrast media; Arrhythmias, proarrhythmia; Arteriovenous fistula; Bleeding related to anticoagulation; Bradycardia; Cardiac perforation of the heart or other organs during transseptal puncture or other procedures; Cardiac tamponade; Cardiac thromboembolism; Cerebrovascular accident (CVA) or transient ischemic attack (TIA); Chest discomfort; Chronic cough; Death; Dislodgement of implantable cardioverter; defibrillator (ICD) or permanent pacing leads; Fever; Heart failure; Hematoma; Hemoptysis; High creatinine phosphokinase or troponin level; Hypotension; Infections; Mitral valve trauma; Myocardial infarction or ischemia; Obstruction, perforation, damage, or spasm of the vascular system including the coronary circulation system; Pericarditis or endocarditis; Pleural or pericardial effusion; Pneumonia; Pulmonary embolism; Pulmonary infiltrates; Pulmonary vein narrowing or stenosis; Pseudoaneurysm in groin; Radiation injury or damage and late malignancy; Respiratory depression; Retroperitoneal bleed; Thrombotic or embolic events; Valvular insufficiency or damage; Vasovagal reaction.

    Refer to the device manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Affera™ Mapping and Ablation System ISW

    Affera™ Mapping and Ablation System

    Indications

    The Sphere-9 catheter is indicated for use in cardiac electrophysiological mapping (stimulation and electrogram recording) and for treatment of drug refractory, recurrent, symptomatic persistent atrial fibrillation (episode duration less than 1 year) and radiofrequency ablation of cavotricuspid isthmus dependent atrial flutter when used with the Affera mapping system.

    The Affera Mapping System is intended to be used for catheter-based cardiac electrophysiological mapping. The mapping system allows pacing and real-time visualization of compatible catheters as well as display of cardiac maps in multiple formats. The acquired patient signals, including intracardiac electrograms, may also be recorded and displayed on the system’s display screen.

    Contraindications

    Do not use this device under the following circumstances:

    • In patients with an active systemic infection.
    • In patients who have had cardiac surgery in the preceding eight weeks, as the risk of perforation may increase.
    • In patients with intracardiac thrombus or myxoma, as the catheter may precipitate an embolus.
    • In coronary vessels with diameter smaller than the expandable ablation electrode, as the catheter may damage the coronary vessels.
    • In patients with prosthetic valves, as the catheter may damage the prosthesis.
    • Using the transaortic retrograde approach in patients who have had aortic valve replacement.
    • Using the transseptal approach in patients with an interatrial baffle or patch, as the opening could persist and result in an iatrogenic atrial shunt.

    Warnings and Precautions

    Do not reuse, reprocess, or resterilize devices labeled single-use only. Only use with compatible devices listed in the IFU. The Affera Mapping System requires use of a disposable Location Reference Patch Kit to detect patient displacement and respiratory motion.

    Treatment location should be confirmed using alternative techniques (e.g. fluoroscopy, intracardiac electrograms, intracardiac echocardiography) before treatment.  

    A connection to a compatible cardiac stimulator is allowed provided the stimulator is electrically isolated or physically disconnected when RF or PF energy is applied to the patient, outputs of the generator and stimulator must be isolated to prevent patient injury or damage to equipment.

    The pacing functionality in the Affera Mapping System is not a life support device and is for diagnostic purposes only. Pacing may induce intentional or unintentional life-threatening cardiac arrhythmias.

    Intravenous heparin must be used to reduce the likelihood of thromboemboli developing during the procedure. Patient injury may result from excessive delivery of fluids. Anticoagulation treatment should adhere to consensus guidelines,

    Avoid steering the Sphere-9 catheter near other catheters to reduce the possibility of the catheters becoming entangled. Cardiac devices may be damaged by energy delivery.  Catheter interactions with implantable leads may result in lead dislodgement or possible thrombus.

    Cardiac ablation may induce intentional or unintentional life-threatening cardiac arrhythmias.

    Care should be taken when ablating near sensitive structures (i.e., conduction system, coronary arteries) as unintended patient harm may occur. Catheter entrapment within the heart is a possible complication of cardiac ablation procedures that could necessitate surgical intervention.

    The Affera Mapping and Ablation System has not been evaluated for safety and compatibility in the magnetic resonance (MR) environment. System operation may be temporarily interrupted if exposed to excessive external electromagnetic disturbance or ESD.

    Potential Adverse Events or Potential Complications

    Atrioesophageal fistula, Cardiac perforation / tamponade, Cardiac or respiratory arrest, Stroke Conduction system injury, Coronary artery spasm / occlusion / stenosis, Damage / dislodgement to ICD or implantable pacemaker, Death, Embolism, Hemoptysis, Infection, Myocardial infarction, Phrenic nerve palsy / paralysis, Pulmonary edema, Pulmonary vein stenosis, Valve damage, Vessel dissection

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_85060

    Back to top

    Arctic Front Advance™ Cardiac Cryoablation Catheter ISW

    Indications (or intended use)

    The Arctic Front Advance™ and Arctic Front Advance Pro™ cardiac cryoablation catheters are indicated for the treatment of drug refractory recurrent symptomatic paroxysmal and persistent atrial fibrillation (episode duration less than 6 months).

    The Arctic Front Advance™ and Arctic Front Advance Pro™ cardiac cryoablation catheters are also indicated for the treatment of recurrent symptomatic paroxysmal atrial fibrillation as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy.

    Contraindications

    Use of the cryoballoon is contraindicated: 1) In the ventricle because of the danger of catheter entrapment in the chordae tendineae, 2) In patients with one or more pulmonary vein stents, 3) In patients with cryoglobulinemia, 4) In patients with active systemic infections, and 5) In conditions where the manipulation of the catheter within the heart would be unsafe (e.g., intracardiacmural thrombus).

    Warnings and precautions

    Do not reprocess or resterilize this device for the purpose of reuse. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided and transseptal cardiac procedures. The Arctic Front family of cryoballoons have not been studied for the safety of changes in anticoagulation therapy in patients with paroxysmal atrial fibrillation. Atrial fibrillation patients with significant left ventricular dysfunction, advanced heart failure, severe left atrial enlargement or significant structural heart disease were excluded from the clinical trials that supported the approved indications. For baseline demographics and clinical characteristics of the patients studied, please see the Clinical Summaries listed in the instructions for use. Do not inflate the balloon inside the sheath or while the catheter is positioned inside a pulmonary vein. Always inflate the balloon in the atrium and then position it at the pulmonary vein ostium. If the balloon cannot be inflated or deflated using the CryoConsole, have a Manual Retraction Kit on hand during the procedure. (Refer to the CryoConsole Operator’s Manual for more detailed instructions on the Manual Retraction Kit). Disconnect the catheter’s electrical connection before cardioversion or defibrillation.

    Catheter handling:

    • Use extreme care when manipulating the catheter.
    • Do not use excessive force to advance, withdraw, or rotate the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened.
    • If the catheter becomes kinked or damaged while in the patient, remove it and use a new catheter.
    • Straighten the shaft before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or balloon segment.
    • Catheter advancement should be performed using fluoroscopy or other appropriate techniques.
    • Do not position the cryoballoon catheter within the tubular portion of the pulmonary vein.

    Do not advance the balloon beyond the guide wire or circular mapping catheter to reduce the risk of tissue damage. Ensure that the guide wire or circular mapping catheter is inserted into the catheter and through the balloon portion for adequate support during vascular access insertion. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Do not pull on the balloon catheter, circular mapping catheter, sheath, umbilical cables, or CryoConsole while the balloon catheter or circular mapping catheter are frozen to tissue. Before moving these components, use appropriate techniques to ensure that the balloon catheter and circular mapping catheter are not adhered to tissue.

    Always advance and withdraw components slowly to minimize the vacuum created and therefore minimize the risk of air embolism. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. The use of fluoroscopy during catheter ablation procedures presents the potential for significant x-ray exposure to both patients and laboratory staff. Give careful consideration before using the device in pregnant women. Flush the guide wire lumen before initial insertion and then frequently throughout the procedure to prevent coagulation of blood in the lumen. Flush the guide wire lumen with saline after each contrast injection. Use only 0.081 cm (0.032 in) or 0.089 cm (0.035 in) guide wires with the catheter. Do not connect the cryoablation catheter to a radiofrequency (RF) generator or use it to deliver RF energy. Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole and catheters. Avoid catheter entanglement with other catheters, devices, or wires.

    Before powering up an RF generator or applying RF energy, disconnect the cryoablation catheter from the CryoConsole. Always deflate the balloon and withdraw the balloon into the transseptal sheath before removing the balloon from the left atrium. If the sterile packaging or catheter is damaged, do not use the catheter. Use only Medtronic cryoablation catheters, 12 FR inner diameter sheaths, circular mapping catheters, refrigerant tanks, and components with the CryoConsole. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. This cryoablation system should be performed only in a fully equipped facility under the supervision of physicians trained in cryoablation procedures.

    Potential adverse events or potential complications

    Potential complications/adverse events from cardiac catheterization and ablation include, but are not limited to, the following: Access site complications (e.g., bruising, ecchymosis); Anemia; Anxiety; Arrhythmia (e.g., atrial flutter, bradycardia, heart block, tachycardia); Back pain; Bleeding from puncture sites; Bronchial constriction; Bronchial fistula; Bronchitis; Bruising; Cardiac tamponade; Cardiopulmonary arrest; Cerebral vascular accident; Chest discomfort/pain/pressure; Cold feeling; Coronary artery spasm; Cough; Death; Diarrhea; Dizziness; Embolism; Esophageal damage (including esophageal fistula); Fatigue; Fever; Headache; Hemoptysis; Hypotension/Hypertension; Infection (e.g., pericarditis, sepsis, urinary); Lightheadedness; Myocardial infarction; Nausea/vomiting; Perforation; Pericardial effusion; Phrenic nerve injury; Pleural effusion; Pneumonia; Pneumothorax; Pseudoaneurysm; Pulmonary edema; Pulmonary hemorrhage; Pulmonary vein dissection; Pulmonary vein stenosis; Shivering; Shortness of breath; Sore throat; Transient ischemic attack; Vagal nerve injury (e.g., gastroparesis); Vasovagal reaction; Visual Changes (e.g., blurred vision).

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.
     

    Back to top

    CardioInsight™ Mapping System ISW

    Indications

    The CardioInsight™ cardiac mapping system is intended for acquisition, analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.

    Contraindications

    There are no known contraindications.

    Warnings and precautions

    Cardiac mapping system

    Warnings
    • Do not modify the attachment plug or use a power adapter. This could cause an electrical hazard. If you require a different electrical socket plug, contact your local Medtronic Representative. CardioInsight™ must always be connected to the power source properly.
    • Ensure that all power sources are appropriately rated and are properly grounded or earthed. If the CardioInsight™ system is not properly grounded or earthed, it becomes a possible electric shock hazard. Protection against electrical shock has been provided through an isolation transformer and chassis grounding via a plug to an appropriate power source.
    • Electroanatomical mapping with CardioInsight™ should ONLY be performed after the risks of the entire procedure, including radiation exposure and time required for signal collection, have been adequately considered for each patient.
    Precautions
    • The installation and setup of CardioInsight™ and its software should ONLY be performed by trained Medtronic personnel.
    • Portable or mobile RF communications equipment may affect CardioInsight™.
    • Extension cords and electrical power bars should NEVER be used with CardioInsight™.
    • CardioInsight™ should not be connected to any equipment that is not supported by or part of the system.
    • The isolation transformer should NEVER be placed on the floor for use.
    • Do not stack other equipment on the mapping amplifier or the system cart.
    • Do not use the cart for any other purpose than storing and using CardioInsight™.
    • The workstation that is supplied as part of CardioInsight™ is not intended for use without the isolation transformer.
    • Devices that connect to CardioInsight™ via Universal Serial Bus (USB) such as an external hard drive should be used ONLY after approval by Medtronic as they may introduce computer viruses.
    • Installation of software not authorized by Medtronic on the CardioInsight™ workstation can cause the system to display inaccurate results or otherwise malfunction, and will void the terms of the product warranty.
    • Do not replace the amplifier fuses while the system is in use or connected to the patient.
    • Assembly, repair, and modifications of the system over its service life will be evaluated based on the requirements of IEC 60601-1 prior to implementation.
    • CardioInsight™ should ONLY be used by trained personnel or under the guidance of trained Medtronic personnel.
    • CardioInsight™ should ONLY be used in an institution’s environment.
    • Do not use CardioInsight™ in the presence of flammable anesthetic mixtures with air, oxygen, or nitrous oxide.
    • The CardioInsight™ acquisition should be performed on the same day as the completion of the CT scan.
    • The system cables, including the Sensor Array signal cables and patient ground reference cable are provided non-sterile. DO NOT sterilize the cables.

    Sensor array

    Warnings
    • DO NOT use the Sensor Array if the patient has sensitivity, open sores, or a severe skin condition or disease of the thorax area.
    • DO NOT perform magnetic resonance (MR) imaging with the Sensor Array on the patient. The Sensor Array may cause harm to the patient if used in MR imaging. Remove Sensor Array prior to performing MR imaging studies.
    • Remove or peel back front Sensor Array panels prior to using an external defibrillator on the patient.
    Precautions
    • The Sensor Array should only be connected to the CardioInsight™ Cardiac Mapping System.
    • The Sensor Array is meant to be used only during computed tomography (CT) imaging procedures that use legally marketed CT scanners.
    • The CardioInsight™ acquisition should be performed on the same day as the completion of the CT scan. The Sensor Array should not be removed or repositioned between the CT scan and the acquisition.
    • The Sensor Array is not sterile and cannot be sterilized. Care should be taken to keep the Sensor Array outside of any sterile field.
    • DO NOT expose the Sensor Array to organic solvents such as alcohol. If an organic solvent is used on patient, allow to dry for at least one minute prior to applying Sensor Array.
    • DO NOT expose the Sensor Array and electrical connectors to fluids or solvents, except when following the cleaning instructions in the Operator’s Manual.
    • Store Sensor Array flat (parallel to the floor) with the correct side facing up, as labeled, according to the environmental storage conditions.
    • Store Sensor Array panels in their sealed protective pouches until use.
    • The Sensor Array is intended for single use ONLY. Reusing the Sensor Array may result in poor system performance or transmission of infection.
    • Panels from different Sensor Array sizes should NEVER be mixed and matched for use.
    • DO NOT cut or fold the circuitry on the Sensor Array.

    Potential Adverse Events

    None known


    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    DiamondTemp™ Ablation Catheter ISW

    Indications (intended use)

    The DiamondTemp™ ablation catheter is indicated for use in cardiac electrophysiological mapping (stimulation and recording) and for treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation when used in conjunction with the DiamondTemp™ RF generator and accessories (DiamondTemp™ catheter-to-RF generator cable, DiamondTemp™ GenConnect™ cable, DiamondTemp™ EGM cable, DiamondTemp™ irrigation pump, DiamondTemp™ irrigation tubing set) and compatible mapping system.

    Contraindications

    Use of the DiamondTemp™ catheter is contraindicated for: 1) patients with active systemic infection, 2) patients with prosthetic valves, 3) patients with intracardiac thrombus or myxoma or interatrial baffle or patch via transseptal approach, 4) patients unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation, 5) pregnant women and children < 18 years of age, and 6) patients who are hemodynamically unstable.

    Warnings and precautions

    Cardiac ablation procedures should be performed only by physicians trained in the techniques of radiofrequency (RF) catheter ablation in a fully equipped electrophysiology (EP) laboratory. The catheter is for single use only. Do not reprocess or resterilize. Reusing, reprocessing, or resterilizing may compromise the structural integrity of the device or lead to product failure, which may result in patient injury, illness, or death. Reuse, reprocessing, or resterilizing may also create a risk of contamination of the device. Contamination may lead to injury, illness, or death of the patient. Pacemakers, implantable cardioverter defibrillators (ICDs), and leads can be adversely affected by RF signals. ICDs should be deactivated prior to ablation, precautions should be taken when the catheter is in close proximity to leads, and complete system analysis should be performed after ablation. Long-term risks of RF ablation lesions have not been established. Ablation too close to the esophageal area can result in esophageal fistula. Ablation near the AV node can cause permanent or partial conduction block. To ensure proper operation of the tissue contact impedance measurement function, all four electrodes and six thermocouples on the catheter tip must protrude from the distal tip of the guiding sheath. Carefully monitor the tissue contact impedance before delivery of RF energy. Do not place the RF electrode in proximity to any other mapping or ablation electrodes, as this may cause inadvertent, ineffective, or unsafe tissue ablation and may increase chances of char, coagulum, or steam pops. Although a higher contact impedance value typically indicates acceptable tissue contact, and low contact impedance values typically indicate lack of tissue contact, caution should be exercised. Areas of previously ablated tissue may also display a low contact impedance value. Other parameters, such as EGM, fluoroscopic images, and intracardiac ultrasound should be monitored before deciding to apply RF. Stimulation of cardiac tissues caused by pacing stimulus or RF energy may lead to inadvertent induction of arrhythmias. These arrhythmias may require defibrillation that could also result in skin burns. Do not use the catheter for epicardial ablation. Using ablation parameters (such as temperature set-point, ablation duration, or irrigation flow rate) other than those recommended by Medtronic may be hazardous to patients. Exercise caution and sound medical reasoning when deciding to deviate from recommended parameters. Perform catheter advancement under fluoroscopic guidance in conjunction with internal contact, electrograms, and impedance monitoring to minimize the risk of cardiac damage, perforation, or tamponade. Tip-to-tissue contact impedance is actively monitored only before and after ablation. During ablation, use caution when the temperature drops suddenly. A drop in temperature may be associated with loss of tissue contact. In case of steam pop or automatic shut off, discontinue RF energy. Remove the catheter for visual inspection and check for coagulum, charring, or other catheter defects.

    Manual prebending of the distal curve may damage the steering mechanism and may cause patient injury. Do not attempt ablation with the catheter without the use of the DiamondTemp™ irrigation pump and DiamondTemp™ generator and approved accessories. Do not attempt ablation without the use of the irrigation pump. Before attempting ablation, make sure the pump flow rate is at the minimum continuous flow and the pump is actively communicating with the generator. The potential adverse events that may be associated with ablation procedures can vary greatly in frequency and severity and may necessitate additional medical intervention, including surgery. Carefully review the specific indications, contraindications, warnings, precautions, and adverse events included with each DiamondTemp™ catheter, prior to use of the DiamondTemp™ generator or irrigation pump. The irrigation pump is designed for use only with sterile heparinized normal saline solution. Specified flow-rate accuracy may not be maintained when used with incompatible fluids or delivery devices. The air bubble detector is disabled during irrigation pump priming and purging functions. Do not prime or purge the catheter when it is inserted in the vasculature of the patient. Do not remove the irrigation tubing set from the irrigation pump while the tubing set is in-line with a catheter that is inside the patient. The DiamondTemp™ generator connection box E is to be used with the DiamondTemp™ ablation system and Ensite™ cardiac mapping and navigation systems configured to use NavX™ navigation technology. Use with other systems has not been assessed and may compromise patient or operator safety. Do not connect the generator connection box E to the Ensite™ amplifier with both the primary and secondary connectors. Only connect using one of the connector options.

    Potential adverse events or potential complications

    Potential complications/adverse events from cardiac catheterization and ablation include, but are not limited to, the following: abnormal vision; air embolism; anaphylaxis; anemia; aneurysm; angina; arrhythmia (including new or worsening of existing condition, or requiring cardioversion); arterial or venous thrombus; atrial septal defect; AV fistula; cardiac arrest; cardiac tamponade; catheter entrapment leading to valve or heart wall damage; catheter insertion site hematoma; chest pain (nonspecific); congestive heart failure exacerbation; component damage to ICD or pacemaker; coronary artery dissection; death; dislodgement of implantable device or permanent pacing lead; dizziness; embolic events, including infarction of other tissues, coronary, pulmonary, and bowel structures; endocarditis; esophageal damage or necrosis; exacerbation of COPD; exacerbation of pre-existing atrial fibrillation; fluid overload; gastroparesis or GI event; hemorrhage; hemothorax; hypotension; hypoxia; inadvertent AV block; infection; myocardial infarction; neck pain, back pain, or groin pain; palpitations; perforation (cardiac); pericardial effusion; pericarditis; peripheral venous thrombosis; phrenic nerve damage; pleural effusion; pneumonia; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary vein stenosis; radiation injury resulting in dermatitis, erythema, etc.; renal insufficiency or failure; respiratory failure; seizure; sepsis; skin burns; stroke or cerebrovascular incident; syncope; thromboembolic event; transient ischemic attack; vasovagal reaction; ventricular arrhythmia; vessel wall or valvular damage or insufficiency.

    See the appropriate product device manuals for detailed information regarding the RF ablation procedure, indications (or intended use), contraindications, warnings, precautions, and potential complications/adverse events. See the appropriate electronic instructions for use (eIFUs) for the DiamondTemp™ catheters, DiamondTemp™ RF generator, DiamondTemp™ irrigation pump, DiamondTemp™ irrigation tubing set, DiamondTemp™ catheter-to-RF generator cable, DiamondTemp™ GenConnect™ cable, EGM cable, and DiamondTemp™ generator connection box E. or further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Flexcath Advance™ Steerable Sheath ISW

    The FlexCath Advance™ steerable sheath is intended for percutaneous catheter introduction into the vasculature and into the chambers of the heart. The sheath deflection facilitates catheter positioning.

    Contraindications

    The FlexCath Advance™ steerable sheath is contraindicated for placement in the left atrium or ventricle if:

    • The patient has an intra-atrial septal patch or has had other surgical intervention in or adjacent to the intra-atrial septum.
    • The patient has had a previous embolic event from the left side of the heart within two months of the procedure.
    • The patient has known or suspected atrial myxoma.

    The sheath should not be used to perform the transseptal puncture.

    Warnings/precautions

    This is a single-use sheath to be used in a single patient. Do not resterilize this sheath for purpose of reuse. Use this sheath with compatible Medtronic diagnostic and ablations catheters that are 10.5 Fr or smaller. Do not use the sheath if it is kinked or damaged. The sheath and dilator have not been tested for compatibility with transseptal needles. Administer appropriate levels of peri-procedural anticoagulation therapy, during and post-procedure anticoagulation therapy according to patient conditions and institutional standards. Introducing any catheter or sheath into the circulatory system entails the risk of air embolism, which can occlude vessels and lead to tissue infarction with serious consequences. To minimize the risk of air embolism, observe and remove any air prior to introducing the sheath and during the procedure. Remove the guide wire and dilator from the sheath or insert the catheter into the sheath before slowly aspirating and flushing the sheath. Minimize catheter exchanges and always advance and withdraw catheters slowly. Follow advancement or withdrawal of catheters with appropriate aspiration and flushing according to institutional standards or consensus statements. Connect to a continuous drip to minimize back-bleeding. Do not pass the sheath through a prosthetic heart valve (mechanical or tissue). The sheath may become trapped in the valve, damaging the valve and causing valvular insufficiency or premature failure of the prosthetic valve. Cardiac catheterization procedures should be performed only in a fully equipped facility. This sheath should be used only by, or under the supervision of, physicians trained in cardiac catheterization procedures. Use extreme care when manipulating the sheath. Do not use excessive force to advance or withdraw the sheath, especially if resistance is encountered.

    Potential adverse events or potential complications

    Potential adverse events associated with cannulation of the peripheral vasculature and intracardiac placement of the sheath and dilator may include the following conditions:

    Access site complications (hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage); air embolism; arrhythmia (atrial fibrillation, atrial flutter, tachycardia); cardiac arrest; chest discomfort, pain, or pressure; coronary artery spasm, dissection, thrombosis; death; endocarditis; heart block, requiring permanent pacemaker; hemothorax; myocardial infarction; perforation of venous cardiac or surrounding tissue; pericardial effusion, tamponade; pericarditis; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; atroke; thrombus; transient ischemic attack (TIA); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

    Back to top

    FlexCath Contour™ Steerable Sheath ISW

    Intended use

    The FlexCath Contour™ steerable sheath facilitates introducing various cardiovascular catheters into the heart.

    Indications for use

    The FlexCath Contour™ steerable sheath is indicated for percutaneous catheter, or transseptal needle introduction into the vasculature and into the chambers of the heart, including the left side of the heart through the interatrial septum. The sheath deflection facilitates device positioning.

    Contraindications

    The FlexCath Contour™ steerable sheath is contraindicated for placement in the left atrium or ventricle if:

    • The patient has an intra-atrial septal patch or has had other surgical intervention in or adjacent to the intra-atrial septum
    • The patient has had a previous embolic event from the left side of the heart within two months of the procedure
    • The patient has known or suspected atrial myxoma

    Compatible catheter sizes:

    • FlexCath Contour™ steerable device (10 Fr) 
      The sheath can be used with Medtronic diagnostic and ablation catheter sizes from 7 Fr (2.3 mm) up to 9.5 Fr (3.2 mm). 
    • FlexCath Contour™ steerable device (12 Fr) 
      The sheath can be used with Medtronic diagnostic and ablation catheter sizes from 7 Fr (2.3 mm) up to 10.5 Fr (3.5 mm).

    Warnings/precautions

    • This is a single-use sheath to be used in a single patient. Do not resterilize this sheath for purpose of reuse. 
    • The dilator is compatible with transseptal needles that are at least 89 cm in length and less than 21 gauge outer diameter. 
    • Do not use the sheath if it is kinked or damaged. 
    • Only physicians trained in left-sided catheterization should use this sheath during transseptal puncture.
    • Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided, right-sided, and transseptal cardiac procedures. 
    • Administer anticoagulation therapy during and post-procedure according to patient conditions and institutional standards. 
    • Introducing any catheter or sheath into the circulatory system entails the risk of air embolism, which can occlude vessels and lead to tissue infarction with serious consequences. 
    • To minimize the risk of air embolism, observe and remove any air prior to introducing the sheath and during the procedure. 
    • Do not advance the dilator or sheath through the interatrial septum without first confirming left atrial access to prevent advancing these components into an undesired location. 
    • Remove the guide wire and dilator from the sheath or insert the catheter into the sheath before slowly aspirating and flushing the sheath. 
    • Minimize catheter exchanges and always advance and withdraw catheters slowly. 
    • Follow advancement or withdrawal of catheters with appropriate aspiration and flushing according to institutional standards or consensus statements. 
    • Connect to a continuous drip to minimize back-bleeding. 
    • Do not pass the sheath through a prosthetic heart valve (mechanical or tissue). 
    • The sheath may become trapped in the valve, damaging the valve and causing valvular insufficiency or premature failure of the prosthetic valve. 
    • Cardiac catheterization procedures should be performed only in a fully equipped facility. 
    • This sheath should be used only by, or under the supervision of, physicians trained in cardiac catheterization procedures. 
    • Use extreme care when manipulating the sheath. 
    • Do not use excessive force to advance or withdraw the sheath, especially if resistance is encountered.
    • Only physicians trained in left-sided catheterization should use this sheath during transseptal puncture.

    Potential adverse events or potential complications

    • Potential adverse events associated with cannulation of the peripheral vasculature and intracardiac placement of the sheath and dilator may include the following conditions:
    • Access site complications (hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage)
    • Air embolism
    • Arrhythmia (such as atrial fibrillation, atrial flutter, heart block requiring permanent pacemaker, ventricular tachycardia)
    • Cardiac arrest
    • Chest discomfort, pain, or pressure
    • Coronary artery spasm
    • Damage to heart tissue or vasculature
    • Death
    • Endocarditis
    • Entrapment of the sheath within the patient
    • Hemothorax 
    • Latrogenic atrial septal defect (iASD)
    • Infection (such as pericarditis, sepsis, urinary)
    • Myocardial infarction
    • Perforation of venous, cardiac or surrounding tissue
    • Pericardial effusion, tamponade
    • Pericarditis
    • Pleural effusion
    • Pneumothorax
    • Pseudoaneurysm
    • Pulmonary edema
    • Pulmonary embolism
    • PV stenosis
    • Stroke
    • Thrombus
    • Transient ischemic attack (TIA)
    • Valve damage
    • Vasovagal reaction

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 and/or consult the Medtronic website at www. medtronic.com.

    Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

    FlexCath Cross™ Transseptal Solution ISW

    Prior to using these devices, please review the instructions for use for a complete list of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. FlexCath Cross™ devices are FDA cleared. Not all FlexCath Cross™ devices are CE marked.

    Back to top

    Freezor™ Cardiac Cryoablation Catheter ISW

    Freezor™ cardiac cryoablation catheter

    Indications

    The Freezor™ cardiac cryoablation catheter, CryoConsole™ system, and related accessories are indicated for the cryoablation of the conducting tissues of the heart in the treatment of adult and pediatric patients over two years of age, with atrioventricular nodal reentrant tachycardia (AVNRT).

    Contraindications

    This device is contraindicated in patients with active systemic infection, cryoglobulinemia, intracardiac mural thrombus, myxoma, interatrial baffle or patch.

    Warnings/Precautions

    Closely monitor AV conduction during cryo energy delivery near the AV node due to possible risk of complete atrioventricular (AV) block. Immediately terminate energy delivery if partial or complete AV block is noted. Cryoablation involving coronary vessels has been associated with subsequent clinically significant arterial stenosis. Care should be taken to minimize unnecessary contact with coronary vessels during cryoablation. Endotoxins may cause pyrogenic responses in patients including inflammation and fever which can result in anaphylactic shock and death. Caution should be used with regard to endotoxins in pediatric populations as standard endotoxin limits do not differentiate between adult and pediatric populations. Ethylene oxide residuals remaining after sterilization are known to cause a potential increase in a number of biological effects including irritation, organ damage, mutagenicity and carcinogenicity. Calculations for ethylene oxide and ethylene chlorohydrin residuals indicate that the risk of these effects may be increased in patients under 3.8 kg. Avoid catheter entanglement with other catheters devices or wires. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. Do not re-use, reprocess, or resterilize this device for purpose of reuse. This device is intended only to be used once for a single patient. The use of CryoMapping mode does not prevent injuries to the patient. CryoMapping mode is used to determine if the site is appropriate for ablation. The Freezor™ catheter contains a pressurized refrigerant during operation. Release of this gas into the circulatory system due to equipment failure or misuse could result in gas embolism. Do not pull on the catheter, sheath, umbilical cables, or console while the catheter tip is frozen to the tissue, as this may lead to tissue injury. Always advance and withdraw components slowly to minimize the vacuum created and therefore minimize the risk of air embolism. Do not connect the Freezor™ catheter to any radiofrequency (RF) generator or use the Freezor™ catheter to deliver RF ablation energy. Before powering up an RF generator of applying RF energy, disconnect the cryoablation catheter from the CryoConsole™ system. The use of fluoroscopy during catheter ablation procedures presents the potential for significant X-ray exposure to both patients and laboratory staff. Give careful consideration before using the device in pregnant women. Avoid positioning the catheter around the chordae tendineae, as this increases the likelihood of catheter entrapment within the heart. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue).

    Catheter handling: 

    • Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade. 
    • Do not use excessive force to advance, withdraw, the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened.
    • Straighten the cooling segment before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or cooling segment.
    • Catheter advancement should be performed under fluoroscopic guidance or other appropriate visualization technique.

    Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole™ system and catheters. The Medtronic cryoablation catheters, refrigerant tanks, and other Medtronic CryoConsole™ components should only be used with the Medtronic CryoConsole™ system. If the sterile packaging or catheter is damaged, do not use the catheter. This equipment should be used only by physicians that perform cardiac ablation. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. Disconnect the catheter’s electrical connection prior to cardioversion/defibrillation. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing right-sided procedures. The Freezor™ catheter has not been evaluated for safety and compatibility in the magnetic resonance (MR) environment. Scanning a patient during the use of this device may result in patient injury.

    Potential Complications

    Potential complications that may be associated with cardiac catheterization and ablation listed alphabetically below include, but are not limited to: Access site complications including, hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage; arrhythmias (such as atrial fibrillation, atrial flutter, tachycardia); cardiac arrest and/or death; chest discomfort, pain or pressure; coronary artery spasm/stenosis; damage to heart tissue or vasculature; endocarditis; entrapment; heart block, requiring permanent pacemaker; hemothorax; infection; perforation of venous, cardiac or surrounding tissue, pericardial effusion, tamponade; pericarditis; phrenic nerve injury; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; stroke; tissue infarction (such as myocardial infarction or renal infarction); thrombus; transient ischemic attack; vagal nerve injury (such as gastroparesis); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-238-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Freezor™ MAX cardiac cryoablation catheter

    Indications

    The Freezor™ MAX cardiac cryoablation catheter is used as an adjunctive device in the endocardial treatment of paroxysmal and persistent atrial fibrillation (episode duration less than six months) in conjunction with the Arctic Front™ family of cardiac cryoablation catheters for the following uses: 1) Gap cryoablation to complete electrical isolation of the pulmonary veins 2) Cryoablation of focal trigger sites and 3) Creation of ablation line between the inferior vena cava and the tricuspid valve.

    Contraindications

    Use of Freezor™ MAX cardiac cryoablation catheter is contraindicated in patients with active systemic infections, in patients with cryoglobulinemia, intracardiac mural thrombus, myxoma or interatrial baffle or patch. The Freezor™ MAX cardiac cryoablation catheter is also contraindicated in patients with a body mass under 4.4 kg.

    Warnings/Precautions

    Do not reuse or reprocess this device for purpose of reuse. This catheter is intended only to be used once for a single patient. Do not connect the cryoablation catheter to a radiofrequency (RF) generator or use it to deliver RF energy. Disconnect the catheter’s electrical connection prior to cardioversion/defibrillation.

    Catheter handling:

    • Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade.
    • Do not use excessive force to advance, withdraw the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened. Straighten the cooling segment before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or cooling segment.
    • Catheter advancement should be performed under fluoroscopic guidance or other appropriate visualization technique.

    Avoid positioning the catheter around the chordae tendineae. The catheter contains pressurized refrigerant during operation. Release of this gas into the circulatory system due to equipment failure or misuse could result in gas embolism. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Use adequate fluoroscopic visualization or other appropriate visualization technique during a transaortic approach to avoid placing the ablation catheter within the coronary vasculature. Do not pull on the catheter, sheath, umbilical cables, or console while the catheter is frozen to the tissue, as this may lead to tissue injury. Always advance and withdraw components slowly to minimize the vacuum created. Closely monitor AV conduction during cryo energy delivery near the AV node due to possible risk of complete atrioventricular block.

    Perform cryoablation procedures only within the environmental parameters. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. The use of fluoroscopy during catheter ablation procedures presents the potential for significant X-ray exposure to both patients and laboratory staff. Give careful consideration before using the catheter in pregnant women. Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole™ system and catheters. The safety of the catheter in the MR environment is unknown (such as any heating, migration, or image artifacts). Scanning a patient during the use of this device may result in patient injury. Avoid catheter entanglement with other catheters, devices, or wires. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. Before powering up an RF generator or applying RF energy, disconnect the cryoablation catheter from the CryoConsole™ system. If the device is damaged or the integrity of the sterilization barrier has been compromised, do not use the product. The Medtronic cryoablation catheters, refrigerant tanks, and other Medtronic CryoConsole™ components should only be used with the Medtronic CryoConsole™ system.

    The Freezor™ MAX catheter was not studied for safety of changes in anticoagulation therapy in patients with paroxysmal atrial fibrillation. This equipment should be used only by physicians that perform cryoablation procedures. Cryoablation procedures should be performed only in a fully equipped facility.

    Potential Complications

    Potential complications/adverse events from cardiac catheterization and ablation include, but are not limited to the following: Access site complications including, hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from the puncture site, hemorrhage; arrhythmias (such as atrial fibrillation, atrial flutter, tachycardia); cardiac arrest; chest discomfort, pain or pressure; coronary artery spasm/stenosis; damage to heart tissue or vasculature; death; endocarditis; entrapment; esophageal damage (such as atrio-esophageal fistula); heart block, potentially requiring implantation of a permanent pacemaker; hemothorax; infection; perforation of venous, cardiac or surrounding tissue, pericardial effusion, tamponade; pericarditis; phrenic nerve injury; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; stroke; tissue infarction (such as myocardial infarction or renal infarction); thrombus; transient ischemic attack; vagal nerve injury (such as gastroparesis); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal Law (United States) restricts this device to sale by or on the order of a physician.

    Back to top

    Freezor™ Xtra cardiac cryoablation catheter

    Indications

    The Freezor™ Xtra cardiac cryoablation catheter, CryoConsole™ system, and related accessories are indicated for the cryoablation of the conducting tissues of the heart in the treatment of adult and pediatric patients over two years of age with atrioventricular nodal reentrant tachycardia (AVNRT). The Freezor™ Xtra catheter is also intended for minimally invasive cardiac surgery procedures, including surgical treatment of cardiac arrhythmias. The Freezor™ Xtra catheter freezes the target tissue and blocks the electrical conduction by creating an inflammatory response or cryonecrosis.

    Contraindications

    The Freezor™ Xtra cardiac cryoablation catheter is contraindicated in patients with the following conditions:

    • Active systemic infections
    • Cryoglobulinemia
    • Intracardiac mural thrombus
    • Myxoma
    • Interatrial baffle or patch

    Warnings/Precautions

    Do not reuse, reprocess, or resterilize this catheter for purpose of reuse. This catheter is intended only to be used once for a single patient. Closely monitor AV conduction during cryo energy delivery near the AV node due to possible risk of complete atrioventricular (AV) block. Immediately terminate energy delivery if partial or complete AV block is noted. The use of CryoMapping mode does not prevent injuries to the patient. CryoMapping mode is used to determine if the site is appropriate for ablation. The catheter contains pressurized refrigerant during operation. Release of this gas into the body or circulatory system due to equipment failure or misuse could result in gas embolism, pericardial tamponade, tissue emphysema, or other patient injury. Always advance and withdraw components slowly to minimize the vacuum created and therefore minimize the risk of air embolism. Endotoxins may cause pyrogenic responses in patients including inflammation and fever which can result in anaphylactic shock and death. Caution should be used with regard to endotoxins in pediatric populations as standard endotoxin limits do not differentiate between adult and pediatric populations. Ethylene oxide residuals remaining after sterilization are known to cause a potential increase in a number of biological effects including irritation, organ damage, mutagenicity, and carcinogenicity. Calculations for ethylene oxide and ethylene chlorohydrin residuals indicate that the risk of these effects may be increased in patients under 3.8kg. Avoid catheter entanglement with other catheters, devices, or wires. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. Do not pull on the Freezor™ Xtra catheter, sheath, umbilical cables, or console while the catheter is frozen to the tissue, as this may lead to tissue injury. Do not connect the Freezor™ Xtra catheter to a radiofrequency (RF) generator or use it to deliver RF ablation energy. Before powering up an RF generator or applying RF energy, disconnect the cryoablation catheter from the CryoConsole™ system. The use of fluoroscopy during ablation procedures presents the potential for significant X-ray exposure to both patients and laboratory staff. Give careful consideration before using the device in pregnant women.

    Catheter handling: 

    • Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade.
    • Do not use excessive force to advance or withdraw the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened.
    • Straighten the cooling segment before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or cooling segment.
    • Catheter advancement should be performed under fluoroscopic guidance or other appropriate visualization technique.

    Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole™ system and catheters. The Freezor™ Xtra catheter has not been evaluated for safety and compatibility in the magnetic resonance (MR) environment. Scanning a patient during the use of this device may result in patient injury. The Medtronic cryoablation catheters, refrigerant tanks, and other Medtronic CryoConsole™ components should only be used with the Medtronic CryoConsole™ system. If the sterile packaging or catheter is damaged, do not use the catheter. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. Disconnect the catheter’s electrical connection prior to cardioversion/defibrillation. Cryoablation involving coronary vessels with liquid nitrous oxide systems has been associated with subsequent clinically significant arterial stenosis. Care should be taken to minimize unnecessary contact with coronary vessels during cryoablation.

    Avoid positioning the catheter around the chordae tendineae, as this increases the likelihood of catheter entrapment within the heart. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing endocardial right-sided procedures. This equipment should be used only by physicians that perform cardiac ablation.

    Potential Complications

    Potential complications that may be associated with cardiac catheterization and ablation listed alphabetically below include, but are not limited to: Access site complications including, hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage; arrhythmias (such as atrial fibrillation, atrial flutter, tachycardia); cardiac arrest and/or death; chest discomfort, pain or pressure; coronary artery spasm/stenosis; damage to heart tissue or vasculature; endocarditis; entrapment; heart block, requiring permanent pacemaker; hemothorax; infection; perforation of venous, cardiac or surrounding tissue, pericardial effusion, tamponade; pericarditis; phrenic nerve injury; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; stroke; tissue infarction (such as myocardial infarction or renal infarction); thrombus; transient ischemic attack; vagal nerve injury (such as gastroparesis); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518.

    Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

    Back to top

    Nitron CryoConsole™ Cardiac Cryoablation System ISW

    Intended use

    The Nitron CryoConsole™ (the console), together with its components and specified catheters, is for use in performing cardiac ablation procedures.

    Contraindications

    See the technical manual for the compatible Medtronic catheter being used.

    Warnings and precautions

    These warnings apply in general to using the Nitron CryoConsole™ for cardiac cryoablation. Refer to the technical manual for console-compatible catheters for more information related to catheter use.

    • Connected electrophysiology (EP) lab equipment. Any equipment (e.g., EP recording system, HDMI) connected to the upper rear connection panel or to the auto connection box ECG cable receptacle of the device shall be IEC 60601-1 compliant or have a 60601-1-compliant isolation transformer on the interconnect cable between the Nitron CryoConsole™ and the EP lab equipment.
    • Electric shock. To avoid risk of electric shock, this equipment must only be connected to a supply main with protective earth.
    • Cryoadhesion. Do not pull on the catheter, sheath, umbilical cables, or console while the catheter is frozen to the tissue, as this may lead to tissue injury.
    • Improper connection. Do not connect a cryoablation catheter to a radiofrequency (RF) generator or use it to deliver RF energy. Doing this may cause catheter malfunction or patient harm.
    • Other accessories, transducers, and cables. Use of accessories, transducers, and cables other than those specified or provided by the manufacturer of this equipment could result in increased electromagnetic emissions or decreased electromagnetic immunity of this equipment and result in improper operation.

    The console meets the requirements of IEC 60601-1. It is the user’s responsibility after installation to verify and ensure that the console meets the applicable local electrical safety requirements. Perform cryoablation procedures only within the environmental parameters. Cryoablation procedures should be performed only in an electrophysiology facility by or under the supervision of physicians trained in cryoablation.  Do not modify this equipment. Modifications may reduce system effectiveness and impact patient health. The system must be installed by a qualified/trained Medtronic representative. All information technology equipment that is attached to the console must be approved by a third party to the requirements of UL 1950 or EN 60950. Minimize exposure to nitrous oxide to prevent short-term behavioral and long-term reproductive health effects.  The console and its accessories have not been evaluated for safety and compatibility in the magnetic resonance (MR) environment and are unknown which may lead to patient injury. Use only compatible Medtronic cryoablation catheters and components and Medtronic-provided refrigerant tanks with the console. The safety and use of other catheters or components has not been tested.

    Potential adverse events

    Potential adverse events associated with console procedures include, but are not limited to, the following conditions:

    • Electric shock
    • Foreign body/biological reaction
    • Long-term reproductive issues
    • Thermal injury

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at  800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    PulseSelect™ Pulsed Field Ablation System ISW

    Indications (or intended use)

    The PulseSelect™ pulsed field ablation (PFA) system is indicated for use in cardiac electrophysiological mapping (stimulation and recording) and for treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation or persistent atrial fibrillation (episode duration less than one year).

    Contraindications

    The PulseSelect™ PFA loop catheter is contraindicated for use in patients with the following conditions:

    • Active systemic infections
    • A known sensitivity to Heparin
    • Blood clotting abnormalities
    • Permanently implanted metallic objects in the left atrium

    The catheter is also contraindicated in conditions where the manipulation of the catheter within the heart would be unsafe, such as intracardiac mural thrombus.

    The catheter is not recommended for use in patients who cannot undergo standard anticoagulation protocol for a left-sided cardiac procedure, or who have had a recent coagulopathy or embolic event.

    Warnings and precautions

    To reduce the possibility of hazards associated with use of the PulseSelect™ PFA loop catheter: 

    • Use the catheter only in the recommended anatomical location.
    • Maintain the catheter position during the ablation.
    • If coughing occurs, reposition the catheter more proximally and review sedation management.
    • Ensure electrodes are not in contact with any metal during ablations (for example the guide wire).
    • Maintain substantially circular array to ensure uniform field distribution.
    • If the electrode array is deployed to deliver ablation energy, avoid continuing to move the slide control forward to prevent the guide wire lumen from coming too close to the electrode array.

    It is recommended that the array be captured while it is submerged to help reduce the possibility of air becoming entrapped around the electrode array during capture and catheter insertion.

    Catheter integrity

    Use care to avoid damage to the catheter.

    • Do not bend or kink the leading end of the catheter. Doing so could cause damage to the catheter lumen and make it unusable.
    • Monitor the catheter throughout the procedure. If a flash is observed in the luer, replace the catheter immediately.

    Electrode-electrode contact

    Avoid contact between electrodes. Contact between electrodes may create a short circuit.

    Embolism risk

    Introducing any catheter or sheath into the circulatory system entails the risk of air, gas, or thromboembolism, which can occlude vessels and lead to tissue infarction with serious consequences.

    • Avoid unnecessary catheter exchanges to minimize sheath-related embolic events.
    • Always advance and withdraw components slowly to minimize the vacuum created and the risk of air embolism.
    • Aspirate and flush the sheath frequently to help minimize the potential for embolic events resulting from the introduction of air or clot formation within the sheath.

    Fluoroscopy use during catheter placement

    Only perform catheter ablation after giving adequate attention to the potential radiation exposure associated with the procedure and taking steps to minimize this exposure. Give careful consideration before using the device in pregnant women.

    For single use only

    The PFA catheter is intended only to be used once for a single patient. Do not reuse, reprocess, or resterilize the PFA catheter.

    Careful manipulation of the catheter is necessary to avoid cardiac damage, perforation, or tamponade.

    • Do not use excessive force to advance, withdraw, or rotate the catheter, especially if resistance is encountered. Excessive force may lead to catheter damage and blood loss.
    • Use imaging guidance during catheter advancement, manipulation, and placement.
    • Vascular perforation is an inherent risk of catheter placement.
    • Performing ablation with the PFA catheter array inside the sheath may result in damage to the array or the sheath and should be avoided.
    • Performing steering manipulation with the PFA catheter array inside the sheath may result in damage to the catheter steering mechanism or the sheath and should be avoided.
    • The PFA generator is capable of delivering significant energy. Do not touch the ablation electrodes of the PFA catheter while operating the generator.
    • If the system is to be tested outside of the body, the electrode array must be immersed in saline solution in a plastic container. Never test PFA delivery in direct contact with skin.

    Use of imaging during catheter manipulation and placement is strongly advised. Manipulating the catheter without imaging may result in damage to cardiac and vascular structures.

    Other devices, wires, or catheters

    Avoid catheter entanglement with other devices, wires, or catheters, for example, intracardiac echo catheters. Failure to do so may increase the risk of entrapment of the array or damage to the array, which may affect retrieval of the device into the transseptal sheath.

    Phrenic nerve injury

    To reduce the potential for phrenic nerve injury, assess for proximity of the ablation catheter to the nerve using an appropriate technique such as pacing for local phrenic nerve capture or using the test pulse feature before ablation. Stop ablation immediately if phrenic nerve impairment is observed and assess for injury.

    Sheath and guide wire required

    Do not attempt to advance or withdraw the catheter through the vasculature without the use of a sheath and guide wire, as it may result in damage to cardiac and vascular structures.

    Implanted devices, such as pacemakers and implantable cardioverter-defibrillators (ICDs), may be adversely affected by PFA energy.

    • Keep external sources of pacing and defibrillation available during ablation.
    • Program pacemaker sensing parameters to asynchronous pacing to ensure that PFA energy is not sensed as an intrinsic event.
    • Deactivate ICD detection during the delivery of PFA energy.
    • Perform complete implantable device testing before and after ablation.
    • Monitor surface and intracardiac electrograms or vital signs during PFA energy delivery to assess for device interaction. Take appropriate action if any interaction is detected.
    • Refer to the appropriate implantable device technical manual for additional information.

    Electrical safety requirements

    The PFA generator meets the requirements of IEC 60601-1. It is the user’s responsibility after installation to verify and ensure that the generator meets the applicable local electrical safety requirements.

    Electric shock

    To avoid risk of electric shock, this equipment must only be connected to a supply main with protective earth.

    Electromagnetic interference (EMI) radiated

    The generator emits energy during ablation at a frequency level that may cause EMI with unshielded electronic equipment. To minimize EMI, the generator should be moved away from any other electronic device. If EMI is apparent during the application of energy, EMI may be reduced by repositioning the generator or other equipment.

    Electromagnetic interference (EMI) susceptibility

    The generator has been designed to minimize EMI. If interference should occur, move the generator away from the device generating the interference or place the generator at a different angle.

    Leakage current from connected devices

    Use only isolated equipment (IEC 60601-1 Type CF equipment or equivalent) with the PFA system and catheters, or patient injury or death may occur.

    Potential adverse events or potential complications

    Potential adverse events associated with cardiac catheter ablation procedures include, but are not limited to, the following conditions:

    • Access site complications (such as, bruising, ecchymosis, arteriovenous fistula, hematoma, pseudoaneurysm)
    • Anemia
    • Arrhythmias, proarrhythmia (such as, atrial flutter, bradycardia, heart block, tachycardia)
    • Bleeding, possibly requiring transfusion
    • Bruising
    • Cardiopulmonary arrest
    • Perforation of the heart or other organs during transseptal puncture or other procedures
    • Cardiac tamponade
    • Catheter entrapment in cardiac structures requiring intervention
    • Cerebrovascular accident such as stroke, transient ischemic attack (TIA)
    • Chest discomfort, pain, or pressure
    • Collateral damage to the conduction system or coronary vasculature
    • Cough
    • Death
    • Embolism
    • Esophageal damage (including atrial esophageal fistula)
    • Hemoptysis
    • Hypotension
    • Hypertension
    • Infections (such as, sepsis)
    • Myocardial infarction or ischemia
    • Nerve injury or nerve damage (for example phrenic nerve injury)
    • Pericarditis or endocarditis
    • Pericardial effusion
    • Pneumothorax
    • Pulmonary edema
    • Pulmonary vein dissection
    • Pulmonary vein stenosis
    • Radiation injury or damage and late malignancy
    • Skin laceration or puncture
    • Sore throat
    • Unintended complete or incomplete atrioventricular node (AV-Node) or sinus node block or damage
    • Valvular insufficiency or damage.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    DiamondTemp™ ablation system

    The only open-irrigated RF catheter with industrial diamonds to optimize power based on direct tissue surface temperature measurement. DiamondTemp™ ablation system is a safe and effective tool to treat AF patients.

    Compared to contact force-RF, the DiamondTemp™ ablation system demonstrated26:

    • 40% reduction in RF time
    • 55% reduction in individual RF ablation duration
    • 58% reduction in saline infusion
    See more

    To view the indications, safety, and warnings, scroll down or click on one of the links below to jump you down the page to that product.

    Achieve Advance™ mapping catheter ISW

    Indications (or intended use)

    The Achieve Advance™ Mapping Catheter is indicated for multiple electrode electrophysiological mapping of the cardiac structures of the heart, i.e., recording or stimulation only. The Achieve Advance™ mapping catheter is designed to obtain electrograms in the atrial regions of the heart.

    Contraindications

    The catheter is contraindicated as follows: 1) For use as an ablation device, 2) For use with transseptal sheaths featuring side holes larger than 1.00 mm (0.04 in) in diameter, 3) Retrograde approach.

    Electrophysiology studies are contraindicated when the patient’s underlying cardiac disease makes it likely that induced arrhythmias will be extremely difficult to terminate and carry a high risk of death, as in the following conditions: An active systemic infection, Left atrial thrombus, Pulmonary vein stents, Prosthetic heart valve (tissue or mechanical), Myxoma, Interatrial baffle or patch, Conditions where the manipulation of the catheter within the heart would be unsafe, Acute myocardial infarction.

    Warnings and precautions

    This catheter is intended only to be used once for a single patient. Do not reuse, reprocess, or resterilize these devices for purpose of reuse. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device or create a risk of contamination of the device that could result in patient injury, illness, or death. This equipment should be used only by or under the supervision of physicians trained in cardiac catheterization procedures. If the sterile packaging of the device is damaged, do not use. Do not connect the mapping catheter to a radiofrequency (RF) generator or use it to deliver RF energy.

    Use of fluoroscopy during catheter manipulation and placement is strongly advised. Take all appropriate measures to minimize x-ray exposure to both patients and clinical staff.

    Avoid positioning the catheter around the chordae tendineae as this increases the likelihood of catheter entrapment within the heart. Avoid catheter entanglement with other catheters, devices, or wires. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Introducing any catheter into the circulatory system entails the risk of air or gas embolism, which can occlude vessels and lead to tissue infarction with serious consequences.

    Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade. Do not use excessive force to advance or withdraw the catheter, especially if resistance is encountered. Do not use the catheter if it is kinked, damaged, or cannot be straightened. Bending or kinking the catheter shaft may compromise the structural integrity of the device and increase the risk of catheter failure. Use only isolated equipment (IEC 606011 Type CF equipment, or equivalent) with the mapping catheter. Do not allow the patient to contact grounded equipment that might produce electrical current leakage during ablation or DCCV (Direct Current CardioVersion). Disconnect the catheter from the catheter connecting cable prior to cardioversion/defibrillation. Do not touch the patient or the catheter during cardioversion/defibrillation.

    Use the mapping catheter only with the Medtronic catheter connecting cable Model 2ACHC, and a compatible mating device with a minimum internal diameter of 1.12 mm (0.044 in) and standard 9 Fr hemostasis valve. The mapping catheter is compatible for use with, and may be used to support and position, all catheters in the Medtronic Arctic Front CryoAblation Catheter family. Cardiac catheterization procedures should be performed only in a fully equipped electrophysiology laboratory. Do not immerse the electrical connectors in fluids or solvents. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided and transseptal cardiac procedures. Always rotate the mapping catheter in a clockwise direction to prevent tissue damage. Keep in a dry location away from heat and all sources of light. Exposure to light may cause damage to the catheter. Do not expose the catheter to organic solvents such as alcohol.

    Potential adverse events or potential complications

    Potential adverse events associated with cardiac catheter procedures include, but are not limited to the following conditions: Access site vessel occlusion; Allergic reaction to x-ray contrast media; Arrhythmias, proarrhythmia; Arteriovenous fistula; Bleeding related to anticoagulation; Bradycardia; Cardiac perforation of the heart or other organs during transseptal puncture or other procedures; Cardiac tamponade; Cardiac thromboembolism; Cerebrovascular accident (CVA) or transient ischemic attack (TIA); Chest discomfort; Chronic cough; Death; Dislodgement of implantable cardioverter defibrillator (ICD) or permanent pacing leads; Fever; Heart failure; Hematoma; Hemoptysis; High creatinine phosphokinase or troponin level; Hypotension; Infections; Mitral valve trauma; Myocardial infarction or ischemia; Obstruction, perforation, damage, or spasm of the vascular system including the coronary circulation system; Pericarditis or endocarditis; Pleural or pericardial effusion; Pneumonia; Pulmonary embolism; Pulmonary infiltrates; Pulmonary vein narrowing or stenosis; Pseudoaneurysm in groin; Radiation injury or damage and late malignancy; Respiratory depression; Retroperitoneal bleed; Thrombotic or embolic events; Valvular insufficiency or damage; Vasovagal reaction.

    Refer to the device manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Achieve™ mapping catheter ISW

    Indications (or intended use)

    The Achieve™ Mapping Catheter is indicated for multiple electrode electrophysiological mapping of the cardiac structures of the heart, i.e., recording or stimulation only. The Achieve Mapping Catheter is designed to obtain electrograms in the atrial regions of the heart.

    Contraindications

    The catheter is contraindicated as follows: 1) For use as an ablation device, 2) For use with transseptal sheaths featuring side holes larger than 1.00 mm in diameter, 3) Retrograde approach

    Electrophysiology studies are contraindicated when the patient’s underlying cardiac disease makes it likely that induced arrhythmias will be extremely difficult to terminate and carry a high risk of death, as in the following conditions: An active systemic infection, Left atrial thrombus, Pulmonary vein stents, Prosthetic heart valve (tissue or mechanical), Myxoma, Interatrial baffle or patch, Conditions where the manipulation of the catheter within the heart would be unsafe, Acute myocardial infarction

    Warnings and precautions

    This catheter is intended only to be used once for a single patient. Do not reuse, reprocess, or resterilize these devices for purpose of reuse. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device or create a risk of contamination of the device that could result in patient injury, illness, or death. This equipment should be used only by or under the supervision of physicians trained in cardiac catheterization procedures. If the sterile packaging of the device is damaged, do not use. Do not connect the Achieve Mapping Catheter to a radiofrequency (RF) generator or use it to deliver RF energy.

    Use of fluoroscopy during catheter manipulation and placement is strongly advised. Take all appropriate measures to minimize x-ray exposure to both patients and clinical staff.

    Avoid positioning the catheter around the chordae tendineae as this increases the likelihood of catheter entrapment within the heart. Avoid catheter entanglement with other catheters, devices, or wires. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue).

    Introducing any catheter into the circulatory system entails the risk of air or gas embolism, which can occlude vessels and lead to tissue infarction with serious consequences.

    Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade. Do not use excessive force to advance or withdraw the catheter, especially if resistance is encountered. Do not use the catheter if it is kinked, damaged, or cannot be straightened. Bending or kinking the catheter shaft may compromise the structural integrity of the device and increase the risk of catheter failure. Use only isolated equipment (IEC 60601 Type CF equipment, or equivalent) with the Achieve Mapping Catheter. Do not allow the patient to contact grounded equipment that might produce electrical current leakage during ablation or DCCV (Direct Current CardioVersion). Do not allow any exposed metal portion of the shaft to contact grounded equipment.  Remove the catheter from the patient prior to cardioversion/defibrillation. Do not touch the patient or the catheter during cardioversion/defibrillation. Use the Achieve Mapping Catheter only with Medtronic Achieve Electrical Cable, suitable compatible mating device with a minimum internal diameter of 1.3 mm (0.049”) and standard 9F hemostasis valve. The Achieve Mapping Catheter is compatible for use with the Medtronic Arctic Front CryoAblation Catheter, and may be used to support and position the Arctic Front Catheter. Cardiac catheterization procedures should be performed only in a fully equipped electrophysiology laboratory. Do not immerse the electrical connectors in fluids or solvents. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided and transseptal cardiac procedures. Always rotate the Achieve Mapping Catheter in a clockwise direction to prevent tissue damage. Keep in a dry location away from heat and sunlight. Do not expose the catheter to organic solvents such as alcohol.

    Potential adverse events or potential complications

    Potential adverse events associated with cardiac catheter procedures include, but are not

    limited to the following conditions: Access site vessel occlusion; Allergic reaction to x-ray contrast media; Arrhythmias, proarrhythmia; Arteriovenous fistula; Bleeding related to anticoagulation; Bradycardia; Cardiac perforation of the heart or other organs during transseptal puncture or other procedures; Cardiac tamponade; Cardiac thromboembolism; Cerebrovascular accident (CVA) or transient ischemic attack (TIA); Chest discomfort; Chronic cough; Death; Dislodgement of implantable cardioverter; defibrillator (ICD) or permanent pacing leads; Fever; Heart failure; Hematoma; Hemoptysis; High creatinine phosphokinase or troponin level; Hypotension; Infections; Mitral valve trauma; Myocardial infarction or ischemia; Obstruction, perforation, damage, or spasm of the vascular system including the coronary circulation system; Pericarditis or endocarditis; Pleural or pericardial effusion; Pneumonia; Pulmonary embolism; Pulmonary infiltrates; Pulmonary vein narrowing or stenosis; Pseudoaneurysm in groin; Radiation injury or damage and late malignancy; Respiratory depression; Retroperitoneal bleed; Thrombotic or embolic events; Valvular insufficiency or damage; Vasovagal reaction.

    Refer to the device manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Affera™ Mapping and Ablation System ISW

    Affera™ Mapping and Ablation System

    Indications

    The Sphere-9 catheter is indicated for use in cardiac electrophysiological mapping (stimulation and electrogram recording) and for treatment of drug refractory, recurrent, symptomatic persistent atrial fibrillation (episode duration less than 1 year) and radiofrequency ablation of cavotricuspid isthmus dependent atrial flutter when used with the Affera mapping system.

    The Affera Mapping System is intended to be used for catheter-based cardiac electrophysiological mapping. The mapping system allows pacing and real-time visualization of compatible catheters as well as display of cardiac maps in multiple formats. The acquired patient signals, including intracardiac electrograms, may also be recorded and displayed on the system’s display screen.

    Contraindications

    Do not use this device under the following circumstances:

    • In patients with an active systemic infection.
    • In patients who have had cardiac surgery in the preceding eight weeks, as the risk of perforation may increase.
    • In patients with intracardiac thrombus or myxoma, as the catheter may precipitate an embolus.
    • In coronary vessels with diameter smaller than the expandable ablation electrode, as the catheter may damage the coronary vessels.
    • In patients with prosthetic valves, as the catheter may damage the prosthesis.
    • Using the transaortic retrograde approach in patients who have had aortic valve replacement.
    • Using the transseptal approach in patients with an interatrial baffle or patch, as the opening could persist and result in an iatrogenic atrial shunt.

    Warnings and Precautions

    Do not reuse, reprocess, or resterilize devices labeled single-use only. Only use with compatible devices listed in the IFU. The Affera Mapping System requires use of a disposable Location Reference Patch Kit to detect patient displacement and respiratory motion.

    Treatment location should be confirmed using alternative techniques (e.g. fluoroscopy, intracardiac electrograms, intracardiac echocardiography) before treatment.  

    A connection to a compatible cardiac stimulator is allowed provided the stimulator is electrically isolated or physically disconnected when RF or PF energy is applied to the patient, outputs of the generator and stimulator must be isolated to prevent patient injury or damage to equipment.

    The pacing functionality in the Affera Mapping System is not a life support device and is for diagnostic purposes only. Pacing may induce intentional or unintentional life-threatening cardiac arrhythmias.

    Intravenous heparin must be used to reduce the likelihood of thromboemboli developing during the procedure. Patient injury may result from excessive delivery of fluids. Anticoagulation treatment should adhere to consensus guidelines,

    Avoid steering the Sphere-9 catheter near other catheters to reduce the possibility of the catheters becoming entangled. Cardiac devices may be damaged by energy delivery.  Catheter interactions with implantable leads may result in lead dislodgement or possible thrombus.

    Cardiac ablation may induce intentional or unintentional life-threatening cardiac arrhythmias.

    Care should be taken when ablating near sensitive structures (i.e., conduction system, coronary arteries) as unintended patient harm may occur. Catheter entrapment within the heart is a possible complication of cardiac ablation procedures that could necessitate surgical intervention.

    The Affera Mapping and Ablation System has not been evaluated for safety and compatibility in the magnetic resonance (MR) environment. System operation may be temporarily interrupted if exposed to excessive external electromagnetic disturbance or ESD.

    Potential Adverse Events or Potential Complications

    Atrioesophageal fistula, Cardiac perforation / tamponade, Cardiac or respiratory arrest, Stroke Conduction system injury, Coronary artery spasm / occlusion / stenosis, Damage / dislodgement to ICD or implantable pacemaker, Death, Embolism, Hemoptysis, Infection, Myocardial infarction, Phrenic nerve palsy / paralysis, Pulmonary edema, Pulmonary vein stenosis, Valve damage, Vessel dissection

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_85060

    Back to top

    Arctic Front Advance™ Cardiac Cryoablation Catheter ISW

    Indications (or intended use)

    The Arctic Front Advance™ and Arctic Front Advance Pro™ cardiac cryoablation catheters are indicated for the treatment of drug refractory recurrent symptomatic paroxysmal and persistent atrial fibrillation (episode duration less than 6 months).

    The Arctic Front Advance™ and Arctic Front Advance Pro™ cardiac cryoablation catheters are also indicated for the treatment of recurrent symptomatic paroxysmal atrial fibrillation as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy.

    Contraindications

    Use of the cryoballoon is contraindicated: 1) In the ventricle because of the danger of catheter entrapment in the chordae tendineae, 2) In patients with one or more pulmonary vein stents, 3) In patients with cryoglobulinemia, 4) In patients with active systemic infections, and 5) In conditions where the manipulation of the catheter within the heart would be unsafe (e.g., intracardiacmural thrombus).

    Warnings and precautions

    Do not reprocess or resterilize this device for the purpose of reuse. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided and transseptal cardiac procedures. The Arctic Front family of cryoballoons have not been studied for the safety of changes in anticoagulation therapy in patients with paroxysmal atrial fibrillation. Atrial fibrillation patients with significant left ventricular dysfunction, advanced heart failure, severe left atrial enlargement or significant structural heart disease were excluded from the clinical trials that supported the approved indications. For baseline demographics and clinical characteristics of the patients studied, please see the Clinical Summaries listed in the instructions for use. Do not inflate the balloon inside the sheath or while the catheter is positioned inside a pulmonary vein. Always inflate the balloon in the atrium and then position it at the pulmonary vein ostium. If the balloon cannot be inflated or deflated using the CryoConsole, have a Manual Retraction Kit on hand during the procedure. (Refer to the CryoConsole Operator’s Manual for more detailed instructions on the Manual Retraction Kit). Disconnect the catheter’s electrical connection before cardioversion or defibrillation.

    Catheter handling:

    • Use extreme care when manipulating the catheter.
    • Do not use excessive force to advance, withdraw, or rotate the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened.
    • If the catheter becomes kinked or damaged while in the patient, remove it and use a new catheter.
    • Straighten the shaft before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or balloon segment.
    • Catheter advancement should be performed using fluoroscopy or other appropriate techniques.
    • Do not position the cryoballoon catheter within the tubular portion of the pulmonary vein.

    Do not advance the balloon beyond the guide wire or circular mapping catheter to reduce the risk of tissue damage. Ensure that the guide wire or circular mapping catheter is inserted into the catheter and through the balloon portion for adequate support during vascular access insertion. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Do not pull on the balloon catheter, circular mapping catheter, sheath, umbilical cables, or CryoConsole while the balloon catheter or circular mapping catheter are frozen to tissue. Before moving these components, use appropriate techniques to ensure that the balloon catheter and circular mapping catheter are not adhered to tissue.

    Always advance and withdraw components slowly to minimize the vacuum created and therefore minimize the risk of air embolism. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. The use of fluoroscopy during catheter ablation procedures presents the potential for significant x-ray exposure to both patients and laboratory staff. Give careful consideration before using the device in pregnant women. Flush the guide wire lumen before initial insertion and then frequently throughout the procedure to prevent coagulation of blood in the lumen. Flush the guide wire lumen with saline after each contrast injection. Use only 0.081 cm (0.032 in) or 0.089 cm (0.035 in) guide wires with the catheter. Do not connect the cryoablation catheter to a radiofrequency (RF) generator or use it to deliver RF energy. Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole and catheters. Avoid catheter entanglement with other catheters, devices, or wires.

    Before powering up an RF generator or applying RF energy, disconnect the cryoablation catheter from the CryoConsole. Always deflate the balloon and withdraw the balloon into the transseptal sheath before removing the balloon from the left atrium. If the sterile packaging or catheter is damaged, do not use the catheter. Use only Medtronic cryoablation catheters, 12 FR inner diameter sheaths, circular mapping catheters, refrigerant tanks, and components with the CryoConsole. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. This cryoablation system should be performed only in a fully equipped facility under the supervision of physicians trained in cryoablation procedures.

    Potential adverse events or potential complications

    Potential complications/adverse events from cardiac catheterization and ablation include, but are not limited to, the following: Access site complications (e.g., bruising, ecchymosis); Anemia; Anxiety; Arrhythmia (e.g., atrial flutter, bradycardia, heart block, tachycardia); Back pain; Bleeding from puncture sites; Bronchial constriction; Bronchial fistula; Bronchitis; Bruising; Cardiac tamponade; Cardiopulmonary arrest; Cerebral vascular accident; Chest discomfort/pain/pressure; Cold feeling; Coronary artery spasm; Cough; Death; Diarrhea; Dizziness; Embolism; Esophageal damage (including esophageal fistula); Fatigue; Fever; Headache; Hemoptysis; Hypotension/Hypertension; Infection (e.g., pericarditis, sepsis, urinary); Lightheadedness; Myocardial infarction; Nausea/vomiting; Perforation; Pericardial effusion; Phrenic nerve injury; Pleural effusion; Pneumonia; Pneumothorax; Pseudoaneurysm; Pulmonary edema; Pulmonary hemorrhage; Pulmonary vein dissection; Pulmonary vein stenosis; Shivering; Shortness of breath; Sore throat; Transient ischemic attack; Vagal nerve injury (e.g., gastroparesis); Vasovagal reaction; Visual Changes (e.g., blurred vision).

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.
     

    Back to top

    CardioInsight™ Mapping System ISW

    Indications

    The CardioInsight™ cardiac mapping system is intended for acquisition, analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.

    Contraindications

    There are no known contraindications.

    Warnings and precautions

    Cardiac mapping system

    Warnings
    • Do not modify the attachment plug or use a power adapter. This could cause an electrical hazard. If you require a different electrical socket plug, contact your local Medtronic Representative. CardioInsight™ must always be connected to the power source properly.
    • Ensure that all power sources are appropriately rated and are properly grounded or earthed. If the CardioInsight™ system is not properly grounded or earthed, it becomes a possible electric shock hazard. Protection against electrical shock has been provided through an isolation transformer and chassis grounding via a plug to an appropriate power source.
    • Electroanatomical mapping with CardioInsight™ should ONLY be performed after the risks of the entire procedure, including radiation exposure and time required for signal collection, have been adequately considered for each patient.
    Precautions
    • The installation and setup of CardioInsight™ and its software should ONLY be performed by trained Medtronic personnel.
    • Portable or mobile RF communications equipment may affect CardioInsight™.
    • Extension cords and electrical power bars should NEVER be used with CardioInsight™.
    • CardioInsight™ should not be connected to any equipment that is not supported by or part of the system.
    • The isolation transformer should NEVER be placed on the floor for use.
    • Do not stack other equipment on the mapping amplifier or the system cart.
    • Do not use the cart for any other purpose than storing and using CardioInsight™.
    • The workstation that is supplied as part of CardioInsight™ is not intended for use without the isolation transformer.
    • Devices that connect to CardioInsight™ via Universal Serial Bus (USB) such as an external hard drive should be used ONLY after approval by Medtronic as they may introduce computer viruses.
    • Installation of software not authorized by Medtronic on the CardioInsight™ workstation can cause the system to display inaccurate results or otherwise malfunction, and will void the terms of the product warranty.
    • Do not replace the amplifier fuses while the system is in use or connected to the patient.
    • Assembly, repair, and modifications of the system over its service life will be evaluated based on the requirements of IEC 60601-1 prior to implementation.
    • CardioInsight™ should ONLY be used by trained personnel or under the guidance of trained Medtronic personnel.
    • CardioInsight™ should ONLY be used in an institution’s environment.
    • Do not use CardioInsight™ in the presence of flammable anesthetic mixtures with air, oxygen, or nitrous oxide.
    • The CardioInsight™ acquisition should be performed on the same day as the completion of the CT scan.
    • The system cables, including the Sensor Array signal cables and patient ground reference cable are provided non-sterile. DO NOT sterilize the cables.

    Sensor array

    Warnings
    • DO NOT use the Sensor Array if the patient has sensitivity, open sores, or a severe skin condition or disease of the thorax area.
    • DO NOT perform magnetic resonance (MR) imaging with the Sensor Array on the patient. The Sensor Array may cause harm to the patient if used in MR imaging. Remove Sensor Array prior to performing MR imaging studies.
    • Remove or peel back front Sensor Array panels prior to using an external defibrillator on the patient.
    Precautions
    • The Sensor Array should only be connected to the CardioInsight™ Cardiac Mapping System.
    • The Sensor Array is meant to be used only during computed tomography (CT) imaging procedures that use legally marketed CT scanners.
    • The CardioInsight™ acquisition should be performed on the same day as the completion of the CT scan. The Sensor Array should not be removed or repositioned between the CT scan and the acquisition.
    • The Sensor Array is not sterile and cannot be sterilized. Care should be taken to keep the Sensor Array outside of any sterile field.
    • DO NOT expose the Sensor Array to organic solvents such as alcohol. If an organic solvent is used on patient, allow to dry for at least one minute prior to applying Sensor Array.
    • DO NOT expose the Sensor Array and electrical connectors to fluids or solvents, except when following the cleaning instructions in the Operator’s Manual.
    • Store Sensor Array flat (parallel to the floor) with the correct side facing up, as labeled, according to the environmental storage conditions.
    • Store Sensor Array panels in their sealed protective pouches until use.
    • The Sensor Array is intended for single use ONLY. Reusing the Sensor Array may result in poor system performance or transmission of infection.
    • Panels from different Sensor Array sizes should NEVER be mixed and matched for use.
    • DO NOT cut or fold the circuitry on the Sensor Array.

    Potential Adverse Events

    None known


    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    DiamondTemp™ Ablation Catheter ISW

    Indications (intended use)

    The DiamondTemp™ ablation catheter is indicated for use in cardiac electrophysiological mapping (stimulation and recording) and for treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation when used in conjunction with the DiamondTemp™ RF generator and accessories (DiamondTemp™ catheter-to-RF generator cable, DiamondTemp™ GenConnect™ cable, DiamondTemp™ EGM cable, DiamondTemp™ irrigation pump, DiamondTemp™ irrigation tubing set) and compatible mapping system.

    Contraindications

    Use of the DiamondTemp™ catheter is contraindicated for: 1) patients with active systemic infection, 2) patients with prosthetic valves, 3) patients with intracardiac thrombus or myxoma or interatrial baffle or patch via transseptal approach, 4) patients unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation, 5) pregnant women and children < 18 years of age, and 6) patients who are hemodynamically unstable.

    Warnings and precautions

    Cardiac ablation procedures should be performed only by physicians trained in the techniques of radiofrequency (RF) catheter ablation in a fully equipped electrophysiology (EP) laboratory. The catheter is for single use only. Do not reprocess or resterilize. Reusing, reprocessing, or resterilizing may compromise the structural integrity of the device or lead to product failure, which may result in patient injury, illness, or death. Reuse, reprocessing, or resterilizing may also create a risk of contamination of the device. Contamination may lead to injury, illness, or death of the patient. Pacemakers, implantable cardioverter defibrillators (ICDs), and leads can be adversely affected by RF signals. ICDs should be deactivated prior to ablation, precautions should be taken when the catheter is in close proximity to leads, and complete system analysis should be performed after ablation. Long-term risks of RF ablation lesions have not been established. Ablation too close to the esophageal area can result in esophageal fistula. Ablation near the AV node can cause permanent or partial conduction block. To ensure proper operation of the tissue contact impedance measurement function, all four electrodes and six thermocouples on the catheter tip must protrude from the distal tip of the guiding sheath. Carefully monitor the tissue contact impedance before delivery of RF energy. Do not place the RF electrode in proximity to any other mapping or ablation electrodes, as this may cause inadvertent, ineffective, or unsafe tissue ablation and may increase chances of char, coagulum, or steam pops. Although a higher contact impedance value typically indicates acceptable tissue contact, and low contact impedance values typically indicate lack of tissue contact, caution should be exercised. Areas of previously ablated tissue may also display a low contact impedance value. Other parameters, such as EGM, fluoroscopic images, and intracardiac ultrasound should be monitored before deciding to apply RF. Stimulation of cardiac tissues caused by pacing stimulus or RF energy may lead to inadvertent induction of arrhythmias. These arrhythmias may require defibrillation that could also result in skin burns. Do not use the catheter for epicardial ablation. Using ablation parameters (such as temperature set-point, ablation duration, or irrigation flow rate) other than those recommended by Medtronic may be hazardous to patients. Exercise caution and sound medical reasoning when deciding to deviate from recommended parameters. Perform catheter advancement under fluoroscopic guidance in conjunction with internal contact, electrograms, and impedance monitoring to minimize the risk of cardiac damage, perforation, or tamponade. Tip-to-tissue contact impedance is actively monitored only before and after ablation. During ablation, use caution when the temperature drops suddenly. A drop in temperature may be associated with loss of tissue contact. In case of steam pop or automatic shut off, discontinue RF energy. Remove the catheter for visual inspection and check for coagulum, charring, or other catheter defects.

    Manual prebending of the distal curve may damage the steering mechanism and may cause patient injury. Do not attempt ablation with the catheter without the use of the DiamondTemp™ irrigation pump and DiamondTemp™ generator and approved accessories. Do not attempt ablation without the use of the irrigation pump. Before attempting ablation, make sure the pump flow rate is at the minimum continuous flow and the pump is actively communicating with the generator. The potential adverse events that may be associated with ablation procedures can vary greatly in frequency and severity and may necessitate additional medical intervention, including surgery. Carefully review the specific indications, contraindications, warnings, precautions, and adverse events included with each DiamondTemp™ catheter, prior to use of the DiamondTemp™ generator or irrigation pump. The irrigation pump is designed for use only with sterile heparinized normal saline solution. Specified flow-rate accuracy may not be maintained when used with incompatible fluids or delivery devices. The air bubble detector is disabled during irrigation pump priming and purging functions. Do not prime or purge the catheter when it is inserted in the vasculature of the patient. Do not remove the irrigation tubing set from the irrigation pump while the tubing set is in-line with a catheter that is inside the patient. The DiamondTemp™ generator connection box E is to be used with the DiamondTemp™ ablation system and Ensite™ cardiac mapping and navigation systems configured to use NavX™ navigation technology. Use with other systems has not been assessed and may compromise patient or operator safety. Do not connect the generator connection box E to the Ensite™ amplifier with both the primary and secondary connectors. Only connect using one of the connector options.

    Potential adverse events or potential complications

    Potential complications/adverse events from cardiac catheterization and ablation include, but are not limited to, the following: abnormal vision; air embolism; anaphylaxis; anemia; aneurysm; angina; arrhythmia (including new or worsening of existing condition, or requiring cardioversion); arterial or venous thrombus; atrial septal defect; AV fistula; cardiac arrest; cardiac tamponade; catheter entrapment leading to valve or heart wall damage; catheter insertion site hematoma; chest pain (nonspecific); congestive heart failure exacerbation; component damage to ICD or pacemaker; coronary artery dissection; death; dislodgement of implantable device or permanent pacing lead; dizziness; embolic events, including infarction of other tissues, coronary, pulmonary, and bowel structures; endocarditis; esophageal damage or necrosis; exacerbation of COPD; exacerbation of pre-existing atrial fibrillation; fluid overload; gastroparesis or GI event; hemorrhage; hemothorax; hypotension; hypoxia; inadvertent AV block; infection; myocardial infarction; neck pain, back pain, or groin pain; palpitations; perforation (cardiac); pericardial effusion; pericarditis; peripheral venous thrombosis; phrenic nerve damage; pleural effusion; pneumonia; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary vein stenosis; radiation injury resulting in dermatitis, erythema, etc.; renal insufficiency or failure; respiratory failure; seizure; sepsis; skin burns; stroke or cerebrovascular incident; syncope; thromboembolic event; transient ischemic attack; vasovagal reaction; ventricular arrhythmia; vessel wall or valvular damage or insufficiency.

    See the appropriate product device manuals for detailed information regarding the RF ablation procedure, indications (or intended use), contraindications, warnings, precautions, and potential complications/adverse events. See the appropriate electronic instructions for use (eIFUs) for the DiamondTemp™ catheters, DiamondTemp™ RF generator, DiamondTemp™ irrigation pump, DiamondTemp™ irrigation tubing set, DiamondTemp™ catheter-to-RF generator cable, DiamondTemp™ GenConnect™ cable, EGM cable, and DiamondTemp™ generator connection box E. or further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Flexcath Advance™ Steerable Sheath ISW

    The FlexCath Advance™ steerable sheath is intended for percutaneous catheter introduction into the vasculature and into the chambers of the heart. The sheath deflection facilitates catheter positioning.

    Contraindications

    The FlexCath Advance™ steerable sheath is contraindicated for placement in the left atrium or ventricle if:

    • The patient has an intra-atrial septal patch or has had other surgical intervention in or adjacent to the intra-atrial septum.
    • The patient has had a previous embolic event from the left side of the heart within two months of the procedure.
    • The patient has known or suspected atrial myxoma.

    The sheath should not be used to perform the transseptal puncture.

    Warnings/precautions

    This is a single-use sheath to be used in a single patient. Do not resterilize this sheath for purpose of reuse. Use this sheath with compatible Medtronic diagnostic and ablations catheters that are 10.5 Fr or smaller. Do not use the sheath if it is kinked or damaged. The sheath and dilator have not been tested for compatibility with transseptal needles. Administer appropriate levels of peri-procedural anticoagulation therapy, during and post-procedure anticoagulation therapy according to patient conditions and institutional standards. Introducing any catheter or sheath into the circulatory system entails the risk of air embolism, which can occlude vessels and lead to tissue infarction with serious consequences. To minimize the risk of air embolism, observe and remove any air prior to introducing the sheath and during the procedure. Remove the guide wire and dilator from the sheath or insert the catheter into the sheath before slowly aspirating and flushing the sheath. Minimize catheter exchanges and always advance and withdraw catheters slowly. Follow advancement or withdrawal of catheters with appropriate aspiration and flushing according to institutional standards or consensus statements. Connect to a continuous drip to minimize back-bleeding. Do not pass the sheath through a prosthetic heart valve (mechanical or tissue). The sheath may become trapped in the valve, damaging the valve and causing valvular insufficiency or premature failure of the prosthetic valve. Cardiac catheterization procedures should be performed only in a fully equipped facility. This sheath should be used only by, or under the supervision of, physicians trained in cardiac catheterization procedures. Use extreme care when manipulating the sheath. Do not use excessive force to advance or withdraw the sheath, especially if resistance is encountered.

    Potential adverse events or potential complications

    Potential adverse events associated with cannulation of the peripheral vasculature and intracardiac placement of the sheath and dilator may include the following conditions:

    Access site complications (hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage); air embolism; arrhythmia (atrial fibrillation, atrial flutter, tachycardia); cardiac arrest; chest discomfort, pain, or pressure; coronary artery spasm, dissection, thrombosis; death; endocarditis; heart block, requiring permanent pacemaker; hemothorax; myocardial infarction; perforation of venous cardiac or surrounding tissue; pericardial effusion, tamponade; pericarditis; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; atroke; thrombus; transient ischemic attack (TIA); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

    Back to top

    FlexCath Contour™ Steerable Sheath ISW

    Intended use

    The FlexCath Contour™ steerable sheath facilitates introducing various cardiovascular catheters into the heart.

    Indications for use

    The FlexCath Contour™ steerable sheath is indicated for percutaneous catheter, or transseptal needle introduction into the vasculature and into the chambers of the heart, including the left side of the heart through the interatrial septum. The sheath deflection facilitates device positioning.

    Contraindications

    The FlexCath Contour™ steerable sheath is contraindicated for placement in the left atrium or ventricle if:

    • The patient has an intra-atrial septal patch or has had other surgical intervention in or adjacent to the intra-atrial septum
    • The patient has had a previous embolic event from the left side of the heart within two months of the procedure
    • The patient has known or suspected atrial myxoma

    Compatible catheter sizes:

    • FlexCath Contour™ steerable device (10 Fr) 
      The sheath can be used with Medtronic diagnostic and ablation catheter sizes from 7 Fr (2.3 mm) up to 9.5 Fr (3.2 mm). 
    • FlexCath Contour™ steerable device (12 Fr) 
      The sheath can be used with Medtronic diagnostic and ablation catheter sizes from 7 Fr (2.3 mm) up to 10.5 Fr (3.5 mm).

    Warnings/precautions

    • This is a single-use sheath to be used in a single patient. Do not resterilize this sheath for purpose of reuse. 
    • The dilator is compatible with transseptal needles that are at least 89 cm in length and less than 21 gauge outer diameter. 
    • Do not use the sheath if it is kinked or damaged. 
    • Only physicians trained in left-sided catheterization should use this sheath during transseptal puncture.
    • Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing left-sided, right-sided, and transseptal cardiac procedures. 
    • Administer anticoagulation therapy during and post-procedure according to patient conditions and institutional standards. 
    • Introducing any catheter or sheath into the circulatory system entails the risk of air embolism, which can occlude vessels and lead to tissue infarction with serious consequences. 
    • To minimize the risk of air embolism, observe and remove any air prior to introducing the sheath and during the procedure. 
    • Do not advance the dilator or sheath through the interatrial septum without first confirming left atrial access to prevent advancing these components into an undesired location. 
    • Remove the guide wire and dilator from the sheath or insert the catheter into the sheath before slowly aspirating and flushing the sheath. 
    • Minimize catheter exchanges and always advance and withdraw catheters slowly. 
    • Follow advancement or withdrawal of catheters with appropriate aspiration and flushing according to institutional standards or consensus statements. 
    • Connect to a continuous drip to minimize back-bleeding. 
    • Do not pass the sheath through a prosthetic heart valve (mechanical or tissue). 
    • The sheath may become trapped in the valve, damaging the valve and causing valvular insufficiency or premature failure of the prosthetic valve. 
    • Cardiac catheterization procedures should be performed only in a fully equipped facility. 
    • This sheath should be used only by, or under the supervision of, physicians trained in cardiac catheterization procedures. 
    • Use extreme care when manipulating the sheath. 
    • Do not use excessive force to advance or withdraw the sheath, especially if resistance is encountered.
    • Only physicians trained in left-sided catheterization should use this sheath during transseptal puncture.

    Potential adverse events or potential complications

    • Potential adverse events associated with cannulation of the peripheral vasculature and intracardiac placement of the sheath and dilator may include the following conditions:
    • Access site complications (hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage)
    • Air embolism
    • Arrhythmia (such as atrial fibrillation, atrial flutter, heart block requiring permanent pacemaker, ventricular tachycardia)
    • Cardiac arrest
    • Chest discomfort, pain, or pressure
    • Coronary artery spasm
    • Damage to heart tissue or vasculature
    • Death
    • Endocarditis
    • Entrapment of the sheath within the patient
    • Hemothorax 
    • Latrogenic atrial septal defect (iASD)
    • Infection (such as pericarditis, sepsis, urinary)
    • Myocardial infarction
    • Perforation of venous, cardiac or surrounding tissue
    • Pericardial effusion, tamponade
    • Pericarditis
    • Pleural effusion
    • Pneumothorax
    • Pseudoaneurysm
    • Pulmonary edema
    • Pulmonary embolism
    • PV stenosis
    • Stroke
    • Thrombus
    • Transient ischemic attack (TIA)
    • Valve damage
    • Vasovagal reaction

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 and/or consult the Medtronic website at www. medtronic.com.

    Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

    FlexCath Cross™ Transseptal Solution ISW

    Prior to using these devices, please review the instructions for use for a complete list of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. FlexCath Cross™ devices are FDA cleared. Not all FlexCath Cross™ devices are CE marked.

    Back to top

    Freezor™ Cardiac Cryoablation Catheter ISW

    Freezor™ cardiac cryoablation catheter

    Indications

    The Freezor™ cardiac cryoablation catheter, CryoConsole™ system, and related accessories are indicated for the cryoablation of the conducting tissues of the heart in the treatment of adult and pediatric patients over two years of age, with atrioventricular nodal reentrant tachycardia (AVNRT).

    Contraindications

    This device is contraindicated in patients with active systemic infection, cryoglobulinemia, intracardiac mural thrombus, myxoma, interatrial baffle or patch.

    Warnings/Precautions

    Closely monitor AV conduction during cryo energy delivery near the AV node due to possible risk of complete atrioventricular (AV) block. Immediately terminate energy delivery if partial or complete AV block is noted. Cryoablation involving coronary vessels has been associated with subsequent clinically significant arterial stenosis. Care should be taken to minimize unnecessary contact with coronary vessels during cryoablation. Endotoxins may cause pyrogenic responses in patients including inflammation and fever which can result in anaphylactic shock and death. Caution should be used with regard to endotoxins in pediatric populations as standard endotoxin limits do not differentiate between adult and pediatric populations. Ethylene oxide residuals remaining after sterilization are known to cause a potential increase in a number of biological effects including irritation, organ damage, mutagenicity and carcinogenicity. Calculations for ethylene oxide and ethylene chlorohydrin residuals indicate that the risk of these effects may be increased in patients under 3.8 kg. Avoid catheter entanglement with other catheters devices or wires. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. Do not re-use, reprocess, or resterilize this device for purpose of reuse. This device is intended only to be used once for a single patient. The use of CryoMapping mode does not prevent injuries to the patient. CryoMapping mode is used to determine if the site is appropriate for ablation. The Freezor™ catheter contains a pressurized refrigerant during operation. Release of this gas into the circulatory system due to equipment failure or misuse could result in gas embolism. Do not pull on the catheter, sheath, umbilical cables, or console while the catheter tip is frozen to the tissue, as this may lead to tissue injury. Always advance and withdraw components slowly to minimize the vacuum created and therefore minimize the risk of air embolism. Do not connect the Freezor™ catheter to any radiofrequency (RF) generator or use the Freezor™ catheter to deliver RF ablation energy. Before powering up an RF generator of applying RF energy, disconnect the cryoablation catheter from the CryoConsole™ system. The use of fluoroscopy during catheter ablation procedures presents the potential for significant X-ray exposure to both patients and laboratory staff. Give careful consideration before using the device in pregnant women. Avoid positioning the catheter around the chordae tendineae, as this increases the likelihood of catheter entrapment within the heart. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue).

    Catheter handling: 

    • Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade. 
    • Do not use excessive force to advance, withdraw, the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened.
    • Straighten the cooling segment before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or cooling segment.
    • Catheter advancement should be performed under fluoroscopic guidance or other appropriate visualization technique.

    Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole™ system and catheters. The Medtronic cryoablation catheters, refrigerant tanks, and other Medtronic CryoConsole™ components should only be used with the Medtronic CryoConsole™ system. If the sterile packaging or catheter is damaged, do not use the catheter. This equipment should be used only by physicians that perform cardiac ablation. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. Disconnect the catheter’s electrical connection prior to cardioversion/defibrillation. Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing right-sided procedures. The Freezor™ catheter has not been evaluated for safety and compatibility in the magnetic resonance (MR) environment. Scanning a patient during the use of this device may result in patient injury.

    Potential Complications

    Potential complications that may be associated with cardiac catheterization and ablation listed alphabetically below include, but are not limited to: Access site complications including, hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage; arrhythmias (such as atrial fibrillation, atrial flutter, tachycardia); cardiac arrest and/or death; chest discomfort, pain or pressure; coronary artery spasm/stenosis; damage to heart tissue or vasculature; endocarditis; entrapment; heart block, requiring permanent pacemaker; hemothorax; infection; perforation of venous, cardiac or surrounding tissue, pericardial effusion, tamponade; pericarditis; phrenic nerve injury; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; stroke; tissue infarction (such as myocardial infarction or renal infarction); thrombus; transient ischemic attack; vagal nerve injury (such as gastroparesis); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-238-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Freezor™ MAX cardiac cryoablation catheter

    Indications

    The Freezor™ MAX cardiac cryoablation catheter is used as an adjunctive device in the endocardial treatment of paroxysmal and persistent atrial fibrillation (episode duration less than six months) in conjunction with the Arctic Front™ family of cardiac cryoablation catheters for the following uses: 1) Gap cryoablation to complete electrical isolation of the pulmonary veins 2) Cryoablation of focal trigger sites and 3) Creation of ablation line between the inferior vena cava and the tricuspid valve.

    Contraindications

    Use of Freezor™ MAX cardiac cryoablation catheter is contraindicated in patients with active systemic infections, in patients with cryoglobulinemia, intracardiac mural thrombus, myxoma or interatrial baffle or patch. The Freezor™ MAX cardiac cryoablation catheter is also contraindicated in patients with a body mass under 4.4 kg.

    Warnings/Precautions

    Do not reuse or reprocess this device for purpose of reuse. This catheter is intended only to be used once for a single patient. Do not connect the cryoablation catheter to a radiofrequency (RF) generator or use it to deliver RF energy. Disconnect the catheter’s electrical connection prior to cardioversion/defibrillation.

    Catheter handling:

    • Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade.
    • Do not use excessive force to advance, withdraw the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened. Straighten the cooling segment before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or cooling segment.
    • Catheter advancement should be performed under fluoroscopic guidance or other appropriate visualization technique.

    Avoid positioning the catheter around the chordae tendineae. The catheter contains pressurized refrigerant during operation. Release of this gas into the circulatory system due to equipment failure or misuse could result in gas embolism. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Use adequate fluoroscopic visualization or other appropriate visualization technique during a transaortic approach to avoid placing the ablation catheter within the coronary vasculature. Do not pull on the catheter, sheath, umbilical cables, or console while the catheter is frozen to the tissue, as this may lead to tissue injury. Always advance and withdraw components slowly to minimize the vacuum created. Closely monitor AV conduction during cryo energy delivery near the AV node due to possible risk of complete atrioventricular block.

    Perform cryoablation procedures only within the environmental parameters. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. The use of fluoroscopy during catheter ablation procedures presents the potential for significant X-ray exposure to both patients and laboratory staff. Give careful consideration before using the catheter in pregnant women. Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole™ system and catheters. The safety of the catheter in the MR environment is unknown (such as any heating, migration, or image artifacts). Scanning a patient during the use of this device may result in patient injury. Avoid catheter entanglement with other catheters, devices, or wires. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. Before powering up an RF generator or applying RF energy, disconnect the cryoablation catheter from the CryoConsole™ system. If the device is damaged or the integrity of the sterilization barrier has been compromised, do not use the product. The Medtronic cryoablation catheters, refrigerant tanks, and other Medtronic CryoConsole™ components should only be used with the Medtronic CryoConsole™ system.

    The Freezor™ MAX catheter was not studied for safety of changes in anticoagulation therapy in patients with paroxysmal atrial fibrillation. This equipment should be used only by physicians that perform cryoablation procedures. Cryoablation procedures should be performed only in a fully equipped facility.

    Potential Complications

    Potential complications/adverse events from cardiac catheterization and ablation include, but are not limited to the following: Access site complications including, hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from the puncture site, hemorrhage; arrhythmias (such as atrial fibrillation, atrial flutter, tachycardia); cardiac arrest; chest discomfort, pain or pressure; coronary artery spasm/stenosis; damage to heart tissue or vasculature; death; endocarditis; entrapment; esophageal damage (such as atrio-esophageal fistula); heart block, potentially requiring implantation of a permanent pacemaker; hemothorax; infection; perforation of venous, cardiac or surrounding tissue, pericardial effusion, tamponade; pericarditis; phrenic nerve injury; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; stroke; tissue infarction (such as myocardial infarction or renal infarction); thrombus; transient ischemic attack; vagal nerve injury (such as gastroparesis); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal Law (United States) restricts this device to sale by or on the order of a physician.

    Back to top

    Freezor™ Xtra cardiac cryoablation catheter

    Indications

    The Freezor™ Xtra cardiac cryoablation catheter, CryoConsole™ system, and related accessories are indicated for the cryoablation of the conducting tissues of the heart in the treatment of adult and pediatric patients over two years of age with atrioventricular nodal reentrant tachycardia (AVNRT). The Freezor™ Xtra catheter is also intended for minimally invasive cardiac surgery procedures, including surgical treatment of cardiac arrhythmias. The Freezor™ Xtra catheter freezes the target tissue and blocks the electrical conduction by creating an inflammatory response or cryonecrosis.

    Contraindications

    The Freezor™ Xtra cardiac cryoablation catheter is contraindicated in patients with the following conditions:

    • Active systemic infections
    • Cryoglobulinemia
    • Intracardiac mural thrombus
    • Myxoma
    • Interatrial baffle or patch

    Warnings/Precautions

    Do not reuse, reprocess, or resterilize this catheter for purpose of reuse. This catheter is intended only to be used once for a single patient. Closely monitor AV conduction during cryo energy delivery near the AV node due to possible risk of complete atrioventricular (AV) block. Immediately terminate energy delivery if partial or complete AV block is noted. The use of CryoMapping mode does not prevent injuries to the patient. CryoMapping mode is used to determine if the site is appropriate for ablation. The catheter contains pressurized refrigerant during operation. Release of this gas into the body or circulatory system due to equipment failure or misuse could result in gas embolism, pericardial tamponade, tissue emphysema, or other patient injury. Always advance and withdraw components slowly to minimize the vacuum created and therefore minimize the risk of air embolism. Endotoxins may cause pyrogenic responses in patients including inflammation and fever which can result in anaphylactic shock and death. Caution should be used with regard to endotoxins in pediatric populations as standard endotoxin limits do not differentiate between adult and pediatric populations. Ethylene oxide residuals remaining after sterilization are known to cause a potential increase in a number of biological effects including irritation, organ damage, mutagenicity, and carcinogenicity. Calculations for ethylene oxide and ethylene chlorohydrin residuals indicate that the risk of these effects may be increased in patients under 3.8kg. Avoid catheter entanglement with other catheters, devices, or wires. Closely monitor patients undergoing cardiac ablation procedures during the post-ablation period for clinical adverse events. Do not pull on the Freezor™ Xtra catheter, sheath, umbilical cables, or console while the catheter is frozen to the tissue, as this may lead to tissue injury. Do not connect the Freezor™ Xtra catheter to a radiofrequency (RF) generator or use it to deliver RF ablation energy. Before powering up an RF generator or applying RF energy, disconnect the cryoablation catheter from the CryoConsole™ system. The use of fluoroscopy during ablation procedures presents the potential for significant X-ray exposure to both patients and laboratory staff. Give careful consideration before using the device in pregnant women.

    Catheter handling: 

    • Use extreme care when manipulating the catheter. Lack of careful attention can result in injury such as perforation or tamponade.
    • Do not use excessive force to advance or withdraw the catheter, especially if resistance is encountered.
    • Do not use the catheter if it is kinked, damaged, or cannot be straightened.
    • Straighten the cooling segment before inserting or withdrawing the catheter.
    • Do not at any time preshape or bend the catheter shaft or cooling segment.
    • Catheter advancement should be performed under fluoroscopic guidance or other appropriate visualization technique.

    Use only isolated equipment (IEC 60601-1 Type CF equipment, or equivalent) with the CryoConsole™ system and catheters. The Freezor™ Xtra catheter has not been evaluated for safety and compatibility in the magnetic resonance (MR) environment. Scanning a patient during the use of this device may result in patient injury. The Medtronic cryoablation catheters, refrigerant tanks, and other Medtronic CryoConsole™ components should only be used with the Medtronic CryoConsole™ system. If the sterile packaging or catheter is damaged, do not use the catheter. Do not expose the catheter handle or coaxial and electrical connectors to fluids or solvents. Disconnect the catheter’s electrical connection prior to cardioversion/defibrillation. Cryoablation involving coronary vessels with liquid nitrous oxide systems has been associated with subsequent clinically significant arterial stenosis. Care should be taken to minimize unnecessary contact with coronary vessels during cryoablation.

    Avoid positioning the catheter around the chordae tendineae, as this increases the likelihood of catheter entrapment within the heart. Do not pass the catheter through a prosthetic heart valve (mechanical or tissue). Administer appropriate levels of peri-procedural anticoagulation therapy for patients undergoing endocardial right-sided procedures. This equipment should be used only by physicians that perform cardiac ablation.

    Potential Complications

    Potential complications that may be associated with cardiac catheterization and ablation listed alphabetically below include, but are not limited to: Access site complications including, hematoma, infection, thrombosis, ecchymosis, AV fistula, bleeding from puncture site, hemorrhage; arrhythmias (such as atrial fibrillation, atrial flutter, tachycardia); cardiac arrest and/or death; chest discomfort, pain or pressure; coronary artery spasm/stenosis; damage to heart tissue or vasculature; endocarditis; entrapment; heart block, requiring permanent pacemaker; hemothorax; infection; perforation of venous, cardiac or surrounding tissue, pericardial effusion, tamponade; pericarditis; phrenic nerve injury; pleural effusion; pneumothorax; pseudoaneurysm; pulmonary edema; pulmonary embolism; stroke; tissue infarction (such as myocardial infarction or renal infarction); thrombus; transient ischemic attack; vagal nerve injury (such as gastroparesis); vasovagal reaction.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518.

    Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

    Back to top

    Nitron CryoConsole™ Cardiac Cryoablation System ISW

    Intended use

    The Nitron CryoConsole™ (the console), together with its components and specified catheters, is for use in performing cardiac ablation procedures.

    Contraindications

    See the technical manual for the compatible Medtronic catheter being used.

    Warnings and precautions

    These warnings apply in general to using the Nitron CryoConsole™ for cardiac cryoablation. Refer to the technical manual for console-compatible catheters for more information related to catheter use.

    • Connected electrophysiology (EP) lab equipment. Any equipment (e.g., EP recording system, HDMI) connected to the upper rear connection panel or to the auto connection box ECG cable receptacle of the device shall be IEC 60601-1 compliant or have a 60601-1-compliant isolation transformer on the interconnect cable between the Nitron CryoConsole™ and the EP lab equipment.
    • Electric shock. To avoid risk of electric shock, this equipment must only be connected to a supply main with protective earth.
    • Cryoadhesion. Do not pull on the catheter, sheath, umbilical cables, or console while the catheter is frozen to the tissue, as this may lead to tissue injury.
    • Improper connection. Do not connect a cryoablation catheter to a radiofrequency (RF) generator or use it to deliver RF energy. Doing this may cause catheter malfunction or patient harm.
    • Other accessories, transducers, and cables. Use of accessories, transducers, and cables other than those specified or provided by the manufacturer of this equipment could result in increased electromagnetic emissions or decreased electromagnetic immunity of this equipment and result in improper operation.

    The console meets the requirements of IEC 60601-1. It is the user’s responsibility after installation to verify and ensure that the console meets the applicable local electrical safety requirements. Perform cryoablation procedures only within the environmental parameters. Cryoablation procedures should be performed only in an electrophysiology facility by or under the supervision of physicians trained in cryoablation.  Do not modify this equipment. Modifications may reduce system effectiveness and impact patient health. The system must be installed by a qualified/trained Medtronic representative. All information technology equipment that is attached to the console must be approved by a third party to the requirements of UL 1950 or EN 60950. Minimize exposure to nitrous oxide to prevent short-term behavioral and long-term reproductive health effects.  The console and its accessories have not been evaluated for safety and compatibility in the magnetic resonance (MR) environment and are unknown which may lead to patient injury. Use only compatible Medtronic cryoablation catheters and components and Medtronic-provided refrigerant tanks with the console. The safety and use of other catheters or components has not been tested.

    Potential adverse events

    Potential adverse events associated with console procedures include, but are not limited to, the following conditions:

    • Electric shock
    • Foreign body/biological reaction
    • Long-term reproductive issues
    • Thermal injury

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at  800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    PulseSelect™ Pulsed Field Ablation System ISW

    Indications (or intended use)

    The PulseSelect™ pulsed field ablation (PFA) system is indicated for use in cardiac electrophysiological mapping (stimulation and recording) and for treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation or persistent atrial fibrillation (episode duration less than one year).

    Contraindications

    The PulseSelect™ PFA loop catheter is contraindicated for use in patients with the following conditions:

    • Active systemic infections
    • A known sensitivity to Heparin
    • Blood clotting abnormalities
    • Permanently implanted metallic objects in the left atrium

    The catheter is also contraindicated in conditions where the manipulation of the catheter within the heart would be unsafe, such as intracardiac mural thrombus.

    The catheter is not recommended for use in patients who cannot undergo standard anticoagulation protocol for a left-sided cardiac procedure, or who have had a recent coagulopathy or embolic event.

    Warnings and precautions

    To reduce the possibility of hazards associated with use of the PulseSelect™ PFA loop catheter: 

    • Use the catheter only in the recommended anatomical location.
    • Maintain the catheter position during the ablation.
    • If coughing occurs, reposition the catheter more proximally and review sedation management.
    • Ensure electrodes are not in contact with any metal during ablations (for example the guide wire).
    • Maintain substantially circular array to ensure uniform field distribution.
    • If the electrode array is deployed to deliver ablation energy, avoid continuing to move the slide control forward to prevent the guide wire lumen from coming too close to the electrode array.

    It is recommended that the array be captured while it is submerged to help reduce the possibility of air becoming entrapped around the electrode array during capture and catheter insertion.

    Catheter integrity

    Use care to avoid damage to the catheter.

    • Do not bend or kink the leading end of the catheter. Doing so could cause damage to the catheter lumen and make it unusable.
    • Monitor the catheter throughout the procedure. If a flash is observed in the luer, replace the catheter immediately.

    Electrode-electrode contact

    Avoid contact between electrodes. Contact between electrodes may create a short circuit.

    Embolism risk

    Introducing any catheter or sheath into the circulatory system entails the risk of air, gas, or thromboembolism, which can occlude vessels and lead to tissue infarction with serious consequences.

    • Avoid unnecessary catheter exchanges to minimize sheath-related embolic events.
    • Always advance and withdraw components slowly to minimize the vacuum created and the risk of air embolism.
    • Aspirate and flush the sheath frequently to help minimize the potential for embolic events resulting from the introduction of air or clot formation within the sheath.

    Fluoroscopy use during catheter placement

    Only perform catheter ablation after giving adequate attention to the potential radiation exposure associated with the procedure and taking steps to minimize this exposure. Give careful consideration before using the device in pregnant women.

    For single use only

    The PFA catheter is intended only to be used once for a single patient. Do not reuse, reprocess, or resterilize the PFA catheter.

    Careful manipulation of the catheter is necessary to avoid cardiac damage, perforation, or tamponade.

    • Do not use excessive force to advance, withdraw, or rotate the catheter, especially if resistance is encountered. Excessive force may lead to catheter damage and blood loss.
    • Use imaging guidance during catheter advancement, manipulation, and placement.
    • Vascular perforation is an inherent risk of catheter placement.
    • Performing ablation with the PFA catheter array inside the sheath may result in damage to the array or the sheath and should be avoided.
    • Performing steering manipulation with the PFA catheter array inside the sheath may result in damage to the catheter steering mechanism or the sheath and should be avoided.
    • The PFA generator is capable of delivering significant energy. Do not touch the ablation electrodes of the PFA catheter while operating the generator.
    • If the system is to be tested outside of the body, the electrode array must be immersed in saline solution in a plastic container. Never test PFA delivery in direct contact with skin.

    Use of imaging during catheter manipulation and placement is strongly advised. Manipulating the catheter without imaging may result in damage to cardiac and vascular structures.

    Other devices, wires, or catheters

    Avoid catheter entanglement with other devices, wires, or catheters, for example, intracardiac echo catheters. Failure to do so may increase the risk of entrapment of the array or damage to the array, which may affect retrieval of the device into the transseptal sheath.

    Phrenic nerve injury

    To reduce the potential for phrenic nerve injury, assess for proximity of the ablation catheter to the nerve using an appropriate technique such as pacing for local phrenic nerve capture or using the test pulse feature before ablation. Stop ablation immediately if phrenic nerve impairment is observed and assess for injury.

    Sheath and guide wire required

    Do not attempt to advance or withdraw the catheter through the vasculature without the use of a sheath and guide wire, as it may result in damage to cardiac and vascular structures.

    Implanted devices, such as pacemakers and implantable cardioverter-defibrillators (ICDs), may be adversely affected by PFA energy.

    • Keep external sources of pacing and defibrillation available during ablation.
    • Program pacemaker sensing parameters to asynchronous pacing to ensure that PFA energy is not sensed as an intrinsic event.
    • Deactivate ICD detection during the delivery of PFA energy.
    • Perform complete implantable device testing before and after ablation.
    • Monitor surface and intracardiac electrograms or vital signs during PFA energy delivery to assess for device interaction. Take appropriate action if any interaction is detected.
    • Refer to the appropriate implantable device technical manual for additional information.

    Electrical safety requirements

    The PFA generator meets the requirements of IEC 60601-1. It is the user’s responsibility after installation to verify and ensure that the generator meets the applicable local electrical safety requirements.

    Electric shock

    To avoid risk of electric shock, this equipment must only be connected to a supply main with protective earth.

    Electromagnetic interference (EMI) radiated

    The generator emits energy during ablation at a frequency level that may cause EMI with unshielded electronic equipment. To minimize EMI, the generator should be moved away from any other electronic device. If EMI is apparent during the application of energy, EMI may be reduced by repositioning the generator or other equipment.

    Electromagnetic interference (EMI) susceptibility

    The generator has been designed to minimize EMI. If interference should occur, move the generator away from the device generating the interference or place the generator at a different angle.

    Leakage current from connected devices

    Use only isolated equipment (IEC 60601-1 Type CF equipment or equivalent) with the PFA system and catheters, or patient injury or death may occur.

    Potential adverse events or potential complications

    Potential adverse events associated with cardiac catheter ablation procedures include, but are not limited to, the following conditions:

    • Access site complications (such as, bruising, ecchymosis, arteriovenous fistula, hematoma, pseudoaneurysm)
    • Anemia
    • Arrhythmias, proarrhythmia (such as, atrial flutter, bradycardia, heart block, tachycardia)
    • Bleeding, possibly requiring transfusion
    • Bruising
    • Cardiopulmonary arrest
    • Perforation of the heart or other organs during transseptal puncture or other procedures
    • Cardiac tamponade
    • Catheter entrapment in cardiac structures requiring intervention
    • Cerebrovascular accident such as stroke, transient ischemic attack (TIA)
    • Chest discomfort, pain, or pressure
    • Collateral damage to the conduction system or coronary vasculature
    • Cough
    • Death
    • Embolism
    • Esophageal damage (including atrial esophageal fistula)
    • Hemoptysis
    • Hypotension
    • Hypertension
    • Infections (such as, sepsis)
    • Myocardial infarction or ischemia
    • Nerve injury or nerve damage (for example phrenic nerve injury)
    • Pericarditis or endocarditis
    • Pericardial effusion
    • Pneumothorax
    • Pulmonary edema
    • Pulmonary vein dissection
    • Pulmonary vein stenosis
    • Radiation injury or damage and late malignancy
    • Skin laceration or puncture
    • Sore throat
    • Unintended complete or incomplete atrioventricular node (AV-Node) or sinus node block or damage
    • Valvular insufficiency or damage.

    Refer to the device technical manual for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 and/or consult the Medtronic website at www.medtronic.com.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    Back to top

    Continuous long-term cardiac monitoring

    Continued cardiac monitoring after an AF ablation with the Medtronic LINQ™ family of ICMs provides comprehensive data including AF burden, activity level, and heart rate variability. Insertable cardiac monitors remain the gold standard for the detection of AF recurrence and quantification of AF burden.†,27

    † Compared to intermittent monitoring.

    Find out more
    LINQ™ family of ICMs, including Reveal LINQ™ and LINQ II™ ICM, shown horizontally

    Resources

    Related links

    Follow us on social media.

    Stay up to date on product updates and events. 

    Medtronic 24-hour support

    Phone: 800-505-4636

    Products

    Filter by
    1. Pürerfellner H, Sanders P, Sarkar S, et al. Adapting detection sensitivity based on evidence of irregular sinus arrhythmia to improve atrial fibrillation detection in insertable cardiac monitors. Europace. 2018;20(Fl_3):f321–f328. doi: 10.1093/europace/eux272.
    2. Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61(16):1713–1723. doi: 10.1016/j.jacc.2012.11.064.
    3. Boriani G, Manolis AS, Tukkie R, et al. Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm. 2015;12(6):1192–1200. doi: 10.1016/j.hrthm.2015.02.017.
    4. Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235–2245. doi: 10.1056/NEJMoa1602014.
    5. Kuck KH, Fürnkranz A, Chun KR, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016;37(38):2858–2865. doi: 10.1093/eurheartj/ehw285.
    6. Chun KRJ, Brugada J, Elvan A, et al. The impact of cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation on healthcare utilization and costs: an economic analysis from the FIRE AND ICE Trial. J Am Heart Assoc. 2017;6(8):e006043. doi: 10.1161/JAHA.117.006043.
    7. Passman R, Leong-Sit P, Andrei AC, et al. Targeted anticoagulation for atrial fibrillation guided by continuous rhythm assessment with an insertable cardiac monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study. J Cardiovasc Electrophysiol. 2016;27(3):264–270. doi: 10.1111/jce.12864.
    8. Zuern CS, Kilias A, Berlitz P, et al. Anticoagulation after catheter ablation of atrial fibrillation guided by implantable cardiac monitors. Pacing Clin Electrophysiol. 2015;38(6):688–693. doi: 10.1111/pace.12625.
    9. Mascarenhas DAN, Farooq MU, Ziegler PD, Kantharia BK. Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding. Europace. 2016;18(6):799–806. doi: 10.1093/europace/euv350.
    10. Pothineni NVK, Amankwah N, Santangeli P, et al. Continuous rhythm monitoring-guided anticoagulation after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2021;32(2):345–353. doi: 10.1111/jce.14864.
    11. Witkowski M, Bissinger A, Grycewicz T, Lubinski A. Asymptomatic atrial fibrillation in patients with atrial fibrillation and implanted pacemaker. Int J Cardiol. 2017;277:583–588. doi: 10.1016/j.ijcard.2016.10.097.
    12. Pürerfellner H, Gillis AM, Holbrook R, Hettrick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol. 2004;27(7):983–992. doi: 10.1111/j.1540-8159.2004.00569.x.
    13. Ziegler PD, et al. Accuracy of atrial fibrillation detection in implantable pacemakers. Presented at HRS 2013 (PO02-08).
    14. QADoc DSN026170, Version 2.0, AT/AF duration performance comparison. Medtronic data on file.
    15. Boriani G, Deshmukh A, Brown ML Koehler J, Friedman PA. Understanding the incidence of AF in single chamber ICD patients: a real world analysis. EP Europace. 2017;19(S3):iii154. https://doi.org/10.1093/ehjci/eux151.022
    16. Chen S, Chen K, Tao Q, et al. Reduction of unnecessary right ventricular pacing by managed ventricular pacing and search AV+ algorithms in pacemaker patients: 12-month follow-up results of a randomized study. Europace. 2014;16(11):1595–1602.doi: 10.1093/europace/euu055.
    17. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;1107(23):2932–2937. doi: 10.1161/01.CIR.0000072769.17295.B1.
    18. Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. 2019;42(7):970–979. doi: 10.1111/pace.13696.
    19. Birnie D, Hudnall H, Lemke B, et al. Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. Heart Rhythm. 2017;14(12):1820–1825. doi: 10.1016/j.hrthm.2017.08.017.
    20. Plummer CJ, Frank CM, Bári Z, et al. A novel algorithm increases the delivery of effective cardiac resynchronization therapy during atrial fibrillation: The CRTee randomized crossover trial. Heart Rhythm. 2018;15(3):369–375. doi: 10.1016/j.hrthm.2017.10.026.
    21. Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384(4):316–324. doi: 10.1056/NEJMoa2029554.
    22. Providencia R, Defaye P, Lambiase PD, et al. Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: Is cryoablation more reproducible? Europace. 2017;19(1):48–57. doi: 10.1093/europace/euw080.
    23. Kowalski M, Su WW, Holbrook R, et al. Impact of cryoballoon ablation on electrophysiology lab efficiency during the treatment of patients with persistent atrial fibrillation: A sub-analysis of the STOP Persistent AF Study. J Invasive Cardiol. 2021;33(7):E522–E530.
    24. Kowalski M, DeVille JB, Svinarich JT, et al. Using discrete event simulation to model the economic value of shorter procedure times on EP lab efficiency in the VALUE PVI Study. J Invasive Cardiol. 2016;28(5):176-182.
    25. Lieberman Inc. Blinded market research survey. Medtronic data on file. February 2018.
    26. Kautzner J, Albenque JP, Natale A, et al. A novel temperature-controlled radiofrequency catheter ablation system used to treat patients with paroxysmal atrial fibrillation. JACC Clin Electrophysiol. 2021;7(3):352–363. doi: 10.1016/j.jacep.2020.11.009.
    27. Aguilar M, Macie L, Deyell MW, et al. The influence of monitoring strategy on assessment of ablation success and post-ablation atrial fibrillation burden assessment: Implications for practice and clinical trial design. Circulation. 2022;145(1):21–30. doi: 10.1161/CIRCULATIONAHA.121.056109.